<SEC-DOCUMENT>0000950103-18-008705.txt : 20180720
<SEC-HEADER>0000950103-18-008705.hdr.sgml : 20180720
<ACCEPTANCE-DATETIME>20180720060337
ACCESSION NUMBER:		0000950103-18-008705
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		10
FILED AS OF DATE:		20180720
DATE AS OF CHANGE:		20180720

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AC Immune SA
		CENTRAL INDEX KEY:			0001651625
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-224694
		FILM NUMBER:		18961397

	BUSINESS ADDRESS:	
		STREET 1:		EPFL INNOVATION PARK, BUILDING B
		CITY:			1015 LAUSANNE
		STATE:			V8
		ZIP:			00000
		BUSINESS PHONE:		41 21 345 91 21

	MAIL ADDRESS:	
		STREET 1:		EPFL INNOVATION PARK, BUILDING B
		CITY:			1015 LAUSANNE
		STATE:			V8
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>dp93527_424b5.htm
<DESCRIPTION>FORM 424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><B>PROSPECTUS SUPPLEMENT</TD>
    <TD STYLE="width: 50%; text-align: right"><B>Filed Pursuant to Rule 424(b)(5)</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><B>(To Prospectus dated June 8, 2018)</TD>
    <TD STYLE="text-align: right"><B>Registration No. 333-224694</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Subscription Rights to Purchase up to
1,500,000 Common Shares<BR>
<BR>
</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">We are offering pre-emptive subscription
rights to our existing shareholders who held common shares after close of trading on The Nasdaq Global Market on July 2, 2018 (&ldquo;Record
Shareholders,&rdquo; and the close of the trading on The Nasdaq Global Market on July 2, 2018, the &ldquo;Record Date&rdquo;) to
purchase up to 1,500,000 newly issued common shares (the &ldquo;Rights Offering&rdquo;) at the Offering Price referred to below.
The subscription period in respect of the Rights Offering will begin at 3.00 a.m. (New York City time) on July 20, 2018 and will
expire at 4:00 p.m. (New York City time) on July 27, 2018. Record Shareholders who fully exercise their pre-emptive subscription
rights during the subscription period will also have the option of subscribing for additional common shares unclaimed by other
Record Shareholders in the Rights Offering at the same Offering Price, as further described under &ldquo;Subscription Rights Offering.&rdquo;
If and to the extent the pre-emptive subscription rights have not been validly exercised by the Record Shareholders during the
subscription period in the Rights Offering, the remaining common shares will be available for allocation to current shareholders
by our Board of Directors at its discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">Under Swiss law and pursuant to the
resolution by the annual general meeting held on July 6, 2018, our existing shareholders are entitled to statutory
pre-emptive subscription rights to subscribe for any new issuance of common shares and, thus, the newly issued common shares
referred to herein, in proportion to their existing shareholdings. The subscription rights are not transferrable. You may not
sell, transfer, assign or give away your subscription rights. See &ldquo;Subscription Rights Offering.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">Our common shares trade on The Nasdaq
Global Market under the trading symbol &ldquo;ACIU&rdquo;. On July 18, 2018, the last sale price of our common shares as reported
on The Nasdaq Global Market was $11.78 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">On July 17, 2018, we commenced a public
offering (the &ldquo;Public Offering&rdquo;) of 7,391,305 of our common shares and granted the underwriters in the Public Offering
an option for a period of 30 days from the date of the prospectus supplement for the Public Offering to purchase up to 1,108,695
additional shares from us at the public offering price of the commons shares offered in the Public Offering (the &ldquo;Offering
Price&rdquo;), less underwriting discounts and commissions. Concurrently with the Public Offering, we commenced a pre-emptive subscription
rights offering (the &ldquo;Prior Rights Offering&rdquo;) to Record Shareholders giving them the opportunity to subscribe for up
to 8,500,000 of the common shares offered in the Public Offering on a <I>pro rata</I> basis at the Offering Price. The subscription
period for the Prior Rights Offering expired at 4:00 p.m. (New York City time) on July 18, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt"><B>We are an &ldquo;emerging growth company&rdquo;
as defined under the federal securities laws and, as such, are subject to reduced public company reporting requirements. See &ldquo;Prospectus
Supplement Summary&mdash;Implications of Being an Emerging Growth Company&rdquo; and &ldquo;&mdash;Implications of Being a Foreign
Private Issuer.&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt"><B>Investing in our securities involves
a high degree of risk. See &ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Risk Factors</U>&rdquo;</FONT> beginning
on page S-9 of this prospectus supplement.</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy
of this prospectus. Any representation to the contrary is a criminal offense.</B><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="; text-align: center">&nbsp;</TD><TD STYLE="; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="; text-align: center; border-bottom: Black 1pt solid">Per Share</TD><TD STYLE="; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="; text-align: center; border-bottom: Black 1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 78%; padding-bottom: 2.5pt">Public offering price&#9;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 8%; text-align: right; border-bottom: Black 1pt solid">11.75</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="width: 8%; text-align: right; border-bottom: Black 2.5pt double">17,625,000</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Proceeds, before expenses, to us&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">11.75</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">17,625,000</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; background-color: White">Delivery of the common shares is expected to be made on or about July 31, 2018.</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="text-align: right; background-color: White">&nbsp;</TD><TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="text-align: right; background-color: White">&nbsp;</TD><TD STYLE="text-align: left; background-color: White">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is July 20,
2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page --> <P STYLE="color: red; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>Page</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="width: 91%">Presentation of Financial Information</TD>
    <TD STYLE="width: 9%; text-align: right">S-ii</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Trademarks</TD>
    <TD STYLE="text-align: right">S-ii</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>About This Prospectus Supplement</TD>
    <TD STYLE="text-align: right">S-ii</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Special Note Regarding Forward-Looking Statements</TD>
    <TD STYLE="text-align: right">S-iv</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Prospectus Supplement Summary</TD>
    <TD STYLE="text-align: right">S-1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>The Offering</TD>
    <TD STYLE="text-align: right">S-6</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Risk Factors</TD>
    <TD STYLE="text-align: right">S-9</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Use of Proceeds</TD>
    <TD STYLE="text-align: right">S-19</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Dividend Policy</TD>
    <TD STYLE="text-align: right">S-20</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Capitalization</TD>
    <TD STYLE="text-align: right">S-21</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Dilution</TD>
    <TD STYLE="text-align: right">S-22</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Subscription Rights Offering</TD>
    <TD STYLE="text-align: right">S-23</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Price Range of Common Shares</TD>
    <TD STYLE="text-align: right">S-25</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Tax Considerations</TD>
    <TD STYLE="text-align: right">S-26</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Plan of Distribution</TD>
    <TD STYLE="text-align: right">S-33</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Legal Matters</TD>
    <TD STYLE="text-align: right">S-37</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Experts</TD>
    <TD STYLE="text-align: right">S-37</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Where You Can Find More Information</TD>
    <TD STYLE="text-align: right">S-37</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Incorporation By Reference</TD>
    <TD STYLE="text-align: right">S-37</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Statutory Financial Statements</TD>
    <TD STYLE="text-align: right">F-1</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: center"><B>PROSPECTUS</B></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>About This Prospectus</TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Where You Can Find More Information</TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Special Note Regarding Forward-Looking Statements</TD>
    <TD STYLE="text-align: right">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>AC Immune SA</TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Risk Factors</TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Ratio of Earnings to Fixed Charges</TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Use of Proceeds</TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Description of Share Capital and Articles of Association</TD>
    <TD STYLE="text-align: right">4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Comparison of Swiss Law and Delaware Law</TD>
    <TD STYLE="text-align: right">14</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Description of Debt Securities</TD>
    <TD STYLE="text-align: right">20</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Description of Warrants</TD>
    <TD STYLE="text-align: right">21</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Description of Purchase Contracts</TD>
    <TD STYLE="text-align: right">22</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Description of Units</TD>
    <TD STYLE="text-align: right">23</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Description of Subscription Rights</TD>
    <TD STYLE="text-align: right">24</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Plan of Distribution</TD>
    <TD STYLE="text-align: right">25</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Incorporation of Certain Information By Reference</TD>
    <TD STYLE="text-align: right">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Enforcement of Judgments</TD>
    <TD STYLE="text-align: right">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Expenses</TD>
    <TD STYLE="text-align: right">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Legal Matters</TD>
    <TD STYLE="text-align: right">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Experts</TD>
    <TD STYLE="text-align: right">27</TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Presentation
of Financial Information</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">Our financial statements incorporated
by reference herein are presented in Swiss Francs and in accordance with International Financial Reporting Standards, or IFRS,
as issued by the International Accounting Standards Board, or IASB. None of the financial statements included in this prospectus
supplement or incorporated by reference herein were prepared in accordance with generally accepted accounting principles in the
United States. The terms &ldquo;dollar,&rdquo; &ldquo;USD&rdquo; or &ldquo;$&rdquo; refer to U.S. dollars and the term &ldquo;Swiss
Franc&rdquo; and &ldquo;CHF&rdquo; refer to the legal currency of Switzerland, unless otherwise indicated. Unless otherwise indicated,
certain Swiss Franc amounts and certain U.S. dollar amounts have been translated into U.S. dollars and Swiss Francs, respectively,
at a rate of USD 0.9738 to CHF 1.00, the official exchange rate quoted as of December 29, 2017 by the U.S. Federal Reserve Bank.
Such Swiss Franc and U.S. dollar amounts are not necessarily indicative of the amounts of U.S. dollars and Swiss Francs, respectively,
that could actually have been purchased upon exchange of the other currency at the dates indicated or any other date, and such
translated amounts have been provided solely for the convenience of the reader. We have made rounding adjustments to some of the
figures included in this prospectus. Accordingly, any numerical discrepancies in any table between totals and sums of the amounts
listed are due to rounding. Our statutory (non-IFRS) financial statements for the year ending December 31, 2017, are included in
this prospectus supplement for information purposes only. Unless explicitly mentioned otherwise herein, all references to our financial
statements in this prospectus supplement are references to our IFRS financial statements exclusively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Trademarks</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">The Company owns various trademark registrations
and applications, and unregistered trademarks, including Morphomer&trade;, SupraAntigen&trade; and its corporate logo. All other
trademarks, trade names and service marks of other companies appearing in this prospectus supplement are the property of their
respective owners. Solely for convenience, the trademarks and trade names in this prospectus supplement may be referred to without
the &copy; and &trade; symbols, but such references should not be construed as any indicator that their respective owners will
not assert, to the fullest extent under applicable law, their rights thereto. The Company does not intend to use or display other
companies&rsquo; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of the Company by, any
other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">About This
Prospectus Supplement</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">This document consists of two parts. The
first part is this prospectus supplement, which describes the specific terms of this offering. The second part is the accompanying
prospectus, which is part of a registration statement that we filed with the SEC using a &ldquo;shelf&rdquo; registration process.
The accompanying prospectus describes more general information, some of which may not apply to this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Before buying any of our securities that
we are offering, we urge you to carefully read both this prospectus supplement and the accompanying prospectus together with all
of the information incorporated by reference herein, as well as the additional information described under the headings &ldquo;Where
You Can Find More Information&rdquo; and &ldquo;Incorporation by Reference.&rdquo; These documents contain important information
that you should consider when making your investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">To the extent there is a conflict between
the information contained in this prospectus supplement, on the one hand, and the information contained in the accompanying prospectus
or in any document incorporated by reference in this prospectus supplement, on the other hand, you should rely on the information
in this prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another
document having a later date&mdash;for example, a document incorporated by reference in this prospectus supplement&mdash;the statement
in the document having the later date modifies or supersedes the earlier statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">You should rely only on the information
contained in or incorporated by reference in this prospectus and any related free writing prospectus filed by us with the SEC.
We have not authorized anyone to provide you with different information. If anyone provides you with different or inconsistent
information, you should not rely on it. This prospectus supplement does not constitute an offer to sell or the solicitation of
an offer to buy any securities other than</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">the securities described in this prospectus supplement or an
offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is
unlawful. You should assume that the information appearing in this prospectus supplement, the documents incorporated by reference
and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results
of operations and prospects may have changed materially since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">You should also read and consider the information
in the documents to which we have referred you in the sections entitled &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation
by Reference&rdquo; in this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Unless otherwise indicated or the context
otherwise requires, all references in this prospectus supplement to &ldquo;AC Immune&rdquo; or the &ldquo;Company,&rdquo; &ldquo;we,&rdquo;
&ldquo;our,&rdquo; &ldquo;ours,&rdquo; &ldquo;us&rdquo; or similar terms refer to AC Immune SA, a Swiss stock corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Special
Note Regarding Forward-Looking Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">This prospectus supplement contains statements
that constitute forward-looking statements. All statements other than statements of historical facts contained in this prospectus
supplement, including statements regarding our future results of operations and financial position, business strategy, product
candidates, product pipeline, ongoing and planned clinical studies, including those of our collaboration partners, regulatory approvals,
research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations
are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act,
and Section 21E of the Exchange Act of 1934, as amended, or the Exchange Act. Many of the forward-looking statements contained
in this prospectus supplement can be identified by the use of forward-looking words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;should,&rdquo; &ldquo;plan,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;will&rdquo; and &ldquo;potential,&rdquo; among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Forward-looking statements appear in a
number of places in this prospectus supplement and include, but are not limited to, statements regarding our intent, belief or
current expectations. Forward-looking statements are based on our management&rsquo;s beliefs and assumptions and on information
currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially
from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those
identified under the section entitled &ldquo;Risk Factors&rdquo; in this prospectus supplement. These risks and uncertainties include
factors relating to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The success of our and our collaboration partners&rsquo; clinical studies, and our and their ability to obtain regulatory approval
and to commercialize crenezumab, our anti-Tau antibody candidate, ACI-24, ACI-35, and our Tau-PET tracer as well as alpha-synuclein-PET
tracer candidate;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The ability of our competitors to discover, develop or commercialize competing products before or more successfully than we
do;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our Morphomer proprietary technology platform and its success in building additional product candidates for our pipeline;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The identification of serious adverse, undesirable or unacceptable side effects related to our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to maintain our current strategic relationships with our collaboration partners;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Failure to protect our, and not infringe on third parties&rsquo;, intellectual property rights throughout the world;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to raise capital when needed in order to continue our product development programs or commercialization efforts;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The Food and Drug Administration&rsquo;s and applicable foreign regulatory authorities&rsquo; acceptance of data from studies
we conduct outside the United States in the future;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our foreign private issuer status, the loss of which would require us to comply with the Exchange Act&rsquo;s domestic reporting
regime and cause us to incur significant legal, accounting and other expenses;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our incorporation in Switzerland, the laws of which govern our corporate affairs and may differ from those applicable to companies
incorporated in the United States; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The other risk factors discussed under &ldquo;Risk Factors.&rdquo;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">These forward-looking statements speak
only as of the date of this prospectus supplement and are subject to a number of risks, uncertainties and assumptions described
under the section in this prospectus supplement entitled &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus supplement.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified
and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events.
The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could
differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New
risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors
and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements
contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 4pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Prospectus
Supplement Summary</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.45pt; text-indent: 22.3pt"><I>This summary highlights selected
information contained elsewhere in this prospectus supplement and the accompanying prospectus and in the documents we incorporate
by reference. This summary does not contain all of the information you should consider before making an investment decision. You
should read this entire prospectus supplement carefully, especially the risks of investing in our common shares discussed under
&ldquo;Risk Factors&rdquo; beginning on page S-9 of this prospectus supplement, along with our consolidated financial statements
and notes to those consolidated financial statements and the other information incorporated by reference in this prospectus supplement.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.45pt; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-align: center"><B>AC Immune SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt"><B>Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a clinical stage biopharmaceutical
company focused on neurodegenerative diseases with five product candidates in clinical trials. We leverage our two proprietary
technology platforms to discover, design and develop novel, proprietary small molecules, antibodies and vaccines for prevention,
diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. Misfolded proteins are generally recognized
as the leading cause of neurodegenerative diseases, such as Alzheimer&rsquo;s disease, or AD, and Parkinson&rsquo;s disease, or
PD, with common mechanisms and drug targets, such as Abeta, Tau, alpha-synuclein and Tar Binding Protein (TDP-43). We believe that
our large and diverse pipeline of nine therapeutic candidates and three diagnostic candidates has the potential to drive a paradigm
shift in the treatment of a broad spectrum of neurodegenerative and other diseases related to protein misfolding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The diagram below summarizes the status
of our research and development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; color: Red"><IMG SRC="image_s1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 4pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Neurodegenerative diseases and other diseases
associated with protein misfolding are prevalent, but there is currently an absence of reliable, early-stage diagnosis and disease-modifying
treatments for these diseases. The growth in the number of people with neurodegenerative diseases has been significant as evidenced
by the prevalence of people affected by AD and PD, two of the most common neurodegenerative diseases. There remains a significant
unmet medical need for reliable and accurate diagnostics to enable early diagnosis and disease-modifying treatments that slow the
progress of neurodegenerative diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have assembled an outstanding management
team with relevant scientific, clinical and regulatory expertise. Our scientific founders, Dr.&nbsp;Jean-Marie Lehn, Dr.&nbsp;Claude
Nicolau, Dr.&nbsp;Roscoe Brady and Dr.&nbsp;Fred van Leuven, are regarded as pioneers in their respective scientific domains, including
in the study of AD. Our co-founder and Chief Executive Officer, Prof.&nbsp;Andrea Pfeifer, a pharmacologist with a Ph.D. in cancer
research and former National Institute of Health researcher, has a 30 year track record in product innovation and implementation
and was formerly head of Nestl&eacute; Global Research and the co-founder of Nestl&eacute; Venture Fund. Our Chief Scientific Officer,
Dr.&nbsp;Andreas Muhs, has more than 20 years of experience in various aspects of discovery research and drug development, including
working on multiple drug development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Our Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our goal is to become a global leader in
precision medicine for the treatment of neurodegenerative diseases. To that aim we are executing a clear business strategy around
three pillars: (i) Alzheimer&rsquo;s disease, (ii) other significant neurodegenerative diseases and neuro-orphan indications, and
(iii) diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The first pillar is Alzheimer&rsquo;s disease,
where we are developing best-in-class late stage assets, preventive or therapeutic vaccines in partnership or as fully owned assets
and where we are working to establish a pipeline of disease modifying small molecules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The second pillar is other non-AD neurodegenerative
diseases and neuro-orphan indications, where we aim to discover therapeutic treatments for Parkinson&rsquo;s disease and leverage
our AD therapeutics in Down syndrome, progressive supranuclear palsy (PSP) and other neuro-orphan diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The third pillar is represented by diagnostics,
where we accelerate the diagnostic pipeline to late stage development and use the diagnostics to improve clinical trials and to
establish external partnerships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Key elements of our strategy continue to
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Advancing our product candidates, in
partnership or alone, from clinical development to regulatory approval and potential commercialization. Our product candidates
include:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B>Crenezumab</B>. Our collaboration partner, Genentech, will advance crenezumab through Phase 3 clinical studies and seek
regulatory approval. We believe that crenezumab&rsquo;s efficacy, coupled with its safety profile, has the potential to become
a best-in-class disease-modifying treatment for AD.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B>ACI-24</B>. We will continue to advance ACI-24 through a Phase 2 clinical study in people with AD. In the first quarter
of 2018, we reported the safety data from our ongoing Phase 1/2a clinical study to evaluate the safety, tolerability, immunogenicity
and biomarker endpoints in people with mild to moderate AD. Our Phase 1b clinical study of ACI-24 in people with Down syndrome
is intended to assess safety and started in December 2015. We expect to present interim data from our Phase 1b clinical study in
2018. We have received the necessary approvals to begin our Phase 2 clinical study in patients with mild Alzheimer&rsquo;s disease
and expect to start screening our first patient in the third quarter of 2018. We own the global rights to ACI-24 and we intend
to continue to develop ACI-24 in-house as a therapeutic candidate.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B>ACI-35</B>. The Phase 1b clinical study delivered encouraging interim results. We and Janssen Pharmaceuticals will move
the anti-Tau vaccine program forward through the next phase of development; this is supported by scientific advice from regulatory
authorities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 4pt; border: Black 1pt solid; width: 98%">

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B>Our Anti-Tau antibody candidate</B>. Our collaboration partner, Genentech, is advancing an anti-Tau antibody candidate through
a Phase 2 clinical study, which started in the fourth quarter of 2017.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B>Diagnostic candidates</B>. In addition to the above product candidates, we will continue to develop our complementary diagnostic
product candidates for Tau, alpha-synuclein and TDP-43 to advance these through clinical development, either independently or with
collaboration partners.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Expanding into other neurodegenerative
and neuro-orphan diseases</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We will continue to leverage our proprietary
technology platforms to develop product candidates that share the same disease targets like misfolded Abeta, Tau, alpha-synuclein
and TDP-43 proteins, which are the key features of many neurodegenerative diseases. We pursue selected neuro-orphan indications,
such as progressive supranuclear palsy (PSP) and Huntington&rsquo;s disease, as well as Tau-related orphan diseases, such as frontotemporal
dementia and corticobasal degeneration. Pursuing neuro-orphan indications may enable us to obtain a streamlined regulatory approval
pathway and favorable reimbursement treatment of any approved products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Accelerating the advancement of our
diagnostic portfolio</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are also developing a complementary
diagnostics portfolio. We currently have three diagnostics candidates in our pipeline that we developed using our Morphomer platform
that targets Tau (enabling study expected in 2018), alpha-synuclein (enabling study expected in the first half of 2018 and lead
selection expected in 2018) and TDP-43 (lead selection expected in 2018). Our Tau-PET imaging agent is currently undergoing Phase
1 studies and we are working with our partner, Piramal Imaging, to advance this product candidate through the clinical development
process. We expect to undertake a longitudinal study of our Tau-PET imaging agent in 2018. We are also developing PET imaging diagnostics
for diseases resulting from the misfolding of alpha-synuclein and TDP-43 proteins. We expect to start the Phase 1 clinical trial
for our alpha-synuclein-PET tracer in the second half of 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are leveraging the duality of our therapeutic
and diagnostic approaches to seek to become the leader in precision treatment of neurodegenerative diseases. The goal of precision
medicine is to deliver optimally targeted and timed interventions tailored to an individual's molecular drivers of disease. The
biggest limitation in neurodegenerative disease management is the lack of appropriate biomarkers and reliable diagnostics for early
disease detection and the absence of approved disease-modifying therapies. We believe that the future treatment paradigm for neurodegenerative
diseases will likely involve early disease diagnosis and combination therapy, leveraging both symptomatic and disease-modifying
treatments, with different disease-modifying treatments used at various points in the progression of the disease. We believe that
our multi-pronged approach to neurodegenerative disease diagnosis and treatment may result in the generation of individualized
treatment options for patients and improve clinical outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Strategically collaborating or selectively
partnering for the development and commercialization of product candidates</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Historically, we have relied on collaboration
agreements with leading pharmaceutical companies to leverage their scientific, development, manufacturing and commercialization
expertise and other resources in order to accelerate the development of our product candidates. To date, we have entered into collaboration
agreements with leading global pharmaceutical companies, including two collaborations with Genentech and one with Janssen, a Johnson&nbsp;&amp;
Johnson company. We believe that these partnerships validate our core strategy of discovering safe and efficacious therapies using
our proprietary platforms and advancing them through the various stages of regulatory approval. In the future, for any approved
products targeting large markets, we may selectively partner with leading companies that we believe can contribute manufacturing
and marketing expertise, geographic reach and other resources and know-how that can enhance the value of these approved products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 4pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">On July 17, 2018, we commenced
the Public Offering of 7,391,305 of our common shares and granted the underwriters in the Public Offering an option for a period
of 30 days from the date of the prospectus supplement for the Public Offering to purchase up to 1,108,695 additional shares from
us at the public offering price of the commons shares offered in the Public Offering, less underwriting discounts and commissions.
Concurrently with the Public Offering, we commenced the Prior Rights Offering to Record Shareholders giving them the opportunity
to subscribe for up to 8,500,000 of the common shares offered in the Public Offering on a <I>pro rata</I> basis at the Offering
Price. The subscription period for the Prior Rights Offering expired at 4:00 p.m. (New York City time) on July 18, 2018. Delivery
of the common shares sold in the Public Offering is expected to be made on or about July 23, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">Our registered and principal executive
offices are located at EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland, our general telephone number is +41 21 345
91 21 and our internet address is www.acimmune.com. The information contained on our website is not a part of this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt"><B>Implications of Being an &ldquo;Emerging Growth
Company&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">We qualify as an &ldquo;emerging
growth company&rdquo; as defined in the Jumpstart our Business Startups Act of 2012, or the JOBS Act. As an emerging growth company,
we may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies.
These provisions include an exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting pursuant to the Section 404 of the Sarbanes-Oxley Act of 2002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">We may take advantage of these
provisions for up to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an
emerging growth company upon the earliest to occur of (i) the last day of the fiscal year in which we have more than $1.07 billion
in annual revenue; (ii) the date we qualify as a &ldquo;large accelerated filer,&rdquo; with at least $700 million of equity securities
held by non-affiliates; (iii) the issuance, in any three-year period, by our company of more than $1.0 billion in non-convertible
debt securities; or (iv) the last day of the fiscal year ending after the fifth anniversary of our initial public offering (2016).
We may choose to take advantage of some but not all of these reduced burdens. For example, Section 107 of the JOBS Act provides
that an emerging growth company can use the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for
complying with new or revised accounting standards. However, given that we currently report and expect to continue to report under
IFRS, we have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new
or revised accounting standards on the relevant dates on which adoption of such standards is required by the IASB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 4pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt"><B>Implications of Being a Foreign Private Issuer
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">We are also considered a &ldquo;foreign
private issuer.&rdquo; Accordingly, we report under the Exchange Act as a non-U.S. company with foreign private issuer status.
This means that, even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer
under the Exchange Act we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public
companies, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security
registered under the Exchange Act;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities
and liability for insiders who profit from trades made in a short period of time; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the rules under the Exchange Act requiring the filing with the Securities and Exchange Commission, or SEC, of quarterly reports
on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence
of specified significant events.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.45pt; text-indent: 22.3pt">Although as a foreign private
issuer we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S.
companies whose securities are registered under the Exchange Act, we report our results of operations voluntarily on a quarterly
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.45pt; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">We may take advantage of these
exemptions until such time as we are no longer a foreign private issuer. We would cease to be a foreign private issuer at such
time as more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances
applies: (i) the majority of our executive officers or directors are U.S. citizens or residents, (ii) more than 50% of our assets
are located in the United States or (iii) our business is administered principally in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 4pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">The Offering</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt"><I>This summary highlights information
presented in greater detail elsewhere in this prospectus supplement. This summary is not complete and does not contain all the
information you should consider before investing in our securities. You should carefully read this entire prospectus supplement
before investing in our securities including &ldquo;Risk Factors&rdquo; and our financial statements included in this prospectus
supplement or incorporated by reference herein.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 42%; padding-left: 2.2pt"><B>Common shares offered by us</B></TD>
    <TD STYLE="width: 58%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the annual general meeting of shareholders held on July 6,
        2018, our shareholders approved an ordinary capital increase of up to 8,500,000 common shares, and an ordinary capital increase
        of up to 1,500,000 common shares to the extent resolutions approved at the extraordinary shareholders&rsquo; meeting held on April
        27, 2018 have not been carried out.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Rights Offering described below will be carried out based
        on the approved capital increase with respect to up to the remaining newly issued 1,500,000 common shares (the &ldquo;Offered Shares&rdquo;).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.2pt"><B>Offered Shares</B></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Offered Shares will have a nominal value of CHF&nbsp;0.02
        each. We will issue the Offered Shares in an ordinary share capital increase against cash contributions. The Offered Shares will
        be fully fungible and rank <I>pari passu</I> in all respects with each other and with all of our existing shares.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Offered Shares will be issued as uncertificated securities
        (<I>droits-valeurs</I>, within the meaning of Article 973c of the Swiss Code of Obligations) and, when administered by a financial
        intermediary (<I>d&eacute;positaire</I>, within the meaning of the Federal Act on Intermediated Securities, &ldquo;FISA&rdquo;),
        qualify as intermediated securities (<I>titres interm&eacute;di&eacute;s</I>, within the meaning of the FISA). The Offered Shares
        will be registered in the Company&rsquo;s non-public register of uncertificated securities (<I>registre des droits-valeurs</I>).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.2pt"><B>Rights Offering</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.2pt">&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under Swiss law and pursuant to the resolution approved at the
        annual general meeting of shareholders held on July 6, 2018, our existing shareholders are entitled to statutory pre-emptive subscription
        rights to subscribe for any new issuance of common shares and, thus, the Offered Shares, in proportion to their existing shareholdings.
        As a result, we are offering pre-emptive subscription rights to our Record Shareholders, who will have the opportunity to subscribe
        for up to 1,500,000 Offered Shares on a <I>pro rata</I> basis at the Offering Price. The subscription rights are not transferrable. You may not sell, transfer, assign or give away your subscription rights.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See &ldquo;Subscription Rights Offering&rdquo; for more information.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.2pt; padding-right: 5pt"><B>Common shares to be outstanding immediately after this offering</B></TD>
    <TD>66,253,995 common shares. </TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</DIV>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 4pt; border: Black 1pt solid; width: 98%">

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 41%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.2pt"><B>Allocation of rights under the </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.2pt"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.2pt"><B>Rights Offering and subscription ratio</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.2pt">&nbsp;</P></TD>
    <TD STYLE="width: 59%; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Each Record Shareholder will be entitled to one pre-emptive subscription right for each existing common share held by such Record Shareholder on the Record Date, and may subscribe for one Offered Share for every 38.24 pre-emptive subscription rights held by such Record Shareholder in the Rights Offering. Record Shareholders who fully exercise their pre-emptive subscription rights during the subscription period will also have the option of subscribing for additional common shares unclaimed by other Record Shareholders in the Rights Offering at the same Offering Price. See &ldquo;Subscription Rights Offering&rdquo; for more information.</P>
                                            <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.2pt; font-size: 10pt"><B>Subscription period for the Rights Offering</B></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The subscription period for Record Shareholders to exercise
        their pre-emptive subscription rights to acquire Offered Shares pursuant to the Rights Offering will begin concurrently with the
        Public Offering at 3:00 a.m. (New York City time) on July 20, 2018 and will expire at 4:00 p.m. (New York City time) on July 27,
        2018.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each exercise of pre-emptive subscription rights in the Rights
        Offering will be effective at the Offering Price, will be irrevocable and may not be cancelled, modified, rescinded or withdrawn.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.2pt; font-size: 10pt"><B>Subscription price</B></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Offering Price is $11.75 per common share. The Offering
        Price was determined by us and the underwriters in connection with the Public Offering after the close of trading on The Nasdaq
        Global Market on July 18, 2018, on the basis of the number of common shares for which pre-emptive subscription rights were exercised
        in the Prior Rights Offering, investor demand resulting from an accelerated book-building procedure, the price on The Nasdaq Global
        Market for our existing common shares and prevailing market conditions.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.2pt; font-size: 10pt"><B>No fractional common shares</B></TD>
    <TD STYLE="font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">We will accept subscriptions for whole Offered Shares only and will round down any subscription submitted for fractional Offered Shares to the nearest whole number of Offered Shares.</P>
                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.2pt; font-size: 10pt"><B>No rights trading</B></TD>
    <TD STYLE="font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">The pre-emptive subscription rights will not be listed on any securities exchange or tradeable.</P>
                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.2pt; font-size: 10pt"><B>Use of unsubscribed common shares</B></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the expiration of the subscription period of the Rights Offering,
        the Company will issue up to 1,500,000 common shares. Any pre-emptive subscription rights that have not been validly exercised
        during the subscription period of the Rights Offering will expire and become null and void without compensation. Any Offered Shares
        not subscribed for will be available for allocation by the Board of Directors at its discretion in first priority to current shareholders
        and in second priority to institutional investors in a private placement.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</DIV>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 4pt; border: Black 1pt solid; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 41%; padding-left: 2.2pt"><B>Issuance and delivery of new common shares</B></TD>
    <TD STYLE="width: 59%"><P STYLE="margin-top: 0; margin-bottom: 0">After expiration of the subscription period, the Offered Shares which have been validly subscribed and paid for in accordance with the terms of the Rights Offering will be, upon registration of the corresponding share capital increase into the Commercial Register of the Canton of Vaud, validly issued. The delivery of Offered Shares shall be carried out by Computershare Trust Company, N.A. acting as transfer agent and registrar for our common shares.</P>
                           <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.2pt"><B>Use of Proceeds</B></TD>
    <TD><P STYLE="margin-top: 0; margin-bottom: 0">We estimate that the net proceeds to us from this offering will be approximately $17.6 million, after deducting estimated offering expenses payable by us. We intend to use the net proceeds from this offering, together with our other cash resources, primarily to fund research and development expenses for our clinical and pre-clinical research and development activities and for working capital and general corporate purposes. See &ldquo;Use of Proceeds.&rdquo;</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.2pt"><B>Risk Factors</B></TD>
    <TD><P STYLE="margin-top: 0; margin-bottom: 0">You should read the &ldquo;Risk Factors&rdquo; section of this prospectus supplement for a discussion of factors to consider carefully before deciding to purchase our securities.</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 2.2pt"><B>Nasdaq Global Market Symbol</B></TD>
    <TD>&ldquo;ACIU&rdquo;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">As of the date of this prospectus
supplement and including our ongoing registration of 8,500,000 common shares in connection with the Public Offering, our issued
share capital registered in the commercial register of the Canton of Vaud is CHF 1,317,253.80, consisting of 65,862,690 common
shares with a nominal value of CHF&nbsp;0.02 each. The number of our common shares to be outstanding immediately after this offering
is based on 57,362,690 common shares outstanding as of March 31, 2018, but excludes 1,594,943 of our common shares issuable upon
the exercise of options, non-vested restricted shares and non-vested restricted share units outstanding under our existing equity
incentive plans at a weighted-average exercise price of CHF 3.52 per common share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">Unless otherwise indicated, all
information contained in this prospectus also reflects and assumes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.1pt; text-indent: 22pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the issuance of 8,500,000 common shares, of which 7,391,305 common shares will be sold in the Public Offering and the Prior
Rights Offering and 1,108,695 were reserved for possible issuance upon exercise of the option granted to the underwriters in the
Public Offering to purchase up to such number of shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>no exercise of the option granted to the underwriters in the Public Offering to purchase up to an additional 1,108,695 of our
common shares at the Offering Price, less underwriting discounts and commissions; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>exercise in full of the subscription rights offered to existing shareholders pursuant to the Rights Offering described above.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

</DIV>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Risk Factors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt"><I>You should carefully consider the risks
and uncertainties described below and the other information in this prospectus supplement before making an investment in our securities.
Our business, financial condition or results of operations could be materially and adversely affected if any of these risks occurs,
and as a result, the market price of our common shares could decline and you could lose all or part of your investment. This prospectus
supplement also contains forward-looking statements that involve risks and uncertainties. See &ldquo;Special Note Regarding Forward-Looking
Statements.&rdquo; Our actual results could differ materially and adversely from those anticipated in these forward-looking statements
as a result of certain factors.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt"><I>For a discussion of additional risks
related to our business, our relationship with third parties, our intellectual property, our financial condition and capital requirements,
or our regulatory environment, see the section titled &ldquo;Risk Factors&rdquo; in our Annual Report on Form 20-F for the fiscal
year ended December 31, 2017, and our other filings with the Securities and Exchange Commission that are also incorporated by reference
into this prospectus supplement.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Common Shares and the Rights Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>If you subscribe for Offered Shares in the
Rights Offering such subscription will be binding and irrevocable and may be different, perhaps materially, than the price of our
common shares on The Nasdaq Global Market.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Offering Price was determined by us
and the underwriters in connection with the Public Offering after the close of trading on The Nasdaq Global Market on July 18,
2018, on the basis of the number of common shares for which pre-emptive subscription rights were exercised in the Prior Rights
Offering, investor demand resulting from an accelerated book-building procedure, the price on The Nasdaq Global Market for our
existing common shares and prevailing market conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Subscriptions for Offered Shares pursuant
to the exercise of the pre-emptive subscription rights in the Rights Offering will be binding and irrevocable and the Offering
Price may be different, perhaps materially, than the price of the Company&rsquo;s common shares on The Nasdaq Global Market at
the time of delivery of such Offered Shares. The Company cannot assure Record Shareholders that the price on The Nasdaq Global
Market will not decline below the Offering Price and that, following the exercise of the pre-emptive subscription rights in the
Rights Offering, shareholders will be able to sell the Offered Shares at a price equal to or greater than the Offering Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>If you fail to exercise your pre-emptive subscription
rights, your pre-emptive subscription rights will lapse without compensation and result in dilution of your shareholding.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The pre-emptive subscription rights of
Record Shareholders who fail to exercise their pre-emptive subscription rights prior to the end of the subscription period will
expire and become null and void, and Record Shareholders will not receive any compensation for them. The proportionate ownership
and voting interest in our Company of Record Shareholders who fail (or are unable) to exercise their pre-emptive subscription rights
will be diluted. We will receive the net proceeds of any sale of Offered Shares in respect of which any Record Shareholder does
not validly exercise its rights. Even if a Record Shareholder timely exercises its pre-emptive subscriptions rights, such Record
Shareholder and its broker will be responsible for complying with the requirements set by the Company in order to have such rights
honored.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Because shareholders&rsquo; resolutions regarding
a capital increase may be challenged, it is not certain that the share capital increase in connection with the offering will occur
when anticipated. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The issuance of the Offered Shares requires
registration of the share capital increase with the commercial register of the Canton of Vaud. The Rights Offering is based upon
the resolution regarding an ordinary capital increase that was approved at the annual general meeting held on July 6, 2018. All
shareholders&rsquo; resolutions of Swiss corporations are subject to a possible challenge pursuant to articles 706 and 706a of
the Swiss Code of Obligations. The right to challenge lapses if the action is not brought within two months of the shareholders&rsquo;
meeting. In connection with such a challenge, the registration of the capital increase in the commercial register may be blocked
and therefore prevent or delay the completion of an offering such as the Rights Offering, including a delay in the settlement.
Therefore, although the resolution of the shareholders to increase the share capital is scheduled to be registered with the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">commercial register in a timely manner, such registration may,
for reasons beyond our control, not take place in time to enable the Offered Shares to be traded on a timely basis. Consequently,
investors may suffer losses, in particular, if they entered into short selling transactions and are unable to meet their obligations
to deliver Offered Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Shareholders may not be able to exercise pre-emptive
subscription rights.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under laws and regulations of jurisdictions
outside Switzerland, including the European Economic Area, Record Shareholders in those jurisdictions may not be able to exercise
or sell their pre-emptive subscription rights unless we take action to register or otherwise qualify the Rights Offering under
the laws of that jurisdiction. If Record Shareholders in such jurisdictions are unable to exercise or sell their pre-emptive subscription
rights, their ownership interest in us would be diluted. Furthermore, the short subscription period may create a logistical challenge
for Record Shareholders to exercise their statutory pre-emptive subscription rights. Furthermore, the Company may withdraw, cancel
or modify any orders of a Record Shareholder who has elected to participate in the Rights Offering if such Record Shareholder,
or its bank, broker or other intermediary, respectively, does not have a brokerage account which prevents the ability of the Company
to timely verify the eligibility of such Record Shareholder or to execute the order from such Record Shareholder. The pre-emptive
subscription rights of any Record Shareholder that is not permitted or unable to exercise such rights during the subscription period
will expire and become null and void, and such Record Shareholder will not receive any compensation in respect of any such unexercised
or invalid rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>The price of our common shares may be volatile
and may fluctuate due to factors beyond our control.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The share prices of publicly traded emerging
biopharmaceutical and drug discovery and development companies have been highly volatile and are likely to remain highly volatile
in the future. The market price of our common shares may fluctuate significantly due to a variety of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>positive or negative results of testing and clinical studies by us, strategic partners, or competitors;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>delays in entering into strategic relationships with respect to development and/or commercialization of our product candidates or entry into strategic relationships on terms that are not deemed to be favorable to us;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>technological innovations or commercial product introductions by us or competitors;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>changes in government regulations;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>developments concerning proprietary rights, including patents and litigation matters;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>public concern relating to the commercial value or safety of any of our product candidates;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>financing or other corporate transactions;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>publication of research reports or comments by securities or industry analysts;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>general market conditions in the pharmaceutical industry or in the economy as a whole; or</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>other events and factors beyond our control.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Broad market and industry factors may materially
affect the market price of companies&rsquo; stock, including ours, regardless of actual operating performance. Furthermore, issuers
such as ourselves whose securities have historically had limited trading volumes and/or have been susceptible to relatively high
volatility levels can be particularly vulnerable to short seller attacks and trading in our common shares by non-fundamental investors
such as hedge funds and others who may enter and exit positions in our common shares frequently and suddenly, causing increased
volatility of our share price. Short selling is the practice of selling securities that the seller does not own but rather has
borrowed or intends to borrow from a third party with the intention of buying identical securities at a later date to return to
the lender, and profit from a decline in the value of the securities in the process. The publication of any commentary by short
sellers with the intent of creating negative market momentum may bring about a temporary, or possibly long term, decline in the
market price of our common stock.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>There is only a limited free float of our common
shares; this may have a negative impact on the liquidity of and the market price for our common shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of the date hereof, shareholders reported
as each controlling 5% or more of our common shares will, in the aggregate, hold approximately 51.3%<SUP></SUP> of our common
shares. The limited free float may have a negative impact on the liquidity of our common shares and result in a low trading volume
of our common shares, which could adversely affect the price of our common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Certain of our existing shareholders exercise
significant control over us, and your interests may conflict with the interests of our existing shareholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of March 31, 2018, certain principal
shareholders as well as our executive officers and directors together beneficially owned approximately 60.5% of our common shares.
Depending on the level of attendance at our general meetings of shareholders, these shareholders may be in a position to determine
the outcome of decisions taken at any such general meeting. To the extent that the interests of these shareholders may differ from
the interests of the company&rsquo;s other shareholders, the latter may be disadvantaged by any action that these shareholders
may seek to pursue. Among other consequences, this concentration of ownership may have the effect of delaying or preventing a change
in control and might therefore negatively affect the market price of our common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Future sales, or the possibility of future
sales, of a substantial number of our common shares could adversely affect the price of our common shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Future sales of a substantial number of
our common shares, or the perception that such sales will occur, could cause a decline in the market price of our common shares.
If certain of our shareholders sell substantial amounts of common shares in the public market, or the market perceives that such
sales may occur, the market price of our common shares and our ability to raise capital through an issue of equity securities in
the future could be adversely affected. We also entered into a registration rights agreement in connection with the Series E Private
Placement with certain investors in the Series E Private Placement pursuant to which we agreed under certain circumstances to file
a registration statement to register the resale of the common shares held by certain of our existing shareholders, as well as to
cooperate in certain public offerings of such common shares. We will be required to file an amendment to our registration statement
on Form F-3 on or prior to August 27, 2018 to register up to 18,041,000 common shares held by one of our shareholders pursuant
to these rights. In addition, we have adopted a new omnibus equity incentive plan under which we have the discretion to grant a
broad range of equity-based awards to eligible participants. These shares were registered pursuant to the registration statement
on Form S-8 that we filed with SEC and, therefore, can be freely sold in the public market upon issuance, subject to volume limitations
applicable to affiliates. If a large number of our common shares or securities convertible into our common shares are sold in the
public market after they become eligible for sale, the sales could reduce the trading price of our common shares and impede our
ability to raise future capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>If you purchase common shares in
this offering, you will suffer immediate dilution of your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The Offering Price  is substantially
higher than the as adjusted net tangible book value per common share. Therefore, if you purchase common shares in this offering,
you will pay a price per common share that substantially exceeds our as adjusted net tangible book value per common share after
this offering. You will experience immediate dilution of $8.59 (CHF&nbsp;8.19) per common share, representing the difference
between our as adjusted net tangible book value per common share after giving effect to this offering and the Offering Price. To
the extent outstanding options or warrants are exercised, you will incur further dilution. See &ldquo;Dilution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We have broad discretion in the use of our
cash and cash equivalents and may not use them effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our management will have broad discretion
in the application of our cash and cash equivalents. Our decisions concerning the allocation of research, development, collaboration,
management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of
any viable commercial product and may divert resources away from better opportunities. If we make incorrect determinations regarding
the viability or market potential of any of our programs or product candidates or misread trends in the biopharmaceutical industry,
in particular for neurodegenerative diseases, our business, financial condition and results of operations could be materially adversely
affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required
to forego or delay pursuit of opportunities with other product candidates or other diseases</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and disease pathways that may later prove to have greater commercial
potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing
or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain
sole development and commercialization rights. We regularly review the designation of each program as core or seed, and terminate
those programs which do not meet our development criteria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>We do not expect to pay dividends
in the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have not paid any dividends since our
incorporation. Even if future operations lead to significant levels of distributable profits, we currently intend that any earnings
will be reinvested in our business and that dividends will not be paid until we have an established revenue stream to support continuing
dividends. Under our articles of association, the declaration of dividends requires a resolution passed by a simple majority of
the votes cast at a shareholders&rsquo; meeting regardless of abstentions and empty or invalid votes. The proposal to pay future
dividends to shareholders will in addition effectively be at the discretion of our board of directors after taking into account
various factors including our business prospects, cash requirements, financial performance and new product development. In addition,
payment of future dividends is subject to certain limitation pursuant to Swiss law or by our articles of association. Accordingly,
investors cannot rely on dividend income from our common shares and any returns on an investment in our common shares will likely
depend entirely upon any future appreciation in the price of our common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We are a Swiss corporation. The rights of our
shareholders may be different from the rights of shareholders in companies governed by the laws of U.S. jurisdictions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a Swiss corporation. Our corporate
affairs are governed by our articles of association and by the laws governing companies, including listed companies, incorporated
in Switzerland. The rights of our shareholders and the responsibilities of members of our board of directors may be different from
the rights and obligations of shareholders and directors of companies governed by the laws of U.S. jurisdictions. In the performance
of its duties, our board of directors is required by Swiss law to consider the interests of our Company, our shareholders, our
employees and other stakeholders, in all cases with due observation of the principles of reasonableness and fairness. It is possible
that some of these parties will have interests that are different from, or in addition to, your interests as a shareholder. Swiss
corporate law limits the ability of our shareholders to challenge resolutions made or other actions taken by our board of directors
in court. Our shareholders generally are not permitted to file a suit to reverse a decision or an action taken by our board of
directors but are instead only permitted to seek damages for breaches of fiduciary duty. As a matter of Swiss law, shareholder
claims against a member of our board of directors for breach of fiduciary duty would have to be brought in Lausanne, Switzerland,
or where the relevant member of our board of directors is domiciled. In addition, under Swiss law, any claims by our shareholders
against us must be brought exclusively in Lausanne, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Our common shares are issued under the laws
of Switzerland, which may not protect investors in a similar fashion afforded by incorporation in a U.S. state.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are organized under the laws of Switzerland.
There can be no assurance that Swiss law will not change in the future or that it will serve to protect investors in a similar
fashion afforded under corporate law principles in the U.S., which could adversely affect the rights of investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Our status as a Swiss corporation may limit
our flexibility with respect to certain aspects of capital management and may cause us to be unable to make distributions without
subjecting our shareholders to Swiss withholding tax.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Swiss law allows our shareholders to authorize
share capital that can be issued by the board of directors without additional shareholder approval. This authorization is limited
to 50% of the existing registered share capital and must be renewed by the shareholders every two years. Additionally, subject
to specified exceptions, Swiss law grants pre-emptive subscription rights to existing shareholders to subscribe to any new issuance
of shares. Any ordinary share capital increase resolution preserving pre-emptive subscription rights requires a simple majority
of the votes cast at the shareholders&rsquo; meeting regardless of abstentions and empty or invalid votes and shall be implemented
within three months. Swiss law also does not provide as much flexibility in the various terms that can attach to different classes
of shares as the laws of some other jurisdictions. Swiss law also reserves for approval by shareholders certain corporate actions
over which a board of directors would have authority in some other jurisdictions. For example,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">dividends must be approved by shareholders. These Swiss law
requirements relating to our capital management may limit our flexibility, and situations may arise where greater flexibility would
have provided substantial benefits to our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under Swiss law, a Swiss corporation may
pay dividends only if the corporation has sufficient distributable profits from previous fiscal years, or if the corporation has
distributable reserves, each as evidenced by its audited statutory balance sheet. Freely distributable reserves are generally booked
either as &ldquo;free reserves&rdquo; or as &ldquo;capital contributions&rdquo; (<I>apports de capital</I>, contributions received
from shareholders) in the &ldquo;reserve from capital contributions.&rdquo; Distributions may be made out of issued share capital&mdash;the
aggregate nominal value of a company&rsquo;s issued shares&mdash;only by way of a capital reduction. As of December 31, 2017, the
Company has CHF 179.4 million of reserves from capital contributions and CHF 1,146,983.80 of issued share capital (consisting of
57,349,190 common shares each with a nominal value of CHF 0.02 and no preferred shares) on its audited statutory balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expect the aggregate of these amounts
(less the lowest legally possible issued share capital and legal reserve of together CHF 150,000) to represent the amount available
for future dividends or capital reductions on a Swiss withholding tax-free basis. We will not be able to pay dividends or make
other distributions to shareholders on a Swiss withholding tax-free basis in excess of that amount unless the Company increases
its share capital or its reserves from capital contributions. We would also be able to pay dividends out of distributable profits
or freely distributable reserves but such dividends would be subject to Swiss withholding taxes. There can be no assurance that
we will have sufficient distributable profits, free reserves, reserves from capital contributions or registered share capital to
pay a dividend or effect a capital reduction, that our shareholders will approve dividends or capital reductions proposed by us,
or that we will be able to meet the other legal requirements for dividend payments or distributions as a result of capital reductions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Generally, Swiss withholding tax of 35%
is due on dividends and similar distributions to our shareholders, regardless of the place of residency of the shareholder, unless
the distribution is made to shareholders out of (i)&nbsp;a reduction of nominal value or (ii)&nbsp;assuming certain conditions
are met, reserves from capital contributions accumulated on or after January&nbsp;1, 1997. A U.S. holder that qualifies for benefits
under the Convention between the United States of America and the Swiss Confederation for the Avoidance of Double Taxation with
Respect to Taxes on Income, which we refer to as the &ldquo;U.S.-Swiss Treaty,&rdquo; may apply for a refund of the tax withheld
in excess of the 15% treaty rate (or in excess of the 5% reduced treaty rate for qualifying corporate shareholders with at least
10% participation in our voting stock, or for a full refund in the case of qualified pension funds). There can be no assurance
that we will have sufficient reserves from capital contributions to pay dividends free from Swiss withholding tax, or that Swiss
withholding tax rules will not be changed in the future. In addition, we cannot provide assurance that the current Swiss law with
respect to distributions out of reserves from capital contributions will not be changed or that a change in Swiss law will not
adversely affect us or our shareholders, in particular as a result of distributions out of reserves from capital contributions
becoming subject to additional corporate law, tax law or other restrictions. In addition, over the long term, the amount of par
value available to us for nominal value reductions or reserves from capital contributions available to us to pay out as distributions
is limited. If we are unable to make a distribution through a reduction in nominal value or out of reserves from capital contributions,
we may not be able to make distributions without subjecting our shareholders to Swiss withholding taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under present Swiss tax laws, repurchases
of shares for the purposes of cancellation are treated as a partial liquidation subject to 35% Swiss withholding tax on the difference
between the repurchase price and the nominal value of the shares except, since January&nbsp;1, 2011, to the extent attributable
to reserves from capital contributions (<I>apports de capital</I>) if any, and to the extent that, the repurchase of shares is
out of retained earnings or other taxable reserves. No partial liquidation treatment applies and no withholding tax is triggered
if the shares are not repurchased for cancellation but held by the Company as treasury shares. However, should Company not resell
such treasury shares within six years, the withholding tax becomes due at the end of the six year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>U.S. shareholders may not be able to obtain
judgments or enforce civil liabilities against us or our executive officers or members of our board of directors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are organized under the laws of Switzerland
and our registered office and domicile is located in Ecublens, near Lausanne, Switzerland. Moreover, a number of our directors
and executive officers and a number of directors of each of our subsidiaries are not residents of the United States, and all or
a substantial portion of the assets of such persons are located outside the United States. As a result, it may not be possible
for investors to effect service of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">process within the United States upon us or upon such persons
or to enforce against them judgments obtained in U.S. courts, including judgments in actions predicated upon the civil liability
provisions of the federal securities laws of the United States. We have been advised by our Swiss counsel that there is doubt as
to the enforceability in Switzerland of original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities
to the extent solely predicated upon the federal and state securities laws of the United States. Original actions against persons
in Switzerland based solely upon the U.S. federal or state securities laws are governed, among other things, by the principles
set forth in the Swiss Federal Act on Private International Law. This statute provides that the application of provisions of non-Swiss
law by the courts in Switzerland shall be precluded if the result is incompatible with Swiss public policy. Also, certain mandatory
provisions of Swiss law may be applicable regardless of any other law that would otherwise apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Switzerland and the United States do not
have a treaty providing for reciprocal recognition and enforcement of judgments in civil and commercial matters. The recognition
and enforcement of a judgment of the courts of the United States in Switzerland is governed by the principles set forth in the
Swiss Federal Act on Private International Law. This statute provides in principle that a judgment rendered by a non-Swiss court
may be enforced in Switzerland only if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>the non-Swiss court had jurisdiction pursuant to the Swiss Federal Act on Private International Law;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>the judgment of such non-Swiss court has become final and non-appealable;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>the judgment does not contravene Swiss public policy;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>the court procedures and the service of documents leading to the judgment were in accordance with the due process of law; and</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>no proceeding involving the same parties and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland, or was earlier adjudicated in a third state and this decision is recognizable in Switzerland.</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Our status as a Swiss corporation means that
our shareholders enjoy certain rights that may limit our flexibility to raise capital, issue dividends and otherwise manage ongoing
capital needs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Swiss law reserves for approval by shareholders
certain corporate actions over which a board of directors would have authority in some other jurisdictions. For example, the payment
of dividends and cancellation of treasury shares must be approved by shareholders. Swiss law also requires that our shareholders
themselves resolve to, or authorize our board of directors to, increase our share capital. While our shareholders may authorize
share capital that can be issued by our board of directors without additional shareholder approval, Swiss law limits this authorization
to 50% of the issued share capital at the time of the authorization. The authorization, furthermore, has a limited duration of
up to two years and must be renewed by the shareholders from time to time thereafter in order to be available for raising capital.
Additionally, subject to specified exceptions, including exceptions explicitly described in our articles of association, Swiss
law grants pre-emptive subscription rights to existing shareholders to subscribe for new issuances of shares. Swiss law also does
not provide as much flexibility in the various rights and regulations that can attach to different categories of shares as do the
laws of some other jurisdictions. These Swiss law requirements relating to our capital management may limit our flexibility, and
situations may arise where greater flexibility would have provided benefits to our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Swiss law restricts our ability to pay dividends.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The proposal to pay future dividends to
shareholders will effectively be at the discretion of our board of directors and subject to approval by, in their discretion, our
shareholders after taking into account various factors including our business prospects, cash requirements, financial performance
and new product development. In addition, payment of future dividends is subject to certain limitation pursuant to Swiss law or
by our articles of association. Accordingly, investors cannot rely on dividend income from our common shares and any returns on
an investment in our common shares will likely depend entirely upon any future appreciation in the price of our common shares.
Dividends paid on our common shares are subject to Swiss Federal withholding tax, except if paid out of reserves from capital</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">contributions (<I>apports de capital</I>). See &ldquo;Tax Considerations&mdash;Swiss
Tax Considerations&rdquo; for a summary of certain Swiss tax consequences regarding dividends distributed to holders of our common
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Shareholders in countries with a currency other
than Swiss Francs face additional investment risks from currency exchange rate fluctuations in connection with their holding of
our common shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any future payments of dividends, if any,
will likely be denominated in Swiss Francs. The foreign currency equivalent of any dividend, if any, paid on our common shares
or received in connection with any sale of our common shares could be adversely affected by the depreciation of the Swiss Francs
against such other currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We are a foreign private issuer and, as a result,
we are not be subject to U.S. proxy rules and are subject to Exchange Act reporting obligations that, to some extent, are more
lenient and less frequent than those of a U.S. domestic public company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are reporting under the Exchange Act
as a non-U.S. company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act
and although we are subject to Swiss laws and regulations with regard to such matters and intend to furnish quarterly financial
information to the SEC, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies,
including (i)&nbsp;the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect
of a security registered under the Exchange Act; (ii)&nbsp;the sections of the Exchange Act requiring insiders to file public reports
of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time;
and (iii)&nbsp;the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing
unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant
events. In addition, foreign private issuers are not required to file their annual report on Form 20-F until four months after
the end of each financial year, while U.S. domestic issuers that are accelerated filers are required to file their annual report
on Form 10-K within 75 days after the end of each fiscal year. Foreign private issuers are also exempt from the Regulation Fair
Disclosure, aimed at preventing issuers from making selective disclosures of material information. As a result of the above, you
may not have the same protections afforded to shareholders of companies that are not foreign private issuers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>As a foreign private issuer and as permitted
by the listing requirements of Nasdaq, we rely on certain home country governance practices rather than the corporate governance
requirements of Nasdaq.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a foreign private issuer. As a result,
in accordance with Nasdaq Listing Rule 5615(a)(3), we comply with home country governance requirements and certain exemptions thereunder
rather than complying with certain of the corporate governance requirements of Nasdaq. Swiss law does not require that a majority
of our board of directors consist of independent directors. Our board of directors therefore may include fewer independent directors
than would be required if we were subject to Nasdaq Listing Rule 5605(b)(1). In addition, we are not subject to Nasdaq Listing
Rule 5605(b)(2), which requires that independent directors regularly have scheduled meetings at which only independent directors
are present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Although Swiss law also requires that we
adopt a compensation committee, we follow home country requirements with respect to such committee and our compensation, nomination
and governance committee is tasked with certain director nomination and governance responsibilities. As a result, our practice
varies from the requirements of Nasdaq Listing Rule 5605(d), which sets forth certain requirements as to the responsibilities,
composition and independence of compensation committees, and from the independent director oversight of director nominations requirements
of Nasdaq Listing Rule 5605(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Furthermore, in accordance with Swiss law
and generally accepted business practices, our articles of association do not provide quorum requirements generally applicable
to general meetings of shareholders. Our practice thus varies from the requirement of Nasdaq Listing Rule 5620(c), which requires
an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the
outstanding voting stock. Our articles of association provide for an independent proxy holder elected by our shareholders, who
may represent our shareholders at a general meeting of shareholders, and we must provide shareholders with an agenda and other
relevant documents for the general meeting of shareholders. However, Swiss law does not have a regulatory regime for the solicitation
of proxies and company solicitation of proxies is prohibited for public companies in Switzerland, thus our practice varies from
the requirement of Nasdaq Listing Rule 5620(b), which sets forth certain requirements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">regarding the solicitation of proxies. In addition, we have
opted out of shareholder approval requirements for the issuance of securities in connection with certain events such as the acquisition
of stock or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a change
of control of us and certain private placements. To this extent, our practice varies from the requirements of Nasdaq Listing Rule
5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in connection with such
events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As a result of the above, you may not have
the same protections afforded to shareholders of companies that are not foreign private issuers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We may lose our foreign private issuer status,
which would then require us to comply with the Exchange Act&rsquo;s domestic reporting regime and cause us to incur significant
legal, accounting and other expenses.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a foreign private issuer and therefore
we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable
to U.S. domestic issuers. We may no longer be a foreign private issuer as of June&nbsp;30, 2019 (or the end of our second fiscal
quarter in any subsequent fiscal year), which would require us to comply with all of the periodic disclosure and current reporting
requirements of the Exchange Act applicable to U.S. domestic issuers as of January&nbsp;1, 2019 (or the first day of the fiscal
year immediately succeeding the end of such second quarter). In order to maintain our current status as a foreign private issuer,
either (a)&nbsp;a majority of our common shares must be either directly or indirectly owned of record by non-residents of the United
States or (b)(i) a majority of our executive officers or directors may not be United States citizens or residents, (ii)&nbsp;more
than 50 percent of our assets cannot be located in the United States and (iii)&nbsp;our business must be administered principally
outside the United States. If we lost this status, we would be required to comply with the Exchange Act reporting and other requirements
applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We
may also be required to make changes in our corporate governance practices in accordance with various SEC and stock exchange rules.
The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements
applicable to a U.S. domestic issuer may be significantly higher than the cost we would incur as a foreign private issuer. As a
result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would
make some activities highly time consuming and costly. We also expect that if we were required to comply with the rules and regulations
applicable to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director and officer liability
insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules
and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>We are an &ldquo;emerging growth company,&rdquo;
and we cannot be certain if the reduced reporting requirements applicable to &ldquo;emerging growth companies&rdquo; will make
our common shares less attractive to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are an &ldquo;emerging growth company,&rdquo;
as defined in the Jumpstart our Business Startups Act of 2012, or the JOBS Act. For as long as we continue to be an &ldquo;emerging
growth company,&rdquo; we may take advantage of exemptions from various reporting requirements that are applicable to other public
companies that are not &ldquo;emerging growth companies,&rdquo; including not being required to comply with the auditor attestation
requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, exemptions from the requirements of holding a nonbinding advisory
vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We could be an
&ldquo;emerging growth company&rdquo; until the end of our fiscal year 2021, although circumstances could cause us to lose that
status earlier, including if the market value of our common shares held by non-affiliates exceeds $700 million as of any June&nbsp;30
(the end of our second fiscal quarter) before the end of our fiscal year 2021, in which case we would no longer be an &ldquo;emerging
growth company&rdquo; as of the following December&nbsp;31 (our fiscal year end). We cannot predict if investors will find our
common shares less attractive because we may rely on these exemptions. If some investors find our common shares less attractive
as a result, there may be a less active trading market for our common shares and the price of our common shares may be more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>As a result of being a public company we incur
additional costs and we may not manage to comply with our internal control procedures and corporate governance structures.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As a public company, we incur additional
legal, insurance, accounting and other expenses that we did not incur as a private company. For example, as a public company, we
needed to adopt additional internal controls and disclosure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">controls and procedures and bear all of the internal and external
costs of preparing and distributing periodic public reports in compliance with our obligation under the securities laws. However,
if our efforts to comply with evolving laws, regulations and standards differ from the activities intended by regulatory or governing
bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us. This could have
a material adverse impact on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>If we fail to maintain an effective system
of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As
a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the
trading price of our common shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Effective internal controls over financial
reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures,
are designed to prevent fraud among other objectives. Any failure to implement required new or improved controls, or difficulties
encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted
in connection with Section 404 of the Sarbanes-Oxley Act of 2002, or any subsequent testing by our independent registered public
accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses
or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention
or improvement. Inferior internal controls could also subject us to regulatory scrutiny and sanctions, impair our ability to raise
revenue and cause investors to lose confidence in our reported financial information, which could have a negative effect on the
trading price of our common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are required to disclose changes made
in our internal controls and procedures and our management is required to assess the effectiveness of these controls annually.
However, for as long as we are an &ldquo;emerging growth company&rdquo; under the JOBS Act, our independent registered public accounting
firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section
404. We could be an &ldquo;emerging growth company&rdquo; until the end of our fiscal year 2021. An independent assessment of the
effectiveness of our internal controls could detect problems that our management&rsquo;s assessment might not. Undetected material
weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>If securities or industry analysts do not publish
research, or publish inaccurate or unfavorable research, about our business, the price of our common shares and our trading volume
could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The trading market for our common shares
will depend in part on the research and reports that securities or industry analysts publish about us or our business. If no or
too few securities or industry analysts cover our company, the trading price for our common shares would likely be negatively affected.
In addition, if one or more of the analysts who cover us downgrade our common shares or publish inaccurate or unfavorable research
about our business, the price of our common shares would likely decline. If one or more of these analysts cease coverage of our
company or fail to publish reports on us regularly, demand for our common shares could decrease, which might cause the price of
our common shares and trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>An increase in our tax rate could occur, which
could adversely affect our financial results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Swiss Federal government had proposed
changes to align Swiss corporate taxation with international recommendations but voters in Switzerland voted against such proposals
in a national referendum on February 12, 2017. On June 6, 2018, the Swiss Federal Council has published the draft bill of the new
tax reform named &ldquo;Tax Proposal 17&rdquo; (<I>Steuervorlage 17</I>) and the accompanying report (<I>Botschaft</I>) that is
currently being debated by the Swiss Parliament. Thus, uncertainty will continue about the future level of Swiss Federal corporate
income taxes that may apply to us until revised proposals are put forward and gain acceptance. The Tax Proposal 17 is expected
to come into force no earlier than January 1, 2020. The Tax Proposal 17 includes &ndash; amongst other measures &ndash; the following
measures:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>repealing the status companies at the cantonal level as well as certain tax practices at the federal level, including transitional
measures;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>introducing a mandatory patent box regime at the cantonal level; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>introducing an optional R&amp;D &ldquo;super deduction&rdquo; at the cantonal level.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In 2017, the voters of the Canton of Vaud
have approved a change of the Vaud cantonal tax law which includes, among other changes, a reduction of the combined effective
Swiss income tax rate from currently 20.5% to 13.8%. The government of the Canton of Vaud has proposed to implement early such
corporate tax reform in the Canton of Vaud on January 1, 2019 independent from the entry into force of the Tax Proposal 17.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expect that, if these measure come into
force, it is likely that our combined effective Swiss income tax rate would decline from approximately 20.5% to 13.8%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt"><B><I>Although we believe that we were not a &ldquo;passive
foreign investment company,&rdquo; or PFIC, for U.S. federal income tax purposes in 2017, and we do not expect to be a PFIC in
the immediately foreseeable future, if we were a PFIC U.S. shareholders may be subject to adverse U.S. federal income tax consequences.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the Internal Revenue Code of 1986,
as amended, or the Code, we will be a PFIC for any taxable year in which, after the application of certain look-through rules with
respect to subsidiaries, either (i)&nbsp;75% or more of our gross income consists of passive income or (ii)&nbsp;50% or more of
the average quarterly value of our assets consists of assets that produce, or are held for the production of, passive income. Passive
income generally includes dividends, interest, certain non-active rents and royalties, and capital gains. Based on our business
plan and certain estimates and projections, including as to the relative values of our assets, we do not believe that we were a
PFIC for our 2017 taxable year and do not expect to be a PFIC in the immediately foreseeable future. However, there can be no assurance
that the IRS will agree with our conclusion. In addition, whether we will be a PFIC in 2018 or any future years is uncertain because,
among other things, (i)&nbsp;we currently own, a substantial amount of passive assets, including cash, (ii)&nbsp;the amount and
composition of our income as passive or non-passive may vary substantially over time, and (iii) the valuation of our assets that
generate non-passive income for PFIC purposes, including our intangible assets, is uncertain and may vary substantially over time.
Accordingly, there can be no assurance that we will not be a PFIC for any taxable year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If we are a PFIC for any taxable year during
which a U.S. investor holds common shares, we generally would continue to be treated as a PFIC with respect to that U.S. investor
for all succeeding years during which the U.S. investor holds common shares, even if we ceased to meet the threshold requirements
for PFIC status. Such a U.S. investor may be subject to adverse U.S. federal income tax consequences, including (i)&nbsp;the treatment
of all or a portion of any gain on disposition as ordinary income, (ii)&nbsp;the application of a deferred interest charge on such
gain and the receipt of certain dividends, and (iii)&nbsp;compliance with certain reporting requirements. We do not intend to provide
the information that would enable investors to take a qualified electing fund election that could mitigate the adverse U.S. federal
income tax consequences should we be classified as a PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For further discussion, see the section
in this prospectus supplement entitled &ldquo;Tax Considerations.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Use of Proceeds</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">We estimate that the net proceeds to us
from this offering will be approximately $17.6 million, after deducting estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">As of March 31, 2018, after giving effect
to the Public Offering, we would have had had cash and cash equivalents of CHF 109.7 million. We anticipate that we will use our
existing liquidity and the net proceeds from the Rights Offering primarily to fund research and development expenses for our clinical
and pre-clinical research and development activities and for working capital and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">However, due to the uncertainties inherent
in the product development process, it is difficult to estimate with certainty the exact amounts of the net proceeds from the Rights
Offering that may be used for the above purposes. The amount and timing of our actual expenditures will depend upon numerous factors,
including the results of our research and development efforts, the timing and success of our ongoing pre-clinical and clinical
studies or pre-clinical and clinical studies we may commence in the future and the timing of regulatory submissions. As a result,
our management will have broad discretion over the use of the net proceeds from the Rights Offering, and investors will be relying
on our judgment regarding the application of the net proceeds. In addition, we might decide to postpone or not pursue certain pre-clinical
activities or clinical studies if the net proceeds from the Rights Offering and our other sources of cash are less than expected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Pending the use of the proceeds from the
Rights Offering, we intend to invest the net proceeds in interest-bearing, investment-grade securities, certificates of deposit
or direct or guaranteed obligations of the U.S. and Swiss governments. We are likely to convert a substantial amount of the proceeds
into CHF shortly after the closing of the Rights Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Dividend
Policy</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">We have never declared or paid cash dividends
on our capital stock. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion
of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related
to dividend policy will be made at the discretion of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Under Swiss law, any dividend must be proposed
by our board of directors and approved by our shareholders. In addition, our auditors must confirm that the dividend proposal of
our board of directors conforms to Swiss statutory law and our articles of incorporation. A Swiss corporation may pay dividends
only if it has sufficient distributable profits brought forward from the previous business years (&ldquo;<I>report des b&eacute;n&eacute;fices</I>&rdquo;)
or if it has distributable reserves (&ldquo;<I>r&eacute;serves &agrave; libre disposition</I>&rdquo;), each as evidenced by its
audited standalone statutory balance sheet prepared pursuant to Swiss law and after allocations to reserves required by Swiss law
and its articles of association have been deducted. Distributable reserves are generally booked either as &ldquo;free reserves&rdquo;
(&ldquo;<I>r&eacute;serves libres</I>&rdquo;) or as &ldquo;reserve from capital contributions&rdquo; (&ldquo;<I>apports de capital</I>&rdquo;).
Distributions out of nominal share capital, which is the aggregate nominal value of a corporation&rsquo;s issued shares, may be
made only by way of a share capital reduction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Capitalization</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">The table below sets forth our cash and
cash equivalents and our total capitalization (defined as total debt and equity) as of March 31, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>on an actual basis;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>on an as adjusted basis to give effect to our issuance and sale of 7,391,305 common shares in the Public Offering and the Prior
Rights Offering, at the Offering Price after deducting estimated offering expenses payable by us; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>on an as further adjusted basis to give effect to our issuance and sale of 1,500,000 common shares in connection with the Rights
Offering, at the Offering Price after deducting estimated offering expenses payable by us.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Investors should read this table in conjunction
with our consolidated financial statements and related notes included in this prospectus supplement and incorporated by reference
herein. For more details on how you can obtain the documents incorporated by reference in this prospectus supplement and the accompanying
prospectus, see &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The following table assumes that (i) the
subscription rights offered to existing shareholders pursuant to the Rights Offering are exercised in full, and (ii) the underwriters&rsquo;
option to purchase additional shares in the Public Offering has not been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="; text-align: center">&nbsp;</TD><TD STYLE="; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="; text-align: center; border-bottom: Black 1pt solid"><B>As of March 31, 2018</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="; text-align: center"><B>&nbsp;</B></TD><TD STYLE="; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="3" STYLE="; text-align: center; border-bottom: Black 1pt solid"><B>Actual</B></TD><TD STYLE="; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="3" STYLE="; text-align: center; border-bottom: Black 1pt solid"><B>As Adjusted</B></TD><TD STYLE="; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="3" STYLE="; text-align: center; border-bottom: Black 1pt solid"><B>As Further Adjusted</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="; text-align: center">&nbsp;</TD><TD STYLE="">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="; text-align: center"><B>(in thousands of CHF)</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 67%; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents&#9;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; border-bottom: Black 2.5pt double; text-align: right">109,669</TD><TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; border-bottom: Black 2.5pt double; text-align: right">186,798</TD><TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; border-bottom: Black 2.5pt double; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">203,598&nbsp;</P></TD><TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Shareholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Common shares, nominal value CHF 0.02 per share 57,362,690 shares issued and outstanding on an actual basis, 64,753,995 issued and outstanding on a pro forma basis, as adjusted and 66,253,995 issued and outstanding on a pro forma basis, as further adjusted&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,147</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,295</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,325</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Share premium&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">188,357</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">265,338</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">282,108</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated losses&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(83,676</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(83,676</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(83,676</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 27pt">Total equity&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">105,828</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">182,957</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">199,757</P></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -9.35pt; padding-left: 0.5in">Total capitalization&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">105,828</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">182,957</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">199,757</P></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">The number of common shares in the table
above excludes 1,594,943 of our common shares issuable upon the exercise of options, non-vested restricted shares and non-vested
restricted share units outstanding under our existing equity incentive plans at a weighted-average exercise price of CHF 3.52 per
common share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Dilution</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: left"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our common shares in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the price you pay in this offering and the net tangible book value per common share after this offering.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 23.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net tangible book value as of March 31, 2018 was $111.0&nbsp;million (CHF 105.8 million), or $1.94 per common share (CHF 1.84
per common share), based on 57,362,690 common shares then outstanding, excluding 1,594,943 of our common shares issuable upon
exercise of options, non-vested restricted shares and non-vested restricted share units outstanding under our existing equity
incentive plans at a weighted-average exercise price of CHF 3.52 per common share. Net tangible book value per share represents
the amount of our total assets less our total liabilities, excluding intangible assets, divided by 57,362,690, the total number
of our common shares issued and outstanding at March 31, 2018.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 23.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 23.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to (i) the issuance and sale by us of 1,500,000 common shares in connection with this offering at the Offering Price
and (ii) the issuance and sale by us of 7,391,305 common shares in connection with the Public Offering and the Prior Rights Offering,
in each case less estimated offering expenses and the underwriting discounts, our net tangible book value at March 31, 2018 would
have been $209.6&nbsp;million, or $3.16&nbsp;per common share. This represents an immediate increase in net tangible book value
of $1.23&nbsp;per share to existing shareholders and an immediate dilution of $8.59&nbsp;per share to investors in this offering.
The following table illustrates this per share dilution:</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 23.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 11%; layout-grid-mode: char; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>(in
    USD)</U></B></FONT></TD>
    <TD STYLE="width: 11%; layout-grid-mode: char; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>(in
    CHF)</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering Price per share&#9;</FONT></TD>
    <TD STYLE="layout-grid-mode: char; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.75</FONT></TD>
    <TD STYLE="layout-grid-mode: char; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.20</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 31.5pt; text-indent: -9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical
    net tangible book value per share as of March 31, 2018&#9;</FONT></TD>
    <TD STYLE="layout-grid-mode: char; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.94</FONT></TD>
    <TD STYLE="layout-grid-mode: char; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.84</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="padding-left: 31.5pt; text-indent: -9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    per share attributable to new investors purchasing shares in this offering&#9;</FONT></TD>
    <TD STYLE="layout-grid-mode: char; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.23</FONT></TD>
    <TD STYLE="layout-grid-mode: char; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.17</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 31.5pt; text-indent: -9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    adjusted net tangible book value per share after giving effect to this offering, the Public Offering and the Prior Rights
    Offering&#9;</FONT></TD>
    <TD STYLE="layout-grid-mode: char; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.16</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.02</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="padding-left: 31.5pt; text-indent: -9.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution
    per share to new investors&#9;</FONT></TD>
    <TD STYLE="layout-grid-mode: char; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.59</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.19</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage of dilution in net tangible book
    value per common share for new investors&#9;</FONT></TD>
    <TD STYLE="layout-grid-mode: char; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73.08%</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73.08%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 23.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 23.1pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Swiss
Franc amounts have been translated into U.S. dollars at a rate of CHF 0.9532 to USD 1.00, the official exchange rate quoted as
of March 31, 2018 by the U.S. Federal Reserve Bank. Such U.S. dollar amounts are not necessarily indicative of the amounts of
U.S. dollars that could actually have been purchased upon exchange of Swiss Francs on March 31, 2018 and have been provided solely
for the convenience of the reader. The above table assumes that (i) the subscription rights offered to existing shareholders pursuant
to the Rights Offering are exercised in full, and (ii) the underwriters&rsquo; option to purchase additional shares in the Public
Offering has not been exercised.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 23.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 23.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we
have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale
of equity or convertible debt securities, the issuance of such securities may result in further dilution to our shareholders.</FONT></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 23.1pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Subscription
Rights Offering</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Rights Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Under Swiss law and pursuant to the resolution
by the annual general meeting held on July 6, 2018, our existing shareholders are entitled to statutory pre-emptive subscription
rights to subscribe for the Offered Shares in proportion to their existing shareholdings. As a result, we are offering pre-emptive
subscription rights to our Record Shareholders, who will have the opportunity to subscribe for up to 1,500,000 Offered Shares on
a <I>pro rata</I> basis at the Offering Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Each Record Shareholder will be entitled
to one pre-emptive subscription right for each existing common share held by such Record Shareholder after the close of trading
on The Nasdaq Global Market on July 2, 2018. Accordingly, such Record Shareholder may, during the subscription period described
below, subscribe for one Offered Share for every 38.24 pre-emptive subscription rights held by such Record Shareholder. We refer
to this exercise of subscription rights as the basic subscription right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Record Shareholders who fully exercise
their pre-emptive subscription rights under the basic subscription right will also have the option of subscribing for additional
Offered Shares unclaimed by other Record Shareholders in the Rights Offering, at the same Offering Price. We refer to this option
as the over-subscription privilege. If an insufficient number of Offered Shares are available to fully satisfy all over-subscription
privilege requests, the available Offered Shares will be distributed proportionally among Record Shareholders who exercised their
over-subscription privilege based on the number of Offered Shares they subscribed for under the basic subscription right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Record Shareholders who wish to exercise
their over-subscription privilege must deliver the subscription payment for exercise of such privilege before expiration of the
subscription period. Because we will not know the total number of unsubscribed Offered Shares before the expiration of the subscription
period, Record Shareholders who wish to maximize the number of Offered Shares they wish to purchase pursuant to the over-subscription
privilege will need to deliver payment in an amount equal to the Offering Price multiplied by the maximum number of Offered Shares
they wish to purchase. Computershare Trust Company, N.A., as subscription agent, will return any excess payments by mail without
interest or deduction promptly after the expiration of the subscription period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Any Offered Shares not subscribed for will
be available for allocation by the Board of Directors at its discretion in first priority to current shareholders and in second
priority to institutional investors in a private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Record Shareholders may exercise their
pre-emptive subscription rights to acquire the Offered Shares during the subscription period from 3:00 a.m. (New York City time)
on July 20, 2018 to 4:00 p.m. (New York City time) on July 27, 2018. Record Shareholders must exercise their pre-emptive subscription
rights before the end of such subscription period. We reserve the right to suspend or extend the subscription period for the Rights
Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Any pre-emptive subscription rights that
have not been validly exercised prior to the end of the subscription period will expire and become null and void without compensation.
The Company may withdraw, cancel or modify any orders of a Record Shareholder who has elected to participate in the Rights Offering
if the Company cannot verify the eligibility of such Record Shareholder with such shareholder, or its bank, broker or other intermediary,
respectively, Each exercise of pre-emptive subscription rights in the Rights Offering will be effective at the Offering Price,
is irrevocable and may not be cancelled, modified, rescinded or withdrawn. We will accept subscriptions for whole Offered Shares
only and will round down any subscription submitted for fractional Offered Shares to the nearest whole number of Offered Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The pre-emptive subscription rights will
not be listed on any securities exchange or tradeable. The subscription rights are not transferrable. You may not sell, transfer, assign or give away your subscription rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Any eligible Record Shareholder interested
in participating in the Rights Offering should direct the bank, broker or other intermediary administering its securities account
to which such eligible Record Shareholder&rsquo;s existing common shares are credited to contact Georgeson LLC, acting as information
agent, by calling (888) 613-9817 or +1 781-575-2137 prior to the expiration of the subscription period and indicate how many pre-emptive
subscription</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">rights such Record Shareholder wishes to exercise under the
basic subscription right and the over-subscription privilege.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">At the annual general meeting held on July
6, 2018, our shareholders approved an ordinary capital increase of up to 1,500,000 common shares. The Rights Offering will be carried
out based on this approved ordinary capital increase. The wording of the resolutions pertaining to the Rights Offering as approved
by our shareholders is the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the share capital of the Company is increased by way of an ordinary
increase by up to CHF 30,000 by issuing up to 1,500,000 registered shares with a nominal value of CHF 0.02 each;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the pre-emptive subscription rights of the shareholders for the newly
issued registered shares shall be preserved; the Board of Directors shall credit each shareholder with a corresponding number of
non-tradable subscription rights with identical terms as offered to institution investors in the ordinary share capital increase
resolution resolved today. Such subscription rights may be exercised during a subscription period of at least six business days;
any new shares not subscribed shall be allocated by the Board of Directors at its discretion in first priority to current shareholders;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the technical issuance price of the new shares to be paid in cash
shall be determined by the Board of Directors;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the new shares are entitled to dividends for the business year starting
January 1, 2018;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the new shares are subject to the transfer restrictions as outlined
in article 4 of the Articles of Association;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the stamp duty shall be paid by the Company; and</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.1pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the Board of Directors is authorized and instructed to implement and
register this capital increase with the competent commercial register.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Offered Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The Offered Shares will have a nominal
value of CHF&nbsp;0.02 each. We will issue the Offered Shares in an ordinary share capital increase against cash contributions
approved by our shareholders at the annual general meeting held on July 6, 2018. The Offered Shares will be fully fungible and
rank <I>pari passu</I> in all respects with each other and with all of our existing common shares. The Offered Shares are subject
to the transfer restrictions as set forth in article 4 of our articles of association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The Offered Shares will be issued as uncertificated
securities (<I>droits-valeurs</I>, within the meaning of Article 973c of the Swiss Code of Obligations) and, when administered
by a financial intermediary (<I>d&eacute;positaire</I>, within the meaning of the Federal Act on Intermediated Securities, &ldquo;FISA&rdquo;),
qualify as intermediated securities (<I>titres interm&eacute;di&eacute;s</I>, within the meaning of the FISA). The Offered Shares
will be registered in our non-public register of uncertificated securities (<I>registre des droits-valeurs</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">After expiration of the subscription period
of the Rights Offering, the Offered Shares which have been validly subscribed and paid for in accordance with the terms of the
Rights Offering will be, upon registration of the corresponding share capital increase into the Commercial Register of the Canton
of Vaud, validly issued. The delivery of Offered Shares shall be carried out by Computershare Trust Company, N.A. acting as transfer
agent and registrar for our common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Shareholders participating in the Rights
Offerings will be obligated to pay for the subscription price of the common shares allocated to them on the date determined by
the Company at the end of the subscription period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Price Range
of Common Shares</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">The common shares of the Company are listed
on The Nasdaq Global Market under the symbol &ldquo;ACIU&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">The following table sets forth the highest
and lowest intraday sales prices for the common shares as reported by The Nasdaq Global Market for the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD><TD COLSPAN="5" STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nasdaq Global Market&nbsp;</P>

</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid"><B>Year ended December 31, 2018</B></TD><TD STYLE="; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; ; text-align: right"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$ High&nbsp;</P></TD><TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD><TD STYLE="; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; ; text-align: right"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$ Low&nbsp;</P></TD><TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Third Quarter (through July 18, 2018)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16.36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.05</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 78%; text-align: left">Second Quarter&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">11.24</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">7.57</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">First Quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13.91</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10.06</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD><TD COLSPAN="5" STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nasdaq Global Market&nbsp;</P>

</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid"><B>Year ended December 31, 2017</B></TD><TD STYLE="; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; ; text-align: right"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$ High&nbsp;</P></TD><TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD><TD STYLE="; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; ; text-align: right"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$ Low&nbsp;</P></TD><TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 78%; text-align: left">Fourth Quarter&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">13.09</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">10.10</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third Quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Second Quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8.51</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">First Quarter&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">14.06</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10.27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD><TD COLSPAN="5" STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nasdaq Global Market&nbsp;</P>

</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid"><B>Year ended December 31, 2016</B></TD><TD STYLE="; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; ; text-align: right"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$ High&nbsp;</P></TD><TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD><TD STYLE="; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; ; text-align: right"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$ Low&nbsp;</P></TD><TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 78%; text-align: left">Fourth Quarter&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">18.95</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">10.36</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third Quarter (beginning on September 23, 2016)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">19.97</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">14.11</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD><TD COLSPAN="5" STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nasdaq Global Market&nbsp;</P>

</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid"><B>Most recent six months</B></TD><TD STYLE="; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; ; text-align: right"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$ High&nbsp;</P></TD><TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD><TD STYLE="; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; ; text-align: right"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$ Low&nbsp;</P></TD><TD STYLE="border-bottom: Black 1pt solid; ; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>July (through July 18, 2018)&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16.36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.05</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 78%">June &#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">10.35</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">7.57</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>May&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.60</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>April 2018&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8.51</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>March 2018&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12.55</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10.06</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>February 2018&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10.52</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>January 2018&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13.91</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12.31</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Tax Considerations</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Swiss Tax considerations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>The following summary contains a description
of the principal Swiss tax consequences of the allotment and exercise of pre-emptive subscription rights and the acquisition, ownership
and disposition of Offered Shares, but it does not purport to be a comprehensive description of all of the Swiss tax considerations
that may be relevant to a decision to exercise of the pre-emptive subscription rights and to purchase, own or dispose of Offered
Shares. In particular, the summary does not take into account the specific circumstances of any particular investor.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>This summary is based on the tax laws,
regulations and regulatory practices of Switzerland as in effect on the date hereof, all of which are subject to change (or subject
to changes in interpretation), possibly with retroactive effect. This summary does not address any aspects of Swiss taxation other
than aspects of Swiss federal withholding tax, Swiss federal, cantonal and communal income taxes and Swiss federal issuance and
securities turnover tax. Investors are urged to consult their own tax advisors regarding the Swiss tax consequences of allotting
and exercising of pre-emptive subscription rights and of acquiring, owning and disposing of Offered Shares or the receipt of dividends
or distributions, if any, on Offered Shares.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Taxation in respect of pre-emptive subscription
rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt"><B><I>Swiss Withholding Tax</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Neither the allotment nor exercising of
pre-emptive subscription rights are taxable distributions or transactions for purposes of Swiss withholding tax (<I>imp&ocirc;t
anticip&eacute;</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt"><B><I>Swiss Securities Turnover Tax</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Neither the allotment nor exercising of
pre-emptive subscription rights are taxable transactions for purposes of Swiss securities turnover tax (<I>droit de timbre de n&eacute;gotiation</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt"><B><I>Swiss Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt"><I>Pre-emptive subscription rights held by holders
resident outside of Switzerland and with no trade or business in Switzerland</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The allotment or exercising of pre-emptive
subscription rights to or by holders who are not resident in Switzerland for tax purposes, and who, during the relevant taxation
year, have not engaged in a trade or business carried on through a permanent establishment in Switzerland for Swiss tax purposes
are not subject to any Swiss federal, cantonal or communal income tax. See &ldquo;&mdash;<I>Swiss Withholding Tax</I>&rdquo; above
for a summary on the Swiss withholding tax treatment of pre-emptive subscription rights. See &ldquo;&mdash;<I>International Automatic
Exchange of Information</I>&rdquo; below for a summary on the exchange of information in respect of holding pre-emptive subscription
rights in an account or deposit with a financial institution or paying agent in Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt"><I>Pre-emptive subscription rights held by Swiss
resident individuals as private investments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pre-emptive subscription rights allotted
with respect to existing common shares of the Company held by a Swiss resident individual as private investments take on the same
classification as private investments as the existing common shares. For such a holder neither the allotment, holding nor exercising
of the pre-emptive subscription rights allotted are subject to Swiss federal, cantonal or communal income tax. A capital loss incurred
by such a holder for reason of not having validly exercised pre-emptive subscription rights during the subscription period (with
the consequence of the pre-emptive subscription rights expiring without compensation) will not be tax-deductible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">See &ldquo;&mdash;<I>pre-emptive subscription
rights held as assets of a Swiss business</I>&rdquo; below for a summary on the taxation treatment of individuals who are classified
as &ldquo;professional securities dealers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt"><I>Pre-emptive subscription rights held as assets
of a Swiss business</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The allotment of pre-emptive subscription
rights to corporate or individual holders, who hold existing common shares with respect to which such pre-emptive subscription
rights are allotted, and consequentially the pre-emptive subscription rights, as part of a trade or business carried on through
a permanent establishment in Switzerland, and the exercise of such pre-emptive subscription rights for the purchase of Offered
Shares, are generally treated by such holders as a non-recognition transaction for statutory accounting purposes. Consequently,
tax following generally the statutory accounting treatment, neither the allotment nor the exercise of such pre-emptive subscription
rights are</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">normally taxable transactions for such holders
for purposes of Swiss federal, cantonal and communal corporate or individual income tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A capital loss realized in respect of pre-emptive
subscription rights allotted for existing common shares which are held as business assets, and which pre-emptive subscription rights
therefore take on the classification of the existing common shares of the Company as business assets, for reason of not having
validly exercised such pre-emptive subscription rights (with the consequence of them expiring without compensation), are includible
in, or deductible from, gross income in the relevant taxation period for such a holder for purposes of Swiss federal, cantonal
and communal corporate or individual income tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This taxation treatment also applies to
Swiss-resident private individuals who, for income tax purposes, are classified as &ldquo;professional securities dealers&rdquo;
for reasons of, among other things, frequent dealing, or leveraging their investments, in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Taxation in respect of Offered Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt"><B><I>Swiss federal withholding tax</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt"><I>Swiss federal withholding tax on dividends and
similar distributions on the Offered Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dividends on Offered Shares made or paid
by the Company out of capital contribution reserves (<I>apports de capital</I>) and distributions on Offered Shares made or paid
by the Company based upon a reduction of nominal value of Offered Shares (<I>Nennwertherabsetzung</I>) are exempt from Swiss federal
withholding tax (<I>imp&ocirc;t anticip&eacute;</I>). Any other dividends and cash or in-kind distributions (including scrip or
stock dividends) on Offered Shares made or paid by the Company are subject to Swiss federal withholding tax at a rate of 35%. The
withholding tax must be withheld by the Company on the gross amount of the dividend or distribution and be remitted to the Swiss
Federal Tax Administration. Capital gains realized on the sale of Offered Shares are not subject to the withholding tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt"><I>Refund to Swiss-resident recipients</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The relevant Swiss tax authority will refund
or credit the Swiss federal withholding tax deducted by the Company on dividends or distributions on Offered Shares in full to
holders of Offered Shares who are resident in Switzerland and to holders who hold the Offered Shares as part of a trade or business
in Switzerland, and who, in each case, among other things, are the beneficial owners of the Offered Shares and the dividends or
the distributions made or paid on the Offered Shares and who duly report the dividend or distribution in their income tax return
or their statutory financial statements, as applicable, for the relevant tax period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt"><I>Refund to non-resident recipients</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt"><I>(a) In General</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A holder who is not a resident of Switzerland
and who does not hold the Offered Shares as part of a trade or business in Switzerland may be entitled to a full or partial refund
of the Swiss federal withholding tax deducted if the country in which the recipient resides for tax purposes has entered into a
bilateral treaty for the avoidance of double taxation with Switzerland and the other conditions of such treaty are met. A reduction
of the withholding tax at source is not provided for by Switzerland for portfolio holdings and, therefore, is not permissible.
Holders of Offered Shares should be aware that the procedures for claiming treaty benefits (and the time frame required for obtaining
a tax refund) may differ from country to country and should consult their own legal, financial or tax advisors regarding the procedures
for claiming a refund of the withholding tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 49.65pt"><I>(b) Residents of the U.S.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 49.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A holder of Offered Shares who is a resident
of the US for purposes of the Convention between the United States of America and the Swiss Confederation for the Avoidance of
Double Taxation with Respect to Taxes on Income (Treaty), without taxable presence in Switzerland to which the Offered Shares are
attributable or who is a qualified US pension fund and who, in each case, is the beneficial owner of the Offered Shares and the
dividend or distribution and who meets the other conditions of the Treaty may apply for a full refund of the withholding tax in
the case of qualified US pension funds or in excess of the amount of the 15% treaty rate in all other cases. The claim for refund
must be filed on Swiss Tax Form 82 (82C for corporations, 82I for individuals, 82E for other entities and 82R for regulated investment
companies), which forms together with an instruction form may be obtained from any Swiss consulate general in the U.S., the Swiss
Federal Tax Administration at the address below or be down-loaded from the Swiss Federal Tax Administration&rsquo;s website. Four
copies of the form must be duly completed, signed before a notary public of the U.S., and three of them must be sent to the Swiss
Federal Tax Administration, Eigerstrasse 65, CH-3003,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Berne, Switzerland. The form must be accompanied
by suitable evidence of deduction of the Swiss federal withholding, such as certificates of deduction, bank vouchers or credit
slips. The form must be filed no later than December 31 of the third year following the calendar year in which the dividend subject
to the tax became payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt"><B><I>Swiss income taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 49.65pt"><I>Offered Shares held by holders resident
outside of Switzerland and with no trade or business in Switzerland</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 49.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Holders of Offered Shares who are not resident
in Switzerland for tax purposes, and who, during the respective taxation year, have not engaged in a trade or business carried
on through a permanent establishment situated in Switzerland for tax purposes, will not be subject to any Swiss federal, cantonal
or communal income taxes as a result of them realizing gain on the sale or other disposition of Offered Shares or receiving dividends
or other distributions, if any, on Offered Shares. Refer to &ldquo;<I>&#8213;Swiss federal withholding tax</I>&rdquo; above for
a summary on the Swiss withholding tax treatment of dividends and distributions on Offered Shares. Refer to &ldquo;<I>&#8213;International
Automatic Exchange of Information</I>&rdquo; below for a summary on the international exchange of information in tax matters by
Switzerland in respect of Offered Shares held in accounts or deposits with a paying agent in Switzerland. Refer to &ldquo;<I>&#8213;Swiss
Facilitation of the Implementation of the US Foreign Account Tax Compliance Act</I>&rdquo; below for a summary on the implementation
of FATCA by Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 49.65pt"><I>Offered Shares held by Swiss resident
individuals as private investments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 49.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dividends and other distributions, if any,
on Offered Shares, made or paid by the Company out of reserves from capital contributions (<I>apports de capital</I>) and distributions
made or paid by the Company on Offered Shares based upon a capital reduction (<I>reduction de la valeur nominale</I>), if any,
are exempt from Swiss federal, cantonal and communal income taxes for holders of Offered Shares who are individuals resident in
Switzerland for tax purposes and who hold the Offered Shares as private capital investments. Other dividends and distributions,
if any, on Offered Shares will be subject to Swiss federal, cantonal or communal income taxes for such holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A capital gain realized by an individual
resident in Switzerland on the sale of Offered Shares held by her or him as private capital investments classifies as tax-exempt
private capital gain and, conversely, a capital loss as non-tax deductible private capital loss for purposes of Swiss federal,
cantonal and communal income taxes. Refer to &ldquo;&mdash;Offered Shares held as assets of a Swiss business&rdquo; for information
on the taxation of individuals classified as &ldquo;professional securities dealers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 49.65pt"><I>Offered Shares held as assets of a
Swiss business</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 49.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For a holder who holds Offered Shares as
part of a trade or business carried on in Switzerland dividends and distributions, if any, made or paid by the Company on Offered
Shares, and capital gain or loss realized on the sale of Offered Shares, are includible in, or deductible from, respectively, taxable
income in the relevant taxation period for purposes of Swiss federal, cantonal and communal individual or corporate income taxes.
This taxation treatment also applies to Swiss resident private individuals who, for income tax purposes, are classified as &ldquo;professional
securities dealers&rdquo;. Corporate taxpayers may be eligible for dividend relief (<I>r&eacute;ductions pour participations</I>)
in respect of dividends and distributions, if any, on Offered Shares held as part of a Swiss business if the market value of the
Offered Shares held by them equals or exceeds CHF 1 million or represents 10% or more of, the share capital or the dividend rights,
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt"><B><I>Swiss federal issuance stamp tax</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">The Company will be subject to the Swiss
issuance stamp tax (<I>droit de timbre d'&eacute;mission</I>) on the issuance of the Offered Shares of 1% of the subscription price,
net of certain deductions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt"><B><I>Swiss federal securities turnover tax</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 49.65pt"><I>In respect of purchases of Offered
Shares in the Offering</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 49.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">The delivery of Offered Shares against
payment of the subscription price is exempt from Swiss federal securities turnover tax (<I>droit de timbre de n&eacute;gotiation</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 49.65pt"><I>In respect of other transactions in
Offered Shares</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 49.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Any transactions in the Offered Shares
after the offering, where a bank or another securities dealer in Switzerland, as defined in the Swiss Federal Stamp Tax Act, acts
as an intermediary, or is a party, to the transaction, is subject to Swiss federal securities turnover tax at a tax rate of up
to 0.15% of the consideration paid for such Offered Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Subject to applicable statutory exemptions
in respect of the one or the other party to such a transaction, half of the tax is customarily charged to the one party to the
transaction and the other half to the other party to the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt"><B><I>International Automatic Exchange of Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Switzerland has concluded a multilateral
agreement with the EU on the international automatic exchange of information (AEOI) in tax matters. The agreement applies to all
28 EU member states and certain other jurisdictions. Further, Switzerland has entered into the multilateral competent authority
agreement on the automatic exchange of financial account information (MCAA), and based on the MCAA, a number of bilateral AEOI
agreements with other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on such agreements and the implementing
laws of Switzerland, Switzerland commenced collecting or will commence collecting data in respect of financial assets held in,
and income derived thereon and credited to, accounts or deposits with a paying agent in Switzerland for the benefit of individuals
resident in a EU member state or other treaty state from 2017 and began exchanging the data in 2018 or will begin exchanging the
data at a later date, depending on the date of effectiveness of the applicable agreement, including, as the case may be, in respect
of Offered Shares held in such accounts or deposits. Switzerland has signed and intends to sign further AEOI agreements with further
countries. An up-to-date list of the AEOI agreements of Switzerland in effect or signed and becoming effective and the dates of
commencement of data collection and the dates of information exchange, can be found on the website of the State Secretariat for
International Financial Matters SIF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt"><B><I>Swiss Facilitation of the Implementation of
the US Foreign Account Tax Compliance Act</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Switzerland has concluded an intergovernmental
agreement with the U.S. to facilitate the implementation of FATCA. The agreement ensures that accounts held by U.S. persons with
Swiss financial institutions, which accounts may include Offered Shares and income derived thereon, are disclosed to the U.S. tax
authorities either with the consent of the account holder or by means of group requests within the scope of administrative assistance.
Information will not be transferred automatically in the absence of consent, and instead will be exchanged only within the scope
of administrative assistance on the basis of the Treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Material U.S. Federal Income Tax Considerations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">In the opinion of Davis Polk &amp; Wardwell
LLP, the following are the material U.S. federal income tax consequences to U.S. Holders, as defined below, of owning and disposing
our common shares. It does not describe all tax considerations that may be relevant to a particular person&rsquo;s decision to
acquire common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">This discussion applies only to a U.S.
Holder that holds common shares as capital assets for U.S. federal income tax purposes. In addition, it does not describe all of
the U.S. federal income tax consequences that may be relevant in light of a U.S. Holder&rsquo;s particular circumstances, including
alternative minimum tax consequences, the potential application of the provisions of the Code known as the Medicare contribution
tax and tax consequences applicable to U.S. Holders subject to special rules, such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>certain financial institutions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>dealers or traders in securities who use a mark-to-market method of tax accounting;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>persons holding common shares as part of a hedging transaction, straddle, wash sale, conversion transaction or other integrated
transaction or persons entering into a constructive sale with respect to the common shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>U.S. Holder whose functional currency for U.S. federal income tax purposes is not the U.S. dollar;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>entities classified as partnerships for U.S. federal income tax purposes;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>tax-exempt entities, including an &ldquo;individual retirement account&rdquo; or &ldquo;Roth IRA&rdquo;;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>persons that own or are deemed to own ten percent or more of our shares, by vote or value; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>persons holding common shares in connection with a trade or business conducted outside of the United States.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">If an entity that is classified as a partnership
for U.S. federal income tax purposes holds common shares, the U.S. federal income tax treatment of a partner will generally depend
on the status of the partner and the activities of the partnership. Partnerships holding common shares and partners in such partnerships
should consult their tax advisers as to the particular U.S. federal income tax consequences of owning and disposing of the common
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">This discussion does not address the U.S.
federal income tax consequences of the Rights Offering, including the acquisition of newly-issued common shares by our existing
shareholders in either such offering. Current holders of our common shares should consult their tax advisers with respect to the
U.S. federal income tax consequences of the Rights Offering and the acquisition of any common shares in such offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">This discussion is based on the Code, administrative
pronouncements, judicial decisions, final, temporary and proposed Treasury regulations, and the income tax treaty between Switzerland
and the United States (the &ldquo;Treaty&rdquo;) all as of the date hereof, any of which is subject to change or differing interpretations,
possibly with retroactive effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">A &ldquo;U.S. Holder&rdquo; is a holder
who, for U.S. federal income tax purposes, is a beneficial owner of common shares, who is eligible for the benefits of the Treaty
and who is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a citizen or individual resident of the United States;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any
state therein or the District of Columbia; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 42.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">U.S. Holders should consult their tax advisers
concerning the U.S. federal, state, local and non-U.S. tax consequences of owning and disposing of common shares in their particular
circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"><B><I>Taxation of Distributions </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">As discussed above under &ldquo;Dividend
Policy,&rdquo; we do not currently expect to make distributions on our common shares. In the event that we do make distributions
of cash or other property, subject to the passive foreign investment company rules described below, distributions paid on common
shares, other than certain <I>pro rata</I> distributions of common shares, will be treated as dividends to the extent paid out
of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Because we do not
maintain calculations of our earnings and profits under U.S. federal income tax principles, we expect that distributions will be
reported to U.S. Holders as dividends. For so long as our common shares are listed on NASDAQ or we are eligible for benefits under
the Treaty, dividends paid to certain non-corporate U.S. Holders will be eligible for taxation as &ldquo;qualified dividend income&rdquo;
and therefore, subject to applicable limitations, will be taxable at rates not in excess of the long-term capital gain rate applicable
to such U.S. Holder. U.S. Holders should consult their tax advisers regarding the availability of the reduced tax rate on dividends
in their particular circumstances. The amount of a dividend will include any amounts withheld by us in respect of Swiss income
taxes. The amount of the dividend will be treated as foreign-source dividend income to U.S. Holders and will not be eligible for
the dividends-received deduction generally available to U.S. corporations under the Code. Dividends will be included in a U.S.
Holder&rsquo;s income on the date of the U.S. Holder&rsquo;s receipt of the dividend. The amount of any dividend income paid in
Swiss Francs will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive
receipt, regardless of whether the payment is in fact converted into U.S. dollars at that time. If the dividend is converted into
U.S. dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain or loss in respect
of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after
the date of receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Subject to applicable limitations, some
of which vary depending upon the U.S. Holder&rsquo;s particular circumstances, Swiss income taxes withheld from dividends on common
shares at a rate not exceeding the rate provided by the Treaty will be creditable against the U.S. Holder&rsquo;s U.S. federal
income tax liability. The rules governing foreign tax credits are complex and U.S. Holders should consult their tax advisers regarding
the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may,
at their election, deduct foreign taxes, including any Swiss income tax, in computing their taxable income, subject to generally
applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all
foreign taxes paid or accrued in the taxable year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"><B><I>Sale or Other Disposition of Common Shares
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Subject to the passive foreign investment
company rules described below, gain or loss realized on the sale or other disposition of common shares will be capital gain or
loss, and will be long-term capital gain or loss if the U.S. Holder held the common shares for more than one year. The amount of
the gain or loss will equal the difference between the U.S. Holder&rsquo;s tax basis in the common shares disposed of and the amount
realized on the disposition, in each case as determined in U.S. dollars. Subject to certain exceptions, this gain or loss will
be U.S.-source gain or loss for foreign tax credit purposes. The deductibility of capital losses is subject to various limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"><B><I>Passive Foreign Investment Company Rules </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Under the Code, we will be a PFIC for any
taxable year in which, after the application of certain &ldquo;look-through&rdquo; rules with respect to subsidiaries, either (i)&nbsp;75%
or more of our gross income consists of &ldquo;passive income,&rdquo; or (ii)&nbsp;50% or more of the average quarterly value of
our assets consist of assets that produce, or are held for the production of, &ldquo;passive income.&rdquo; For purposes of the
above calculations, we will be treated as if we hold our proportionate share of the assets of, and receive directly our proportionate
share of the income of, any other corporation in which we directly or indirectly own at least 25%, by value, of the shares of such
corporation. Passive income generally includes interest, dividends, rents, certain non-active royalties and capital gains. Based
on our business plan and certain estimates and projections, including as to the relative values of our assets, we do not believe
that we were a PFIC for our 2017 taxable year and do not expect to be a PFIC in the immediately foreseeable future. However, there
can be no assurance that the IRS will agree with our conclusion. In addition, whether we will be a PFIC in 2018 or any future years
is uncertain because, among other things, (i)&nbsp;we currently own, and will own after the completion of this offering, a substantial
amount of passive assets, including cash, (ii) the amount and composition of our income as passive or non-passive may vary substantially
over time, and (iii)&nbsp;the valuation of our assets that generate non-passive income for PFIC purposes, including our intangible
assets, is uncertain and may vary substantially over time. Accordingly, there can be no assurance that we will not be a PFIC for
any taxable year. If we are a PFIC for any year during which a U.S. Holder holds common shares, we generally would continue to
be treated as a PFIC with respect to that U.S. Holder for all succeeding years during which the U.S. Holder holds common shares,
even if we ceased to meet the threshold requirements for PFIC status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">If we were a PFIC for any taxable year
during which a U.S. Holder held common shares (assuming such U.S. Holder has not made a timely mark-to-market election, as described
below), gain recognized by a U.S. Holder on a sale or other disposition (including certain pledges) of the common shares would
be allocated ratably over the U.S. Holder&rsquo;s holding period for the common shares. The amounts allocated to the taxable year
of the sale or other disposition and to any year before we became a PFIC would be taxed as ordinary income. The amount allocated
to each other taxable year would be subject to tax at the highest rate in effect for individuals or corporations, as appropriate,
for that taxable year, and an interest charge would be imposed on the amount allocated to that taxable year. Further, to the extent
that any distribution received by a U.S. Holder on its common shares exceeds 125% of the average of the annual distributions on
the common shares received during the preceding three years or the U.S. Holder&rsquo;s holding period, whichever is shorter, that
distribution would be subject to taxation in the same manner as gain, described immediately above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">A U.S. Holder can avoid certain of the
adverse rules described above by making a mark-to-market election with respect to its common shares, provided that the common shares
are &ldquo;marketable.&rdquo; Common shares will be marketable if they are &ldquo;regularly traded&rdquo; on a &ldquo;qualified
exchange&rdquo; or other market within the meaning of applicable Treasury regulations. If a U.S. Holder makes the mark-to-market
election, it will recognize as ordinary income any excess of the fair market value of the common shares at the end of each taxable
year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the
common shares over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously
included as a result of the mark-to-market election). If a U.S. Holder makes the election, the holder&rsquo;s tax basis in the
common shares will be adjusted to reflect the income or loss amounts recognized. Any gain recognized on the sale or other disposition
of common shares in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss
(but only to the extent of the net amount of income previously included as a result of the mark-to-market election).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">In addition, in order to avoid the application
of the foregoing rules, a United States person that owns stock in a PFIC for U.S. federal income tax purposes may make a &ldquo;qualified
electing fund&rdquo; election (a &ldquo;QEF Election&rdquo;) with respect to such PFIC if the PFIC provides the information necessary
for such election to be made. If a United States person makes a QEF Election with respect to a PFIC, the United States person will
be currently taxable on its <I>pro rata</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">share of the PFIC&rsquo;s ordinary earnings and net capital
gain (at ordinary income and capital gain rates, respectively) for each taxable year that the entity is classified as a PFIC and
will not be required to include such amounts in income when actually distributed by the PFIC. We do not intend to provide information
necessary for U.S. Holders to make qualified electing fund elections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">In addition, if we were a PFIC or, with
respect to particular U.S. Holder, were treated as a PFIC for the taxable year in which we paid a dividend or for the prior taxable
year, the preferential dividend rates discussed above with respect to dividends paid to certain non-corporate U.S. Holders would
not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">If a U.S. Holder owns common shares during
any year in which we are a PFIC, the holder must file annual reports containing such information as the U.S. Treasury may require
on IRS Form 8621 (or any successor form) with respect to us, with the holder&rsquo;s federal income tax return for that year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">U.S. Holders should consult their tax advisers
concerning our potential PFIC status and the potential application of the PFIC rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"><B><I>Information Reporting and Backup Withholding
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Payments of dividends and sales proceeds
that are made within the United States or through certain U.S.-related financial intermediaries are subject to certain information
reporting requirements, and may be subject to backup withholding, unless (i)&nbsp;the U.S. Holder is a corporation or other exempt
recipient or (ii)&nbsp;in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification number and
certifies that it is not subject to backup withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The amount of any backup withholding from
a payment to a U.S. Holder will be allowed as a credit against the holder&rsquo;s U.S. federal income tax liability and may entitle
it to a refund, provided that the required information is timely furnished to the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt"><B><I>Information With Respect to Foreign Financial
Assets </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Certain U.S. Holders who are individuals
(and, under proposed regulations, certain entities) may be required to report information relating to an interest in our common
shares, subject to certain exceptions (including an exception for common shares held in accounts maintained by certain U.S. financial
institutions). U.S. Holders should consult their tax advisers regarding the effect, if any, of this legislation on their ownership
and disposition of the common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Plan of
Distribution</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Any eligible Record Shareholder interested
in participating in the Rights Offering should direct the bank, broker or other intermediary administering its securities account
to which such eligible Record Shareholder&rsquo;s existing common shares are credited to contact Georgeson LLC, acting as information
agent, by calling (888) 613- 9817 or +1 781-575-2137 prior to the expiration of the subscription period and indicate how many pre-emptive
subscription rights such Record Shareholder wishes to exercise under the basic subscription right and the over-subscription privilege.
See &ldquo;Subscription Rights Offering.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">We have agreed to pay the information agent
and the transfer agent and registrar customary fees plus certain expenses in connection with the Rights Offering. We have not employed
any brokers, dealers or underwriters in connection with the solicitation or exercise of the pre-emptive subscription rights offered
hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Disclaimers About Non-U.S. Jurisdictions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Notice to Investors in the European Economic Area</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">In relation to each Member State of the
European Economic Area that has implemented the Prospectus Directive, each a Relevant Member State, no offer of our common shares
to the public in that Relevant Member State will take place prior to the publication of a prospectus in relation to our common
shares that has been approved by the competent authority in that Relevant Member State or, where appropriate, approved in another
Relevant Member State and notified to the competent authority in that Relevant Member State, all in accordance with the Prospectus
Directive, except that they may, with effect from and including the Relevant Implementation Date, make an offer of our common shares
to the public in that Relevant Member State at any time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to any legal entity which is a qualified investor as defined in the Prospectus Directive;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the PD Amending Directive, 150,
natural or legal persons (other than qualified investors as defined in the Prospectus Directive) subject to obtaining the prior
consent of the manager for any such offer; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of our common
shares shall require the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">For the purposes of this provision, the
expression an &ldquo;offer to the public&rdquo; in relation to any of our common shares in any Relevant Member State means the
communication in any form and by any means of sufficient information on the terms of the offer and our common shares to be offered
so as to enable an investor to decide to purchase or subscribe our common shares, as the same may be varied in that Relevant Member
State by any measure implementing the Prospectus Directive in that Member State and the expression Prospectus Directive means Directive
2003/71/EC and (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in each Relevant Member State)
includes any relevant implementing measure in each Relevant Member State.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Notice to Investors in the United Kingdom</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">This prospectus supplement is directed
solely at persons who (i) are outside the United Kingdom, (ii) have professional experience in matters relating to investments
or (iii) are persons falling within Article 49(2)(a) to (d) of The Financial Services and Markets Act (Financial Promotion) Order
2005 (all such persons together being referred to as Relevant Persons). This prospectus supplement must not be acted on or relied
on by persons who are not Relevant Persons. Any investment or investment activity to which this prospectus supplement relates is
available only to relevant persons and will be engaged in with Relevant Persons only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Notice to Prospective Investors in Switzerland</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The shares will not be listed on the SIX
Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared
without regard to the disclosure standards for listing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">prospectuses under art. 27 ff. of the SIX Listing Rules or the
listing rules of any other stock exchange or regulated trading facility in Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Neither this document nor any other offering
or marketing material relating to this offering, the Company, or the shares have been or will be filed with or approved by any
Swiss regulatory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Notice to Prospective Investors in the Dubai International
Financial Centre</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">This prospectus supplement relates to an
Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority, or the DFSA. This prospectus
supplement is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must
not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents
in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information
set forth herein and has no responsibility for the prospectus supplement. The shares to which this prospectus supplement relates
may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their
own due diligence on the shares. If you do not understand the contents of this prospectus supplement you should consult an authorized
financial advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Notice to Prospective Investors in Australia</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">No placement document, prospectus, product
disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission, or
the ASIC, in relation to this offering. This prospectus supplement does not constitute a prospectus, product disclosure statement
or other disclosure document under the Corporations Act 2001, the Corporations Act, and does not purport to include the information
required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Any offer in Australia of the shares may
only be made to persons, the Exempt Investors, who are &ldquo;sophisticated investors&rdquo; (within the meaning of section 708(8)
of the Corporations Act), &ldquo;professional investors&rdquo; (within the meaning of section 708(11) of the Corporations Act)
or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer
the shares without disclosure to investors under Chapter 6D of the Corporations Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The shares applied for by Exempt Investors
in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under this offering,
except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to
an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which
complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian on-sale restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">This prospectus supplement contains general
information only and does not take account of the investment objectives, financial situation or particular needs of any particular
person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors
need to consider whether the information in this prospectus supplement is appropriate to their needs, objectives and circumstances,
and, if necessary, seek expert advice on those matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Notice to Prospective Investors in Hong Kong</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The common shares have not been offered
or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a) to &ldquo;professional investors&rdquo;
as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b) in other
circumstances which do not result in the document being a &ldquo;prospectus&rdquo; as defined in the Companies Ordinance (Cap.
32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation
or document relating to the common shares has been or may be issued or has been or may be in the possession of any person for the
purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed
or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Notice to Prospective Investors in Japan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The common shares have not been and will
not be registered under the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948, as amended) and, accordingly,
will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for re-offering
or resale, directly or indirectly, in Japan or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">to any Japanese Person, except in compliance with all applicable
laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect
at the relevant time. For the purposes of this paragraph, &ldquo;Japanese Person&rdquo; shall mean any person resident in Japan,
including any corporation or other entity organized under the laws of Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Notice to Prospective Investors in Singapore</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">This prospectus supplement has not been
registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus supplement and any other document
or material in connection with the offer or sale, or invitation for subscription or purchase, of Non-CIS Securities may not be
circulated or distributed, nor may the Non-CIS Securities be offered or sold, or be made the subject of an invitation for subscription
or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section
274 of the Securities and Futures Act, Chapter 289 of Singapore, the SFA, (ii) to a relevant person pursuant to Section 275(1),
or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section 275, of the SFA, or (iii)
otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Where the Non-CIS Securities are subscribed
or purchased under Section 275 of the SFA by a relevant person which is: (a) a corporation (which is not an accredited investor
(as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which
is owned by one or more individuals, each of whom is an accredited investor; or (b) a trust (where the trustee is not an accredited
investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,
securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries&rsquo; rights and interest (howsoever
described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the Non-CIS
Securities pursuant to an offer made under Section 275 of the SFA except:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.35pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an
offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.35pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>where no consideration is or will be given for the transfer;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.35pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>where the transfer is by operation of law;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.35pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>as specified in Section 276(7) of the SFA; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.35pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005
of Singapore.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Notice to Canadian Residents</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>Resale Restrictions</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The distribution of the common shares in
Canada is being made only in the provinces of Ontario, Quebec, Alberta and British Columbia on a private placement basis exempt
from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades
of these securities are made. Any resale of the common shares in Canada must be made under applicable securities laws which may
vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under
a discretionary exemption granted by the applicable Canadian securities regulatory authority. Purchasers are advised to seek legal
advice prior to any resale of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>Representations of Canadian Purchasers</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">By purchasing the common shares in Canada
and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the purchase confirmation
is received that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the purchaser is entitled under applicable provincial securities laws to purchase the common shares without the benefit of
a prospectus qualified under those securities laws as it is an &ldquo;accredited investor&rdquo; as defined under National Instrument
45-106 &ndash; Prospectus Exemptions,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the purchaser is a &ldquo;permitted client&rdquo; as defined in National Instrument 31-103 - Registration Requirements, Exemptions
and Ongoing Registrant Obligations,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>where required by law, the purchaser is purchasing as principal and not as agent, and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the purchaser has reviewed the text above under Resale Restrictions.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>Statutory Rights of Action</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Securities legislation in certain provinces
or territories of Canada may provide a purchaser with remedies for rescission or damages if the offering memorandum (including
any amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages
are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province
or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation
of the purchaser&rsquo;s province or territory for particulars of these rights or consult with a legal advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD>Enforcement of Legal Rights</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">All of our directors and officers as well
as the experts named herein may be located outside of Canada and, as a result, it may not be possible for Canadian purchasers to
effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the assets of
those persons may be located outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those
persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD>Taxation and Eligibility for Investment</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Canadian purchasers of the ordinary shares
offered in this offering should consult their own legal and tax advisors with respect to the tax consequences of an investment
in the ordinary shares in their particular circumstances and about the eligibility of the ordinary shares for investment by the
purchaser under relevant Canadian legislation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Legal Matters</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The validity of our common shares and certain
other matters of Swiss law will be passed upon for us by Vischer AG, Zurich, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Experts</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The financial statements of AC Immune SA
appearing in AC Immune SA&rsquo;s Annual Report (Form 20-F) for the year ended December 31, 2017 have been audited by Ernst &amp;
Young AG, Switzerland, an independent registered public accounting firm, as set forth in their report thereon, included therein,
and incorporated herein by reference. Such financial statements are incorporated herein by reference in reliance upon such report
given the authority of such firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The current address of Ernst &amp; Young
AG is Route de Chancy 59, 1213 Petit-Lancy, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Where You
Can Find More Information</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">We have filed
with the U.S. Securities and Exchange Commission, the SEC, a registration statement (including amendments and exhibits to the registration
statement) on Form F-3 under the Securities Act. This prospectus, which is part of the registration statement, does not contain
all of the information set forth in the registration statement and the exhibits and schedules to the registration statement. For
further information, we refer you to the registration statement and the exhibits and schedules filed as part of the registration
statement. If a document has been filed as an exhibit to the registration statement, we refer you to the copy of the document that
has been filed. Each statement in this prospectus relating to a document filed as an exhibit is qualified in all respects by the
filed exhibit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">You may review
a copy of the registration statement, including exhibits and any schedule filed therewith, and obtain copies of such materials
at the SEC&rsquo;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Information on the operation of the Public
Reference Room may be obtained by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet website that contains
reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is&nbsp;<I>www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Incorporation
By Reference</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">The SEC allows us to incorporate by reference
information into this document. This means that we can disclose important information to you by referring you to another document
filed separately with the SEC. The information incorporated by reference is considered to be a part of this document, except for
any information superseded by information that is included directly in this prospectus supplement incorporated by reference subsequent
to the date of this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">We incorporate by reference the following
documents or information that we have filed with the SEC:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our 2017 Annual Report on Form 20-F for the fiscal
year ended December&nbsp;31, 2017;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our Forms 6-K filed on March 20, 2018 (only with respect
to &ldquo;Item 1.C&mdash;2017 Board Compensation&rdquo; and &ldquo;Item 2.C&mdash;2017 Executive Compensation&rdquo; of Exhibit
99.3), March 22, 2018, March 26, 2018, April 27, 2018, May 2, 2018 (only with respect to Exhibits 99.1 and 99.2), June 7, 2018,
July 7, 2018 and July 17, 2018; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The description of our common shares contained in
our registration statement on Form 8-A filed with the SEC on September&nbsp;23, 2016, including any amendments or reports filed
for the purpose of updating such description.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">All annual reports we file with the SEC
pursuant to the Exchange Act on Form 20-F after the date of this prospectus supplement and prior to termination or expiration of
this registration statement shall be deemed incorporated by reference into this prospectus supplement and to be part hereof from
the date of filing of such documents. We may incorporate by reference any Form 6-K subsequently submitted to the SEC by identifying
in such Form 6-K that it is being incorporated by reference into this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">Documents incorporated by reference in
this prospectus are available from us without charge upon written or oral request, excluding any exhibits to those documents that
are not specifically incorporated by reference into those documents. Each person, including any beneficial owner, to whom a prospectus
is delivered can obtain documents incorporated by reference in this document by requesting them from us in writing at EPFL Innovation
Park Building B, 1015 Lausanne, Switzerland or via telephone at +41 21 345 91 21.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 23.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Statutory
Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 25%"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B><IMG SRC="ey.jpg" ALT=""></B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 28%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ernst &amp; Young Ltd</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rue de Chancey 59&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">P.O. Box</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CH-1213 Lancy</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="vertical-align: bottom; width: 47%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone&#9;&nbsp;&nbsp;+41 58 286 86 86</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+41 58 286 86 00&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">www.ey.com/ch</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 68%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the General Meeting of</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AC Immune SA, Ecublens</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="width: 32%">Lancy, 20 March 2018</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Report of the statutory auditor on the financial statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%">&nbsp;</TD>
    <TD STYLE="width: 86%; padding-left: 4pt"><P STYLE="margin-top: 0; margin-bottom: 0">As statutory auditor, we have audited the accompanying financial statements of AC Immune SA, which comprise the balance sheet, income statement and notes, for the year ended 31 December 2017.</P>
                                              <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B><IMG SRC="image_f1a.jpg" ALT=""></B></FONT></TD>
    <TD STYLE="padding-left: 4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board of Directors&rsquo; responsibility</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors is responsible for the preparation of
        the financial statements in accordance with the requirements of Swiss law and the company&rsquo;s articles of incorporation. This
        responsibility includes designing, implementing and maintaining an internal control system relevant to the preparation of financial
        statements that are free from material misstatement, whether due to fraud or error. The Board of Directors is further responsible
        for selecting and applying appropriate accounting policies and making accounting estimates that are reasonable in the circumstances.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B><IMG SRC="image_f1b.jpg" ALT=""></B></FONT></TD>
    <TD STYLE="padding-left: 4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Auditor&rsquo;s responsibility</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our responsibility is to express an opinion on these financial
        statements based on our audit. We conducted our audit in accordance with Swiss law and Swiss Auditing Standards. Those standards
        require that we plan and perform the audit to obtain reasonable assurance whether the financial statements are free from material
        misstatement.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">An audit involves performing procedures to obtain audit evidence
        about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor&rsquo;s judgment,
        including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making
        those risk assessments, the auditor considers the internal control system relevant to the entity&rsquo;s preparation of the financial
        statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing
        an opinion on the effectiveness of the entity&rsquo;s internal control system. An audit also includes evaluating the appropriateness
        of the accounting policies used and the reasonableness of accounting estimates made, as well as evaluating the overall presentation
        of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis
        for our audit opinion.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B><IMG SRC="image_f1c.jpg" ALT=""></B></FONT></TD>
    <TD STYLE="padding-left: 4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Opinion</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In our opinion, the financial statements for the year ended
        31 December 2017 comply with Swiss law and the company&rsquo;s articles of incorporation.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 45; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATUTORY FINANCIAL STATEMENTS &ndash;
AC IMMUNE SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B><IMG SRC="image_f2.jpg" ALT=""></B></FONT></TD>
    <TD STYLE="width: 86%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Report on key audit matters based on the circular 1/2015 of
        the Federal Audit Oversight Authority</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Key audit matters are those matters that, in our professional
        judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed
        in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a
        separate opinion on these matters. For each matter below, our description of how our audit addressed the matter is provided in
        that context.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have fulfilled the responsibilities described in the <I>Auditor&rsquo;s
        responsibilities</I> section of our report, including in relation to these matters. Accordingly, our audit included the performance
        of procedures designed to respond to our assessment of the risks of material misstatement of the financial statements. The results
        of our audit procedures, including the procedures performed to address the matters below, provide the basis for our audit opinion
        on the accompanying financial statements.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE=""><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Collaboration arrangements - revenue
    recognition</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%">&nbsp;</TD>
    <TD STYLE="width: 15%; border-top: gray 1pt solid; border-bottom: gray 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Area
    of focus</B></FONT></TD>
    <TD STYLE="width: 71%; border-top: gray 1pt solid; border-bottom: gray 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AC Immune SA has entered into material revenue generating collaboration
        agreements with various collaboration partners. These arrangements vary in type and structure; however, typically include up-front
        fees, performance milestones and contain separate Research and Development (R&amp;D) service deliverables. Revenue is recognized
        as Contract Revenue on the Income Statement over the estimated performance or agreement period or upon successful accomplishment
        of pre-defined objectives.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Given the nature of the collaboration agreements and the complexity
        and judgement involved, we consider this area as significant to our audit.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Refer to Note 2 and Note 11 in the Financial Statements for
        AC Immune's accounting policy and further details.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Our audit response</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Our audit procedures included assessing the application of the accounting policy for collaboration agreements. For each significant transaction, we evaluated the revenue recognition timing compared to the timing of fulfillment of contractual terms and conditions and corroborated the key judgements applied in this determination.</FONT></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATUTORY FINANCIAL STATEMENTS &ndash;
AC IMMUNE SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B><IMG SRC="image_f3.jpg" ALT=""></B></FONT></TD>
    <TD STYLE="width: 86%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Report on other legal requirements</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We confirm that we meet the legal requirements on licensing
        according to the Auditor Oversight Act (AOA) and independence (article 728 CO and article 11 AOA) and that there are no circumstances
        incompatible with our independence.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accordance with article 728a para. 1 item 3 CO and Swiss
        Auditing Standard 890, we confirm that an internal control system exists, which has been designed for the preparation of financial
        statements according to the instructions of the Board of Directors.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recommend that the financial statements submitted to you
        be approved.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ernst &amp; Young Ltd</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%">&nbsp;</TD>
    <TD STYLE="width: 44%"></TD>
    <TD STYLE="width: 1%; color: white">&nbsp;</TD>
    <TD STYLE="width: 41%; color: white">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">J&uuml;rg Z&uuml;rcher</FONT></TD>
    <TD STYLE="color: white">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Paulina Korecka</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensed audit expert</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified Public Accountant</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Auditor in charge)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%">&nbsp;</TD>
    <TD STYLE="width: 86%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Enclosures</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Wingdings 3; color: #FFE600"><IMG SRC="arrow.jpg" ALT="">&#9;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Financial statements (balance sheet, income statement and notes)</FONT></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATUTORY FINANCIAL STATEMENTS &ndash;
AC IMMUNE SA</B>&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Balance Sheet</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-bottom: black 1pt solid; text-align: center"><B>As at 31 December,&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><B>in CHF thousands</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center"><B>Notes</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><B>2017&nbsp;&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><B>2016&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 70%"><B>Assets</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><B>Current assets</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Cash and cash equivalents</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">5</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">124,631</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">153,831</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Other current receivables</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>- Third parties</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">6</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">918</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">517</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>- Short-term financial receivables</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">6</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">20</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Prepaid expenses</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">7</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1,457</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1,278</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Accrued income</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">2,799</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">889</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD><B>Total current assets</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><B>129,825</B></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><B>156,535</B></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD><B>Non-current assets</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Financial assets</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">4</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">126</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">86</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Property, plant and equipment</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2,353</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1,120</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Prepaid expenses</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">7</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">17</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">-</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD><B>Total non-current assets</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><B>2,496</B></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><B>1,206</B></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD><B>Total assets</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><B>132,321</B></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><B>157,741</B></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD><B>Liabilities and shareholders' equity</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD><B>Current liabilities</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Trade payables</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>- To third parties</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1,092</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2,720</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>- To shareholders</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">39</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Accrued expenses and deferred income</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">8,662</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">7,163</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><B>Total current liabilities</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><B>9,754</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><B>9,922</B></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Non-current liabilities</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Long-term financing obligation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">494</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">-</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD><B>Total non-current liabilities</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><B>494</B></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><B>-</B></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD><B>Shareholders' equity</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Share capital</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1,147</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1,135</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Reserves from capital contributions</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">179,352</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">179,242</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Accumulated losses brought forward</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">(32,558</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">(24,930</TD>
    <TD>)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Loss for the year</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">(25,868</TD>
    <TD STYLE="border-bottom: black 1pt solid">)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">(7,628</TD>
    <TD STYLE="border-bottom: black 1pt solid">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><B>Total shareholders' equity</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><B>122,073</B></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><B>147,819</B></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><B>Total liabilities and shareholders' equity</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><B>132,321</B></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><B>157,741</B></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATUTORY FINANCIAL STATEMENTS &ndash;
AC IMMUNE SA</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Income Statement</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center"><FONT STYLE="color: black"><B>For the Years Ended 31 December,</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="color: black"><B>in CHF thousands</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="color: black"><B>Notes</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="color: black"><B>2017&nbsp;&nbsp;</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="color: black"><B>2016&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 70%"><FONT STYLE="color: black"><B>Contract revenue</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center"><FONT STYLE="color: black">11</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="color: black"><B>20,255</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="color: black"><B>23,214</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD><FONT STYLE="color: black"><B>Operating expenses</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: black">Salaries and related costs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">12</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">(13,206</FONT></TD>
    <TD><FONT STYLE="color: black">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">(10,168</FONT></TD>
    <TD><FONT STYLE="color: black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD><FONT STYLE="color: black">Operating expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">12</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">(27,098</FONT></TD>
    <TD><FONT STYLE="color: black">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">(25,499</FONT></TD>
    <TD><FONT STYLE="color: black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: black">Depreciation of fixed assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">12</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="color: black">(580</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="color: black">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="color: black">(278</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="color: black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD><FONT STYLE="color: black"><B>Total operating expenses</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black"><B>(40,884</B></FONT></TD>
    <TD><FONT STYLE="color: black"><B>)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black"><B>(35,945</B></FONT></TD>
    <TD><FONT STYLE="color: black"><B>)</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD><FONT STYLE="color: black"><B>Operating loss</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black"><B>(20,629</B></FONT></TD>
    <TD><FONT STYLE="color: black"><B>)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black"><B>(12,731</B></FONT></TD>
    <TD><FONT STYLE="color: black"><B>)</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD><FONT STYLE="color: black">Financial income</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">13</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">450</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="color: black">5,238</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="color: black">Financial expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="color: black">13</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="color: black">(5,689</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="color: black">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="color: black">(135</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="color: black">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD><FONT STYLE="color: black"><B>Loss for the period</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="color: black"><B>(25,868</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="color: black"><B>)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="color: black"><B>(7,628</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="color: black"><B>)</B></FONT></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATUTORY FINANCIAL STATEMENTS &ndash;
AC IMMUNE SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notes to the financial statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD>General information</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">AC Immune SA (the &ldquo;Company,&rdquo;
or &ldquo;AC Immune,&rdquo; &ldquo;ACI,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;ours,&rdquo; &ldquo;us&rdquo;) is a
clinical stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel,
proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding.
Misfolded proteins are generally recognized as the leading cause of neurodegenerative diseases, such as Alzheimer&rsquo;s disease,
or AD, and Parkinson&rsquo;s disease, or PD, with common mechanisms and drug targets, such as Abeta, Tau and alpha-synuclein. Our
corporate strategy is founded upon a three-pillar approach that targets Alzheimer&rsquo;s Disease, non-Alzheimer&rsquo;s neurodegenerative
diseases including neuro-orphan indications and diagnostics. Our lead product candidate is crenezumab, a humanized, monoclonal,
conformation-specific anti-Abeta antibody that we developed using our proprietary SupraAntigen platform. The two Phase 3 clinical
studies for crenezumab were commenced in early 2016 and in February 2017, respectively. We use our two unique proprietary platform
technologies, SupraAntigen (conformation-specific biologics) and Morphomer (conformation-specific small molecules), to discover,
design and develop medicines and diagnostics to target misfolded proteins.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company was initially incorporated
as a limited liability company on 13 February 2003 in Basel and effective 25 August 2003 was transformed into a stock company.
The Company&rsquo;s corporate headquarters are located at EPFL Innovation Park Building B, Ecublens/Lausanne, Vaud, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The statutory financial statements of AC
Immune SA for the period ended 31 December 2017 were authorized for issue in accordance with a resolution of the Board of Directors
on 19 March 2018 and will be submitted to the next Ordinary General Assembly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During 2017 and 2016, AC Immune had an
annual average of more than 50 but less than 250 full time equivalent positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD>Summary of significant accounting principles</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The present annual accounts have been prepared
in accordance with the provisions of the Swiss law on accounting and financial reporting (32 <FONT STYLE="font-size: 10pt"><SUP>nd</SUP></FONT>
Title of the Swiss Code of Obligations). The principal accounting policies are set out below. These policies have been consistently
applied to all the years presented, unless otherwise stated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the presentation of the financial statements
for 2017 and 2016, certain amounts were reclassified in 2016 to conform to the 2017 financial statement presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Current vs. non-current classification</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company presents assets and liabilities
in the balance sheet based on current/non-current classification. The Company classifies all amounts to be realized or settled
within twelve months after the reporting period to be current and all other amounts to be non-current.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foreign currency transactions</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The financial statements are presented
in Swiss Francs (CHF). Foreign currency transactions are translated into the functional currency (CHF) using prevailing exchange
rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into CHF
at rates of exchange prevailing at reporting date. Any gains or losses from these translations are included in the income statement
in the period in which they arise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Non-monetary assets and liabilities at
historical costs are converted at the foreign exchange rate at the time of the transaction. Any foreign exchange profits are deferred
in the balance sheet as not having an effect on net income. Foreign exchange losses, on the other hand, are recorded in the profit
and loss account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenue recognition</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Revenue includes upfront fees, milestone
payments as well as revenue from research and development agreements associated with collaborations with third parties and grants
from public institutions and foundations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATUTORY FINANCIAL STATEMENTS &ndash;
AC IMMUNE SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">License of intellectual property</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Revenue from non-refundable, upfront license
payments and performance milestones where the Company has continuing involvement is recognized over the estimated performance or
agreement period, depending on the terms of the agreement. The recognition of revenue is prospectively changed for subsequent changes
in the development or agreement period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For collaboration agreements on product
candidates (i)&nbsp;that are in clinical development, (ii)&nbsp;where the upfront payment reflects a payment for past investments
the Company has made in the development of the product candidate, access to the product candidate, the associated intellectual
property and our knowledge, and, (iii)&nbsp;where there is no further performance commitment, the Company recognizes the fair value
of the upfront payment at the time of entering into the collaboration agreement. For collaboration agreements (i)&nbsp;in clinical
development but where conditions (ii)&nbsp;and (iii)&nbsp;are not met, the Company recognizes revenue from upfront payments under
our collaboration agreements pro-rata over the term of the estimated period of performance under each agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For collaboration agreements, in addition
to receiving upfront payments, the Company is also entitled to milestone and other contingent payments upon achieving pre-defined
objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Milestone payments</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Revenue from milestones, if they are non-refundable
and deemed substantive, is recognized upon successful accomplishment of the milestones. To the extent that non-substantive milestones
are achieved and the Company has remaining performance obligations, milestones are deferred and recognized as revenue over the
estimated remaining period of performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and Development Services</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has certain arrangements with
our collaboration partners that include contracting our full-time employees for research and development programs. These revenues
are recorded in license and collaboration revenues as the services are performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenditures</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Given the stage of development of the Company&rsquo;s
products, all research expenditures are recognized as expenses when incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For external research contracts accrued
expenses are generally estimated based on a rate of completion related to each research project in a clinical study. The Company
estimates its accrued expenses as of the balance sheet date in the financial statement based on facts and circumstances known at
the time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Registration costs for patents are part
of the expenditure for research and development projects. Therefore, registration costs for patents are expensed when incurred
as long as the research and development project concerned does not meet the criteria for capitalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Total research and development related
costs, inclusive of operating expenses, payroll related expenses, and depreciation were CHF 32.1M in 2017 and CHF 25.2M in 2016.
R&amp;D expenses in Alzheimer&rsquo;s disease were driven by the investments related to the completion of the Phase 1b study for
ACI-35, as well as costs related to the combined Phase 1/2a study for ACI-24 AD. In addition, the Company incurred costs for the
next stages of clinical development for each of these respective candidates. In Non-Alzheimer&rsquo;s diseases, the Company continues
to incur costs in ACI-24 for Down syndrome&rsquo;s Phase 1b clinical study. Diagnostic investments entail predominantly increases
in spending related to our alpha-synuclein and TDP-43 PET tracer programs. New discovery programs increase CHF 3.8 million driven
by CHF 3.3 million related to finalizing the proof-of-concept and manufacturing activities for studies related to our lead compounds
in the Anti-Tau Morphomers and investments in new therapeutic and preventive vaccine technology. R&amp;D Expenses not allocated
to specific programs increased CHF 2.5 million predominantly driven by a CHF 1.9 million increase in salaries and related costs,
CHF 0.3 million in depreciation expense and CHF 0.1 million in regulatory costs. Our total research and development costs are likely
to rise substantially in the coming years as the Company continues to develop and advance product candidates from the pre-clinical
to clinical stages across its three-pillar strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATUTORY FINANCIAL STATEMENTS &ndash;
AC IMMUNE SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property, plant and equipment</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Property, plant and equipment is shown
at historical acquisition cost, less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures
that are directly attributable to the acquisition of the property, plant and equipment. Depreciation is calculated using a straight-line
method to write off the cost of each asset to its residual value over its estimated useful life as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="width: 50%; text-align: justify; padding-left: 2pt">IT equipment</TD>
    <TD STYLE="width: 50%; text-align: justify">3 years</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 2pt">Laboratory equipment</TD>
    <TD STYLE="text-align: justify">5 years</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: justify; padding-left: 2pt">Leasehold improvements / furniture</TD>
    <TD STYLE="text-align: justify">5 years</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The assets&rsquo; residual values and useful
lives are reviewed, and adjusted if appropriate, at each balance sheet date. Where an asset&rsquo;s carrying amount is greater
than its estimated recoverable amount, it is written down to its recoverable amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Profits and losses on disposals are determined
by comparing the disposal proceeds with the carrying amount and are included in the income statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial assets &amp; liabilities</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s financial assets and
liabilities are only comprised of receivables, cash and cash equivalents and trade payables and a long-term financing obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Receivables</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Receivables are non-derivative financial
assets with fixed payments that are not quoted in an active market. They arise when the Company provides money, goods or services
directly to a debtor with no intention of trading the receivable. They are included in current assets, except for maturities greater
than 12 months after the balance sheet date, which are classified as long-term assets. Receivables are recognized at their billing
value. An allowance for doubtful accounts is recorded for potential estimated losses when there is objective evidence of the debtor&rsquo;s
inability to make required payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash and cash equivalents</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Cash and cash equivalents include deposits
held with external financial institutions and cash on hand. All cash and cash equivalents are either in cash or in deposits with
less than 3 months&rsquo; duration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Trade payables</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Trade payables are recognized initially
at nominal amount, which represents cost incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Long-term financing obligation</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s long-term financing
obligation is measured as of the period end date based on the repayment terms when originated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATUTORY FINANCIAL STATEMENTS &ndash;
AC IMMUNE SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Significant Shareholders</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Principal shareholders who own more than
5 percent of the voting rights:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-top: black 1pt solid; text-align: center"><B>Shares Owned</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-top: black 1pt solid; text-align: center"><B>Shares Owned</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-bottom: black 1pt solid; text-align: center"><B>2017</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-bottom: black 1pt solid; text-align: center"><B>2016</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 58%"><B>Principal Shareholders</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; text-align: center"><B>Number</B></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 7%; border-bottom: black 1pt solid; text-align: center"><B>Percent</B></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; text-align: center"><B>Number</B></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 7%; border-bottom: black 1pt solid; text-align: center"><B>Percent</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><B>5% Shareholders</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>dievini Hopp BioTech holding GmbH &amp; Co KG<FONT STYLE="font-size: 11pt"><SUP>(1)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">18,041,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">31.5</TD>
    <TD>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">18,041,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">31.7</TD>
    <TD>%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Varuma AG<FONT STYLE="font-size: 11pt"><SUP>(2)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">11,410,700</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">19.9</TD>
    <TD>%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">11,400,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">20.0</TD>
    <TD>%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Andrea Pfeifer, Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2,908,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5.1</TD>
    <TD>%</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Represents 18,041,000 shares held by dievini Hopp BioTech holding CmbH &amp; Co KG. Dietmar Hopp controls the voting and investment
decisions of the ultimate parent company of dievini Hopp BioTech holding CmbH &amp; Co KG. The shares registered in the name of
dievini Hopp BioTech holding CmbH &amp; Co KG may also be deemed to be beneficially owned by Friedrich von Bohlen und Halbach,
who is a managing director of dievini Hopp BioTech holding CmbH &amp; Co KG. The address for dievini Hopp BioTech holding CmbH
&amp; Co KG, Friedrich von Bohlen und Halbach is Johann-Jakob-Astor Str. 57, 69190 Walldorf, Germany.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>The address for Varuma AG is Aeschenvorstadt 55, CH-4051 Basel, Switzerland. Rudolf Maag controls the voting and investment
decisions of Varuma AG.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">*</TD><TD>less than 5 percent held at 31December 2017</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating lease liabilities</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have been a tenant at our current location
in the EPFL Innovation Park in Lausanne since shortly after our inception in 2003. We have entered into long-term rental lease
agreements with respect to these facilities. However, our lease agreements are structured such that we can exit these lease agreements
without penalty provided we give the owner of our premises sufficient notice. As of 31 December 2017, total minimum liability for
the remaining term was CHF 243 thousand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Provisions</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Provisions are recognized when the Company
has a present legal or constructive obligation as a result of past events where it is more likely than not that an outflow of resources
will be required to settle the obligation, and a reliable estimate of the amount can be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Critical judgments and accounting estimates</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The preparation of financial statements
in conformity with Swiss Code of Obligations requires management to make judgments, estimates and assumptions that affect the application
of accounting policies and the reported amounts of assets, liabilities, income and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The areas where AC Immune has had to make
judgments, estimates and assumptions relate to (i) revenue recognition on collaboration and licensing agreements and (ii) clinical
development accruals. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing
basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Information relating to items on Balance
Sheet and Income Statement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATUTORY FINANCIAL STATEMENTS &ndash;
AC IMMUNE SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD>Property, plant and equipment</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As at 31 December,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">in CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>2016</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 78%">Furniture</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">85</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">81</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">IT equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">569</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">298</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Lab equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,163</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,793</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Leasehold improvements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">271</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">103</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total property, plant and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,088</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,275</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,735</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,155</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,353</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,120</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD>Financial assets</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As at 31 December,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">in CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 78%; text-align: left">Rental deposit (restricted cash)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">123</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">83</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Security deposit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">126</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">86</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD>Cash and cash equivalents</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As at 31 December,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">in CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 78%">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">80,631</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">11,366</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Short term deposits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">44,000</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">142,465</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">124,631</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">153,831</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">By Currency</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>CHF</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103,272</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,322</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>EUR</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,694</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,818</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">USD</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,665</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">105,691</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">124,631</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">153,831</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">6.</TD><TD>Other current receivables</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As at 31 December,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">in CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Other current receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 78%; text-align: left">- from third parties</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">918</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">517</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">- short-term financial receivables</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">938</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">537</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">7.</TD><TD>Prepaid expenses</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As at 31 December,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">in CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 78%; text-align: left">Prepaid expenses (current)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1,457</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1,278</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Prepaid expenses (non-current)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,474</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,278</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATUTORY FINANCIAL STATEMENTS &ndash;
AC IMMUNE SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">8.</TD><TD>Trade payables and accrued liabilities</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As at 31 December,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">in CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Trade payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 78%; text-align: left">- to third parties</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">1,092</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">2,720</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">- to shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued payroll expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,420</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,560</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Accrued R&amp;D costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,429</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,265</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">458</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">817</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Current portion of deferred Income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">355</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">521</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total accrued expenses and deferred income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,662</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,163</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total payables and accrued liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,754</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,922</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">9.</TD><TD>Long-term financing obligation</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As at 31 December,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">in CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 78%; text-align: left">Accrued interest &ndash; long-term</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">99</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Long-term financing obligation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">395</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">494</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">10.</TD><TD>Share capital</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As at 31 December 2017, the issued share
capital amounted to CHF 1,146,984 is comprised of 57,349,190 common shares at a par value of CHF 0.02 per common share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">11.</TD><TD>Revenues</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended 31 December,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">in CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 78%; text-align: left; padding-bottom: 1pt">Contract revenue</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; border-bottom: Black 1pt solid; text-align: right">20,255</TD><TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; border-bottom: Black 1pt solid; text-align: right">23,214</TD><TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">20,255</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">23,214</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATUTORY FINANCIAL STATEMENTS &ndash;
AC IMMUNE SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">12.</TD><TD>Operating expenses</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended 31 December,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">in CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">Salaries and related costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 78%; text-align: left">- related to research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">8,294</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">6,441</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">- related to general administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,912</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,727</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total salaries and related cost</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,206</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,168</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">- related to research and development expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23,242</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,489</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total research and development expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">23,242</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,489</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">- related to regular general and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,856</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,168</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">- related to IPO</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,842</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total general and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,856</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,010</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Depreciation of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">580</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">278</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">40,884</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">35,945</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">13.</TD><TD>Financial income and expenses</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the Years Ended 31 December,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">in CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">Financial income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 78%; text-align: left">- interest income</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">330</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">43</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">- foreign exchange gains</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">120</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,195</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total financial income</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">450</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,238</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left">Financial expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">- foreign exchange (losses)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,536</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">- bank fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(119</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">- interest expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(146</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total financial expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,689</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(135</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">14.</TD><TD>Shareholders rights and equity awards</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table presents information
on the allocation of shares and equity awards to executive officers, directors and employees in accordance with Article 959c, paragraph
2, number 11 Swiss Code of Obligations (CO) as at 31 December 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Equity Awards</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">in CHF thousands</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Number</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">KCHF</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">Number</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: Black 1pt solid">KCHF</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 56%; text-align: left">Issued to executive officers and directors <BR></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">4,657,882</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">58,922</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">930,748</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">3,473</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Issued to employees</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">504,664</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,384</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">479,725</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,119</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,162,546</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">65,306</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,410,473</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,592</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATUTORY FINANCIAL STATEMENTS &ndash;
AC IMMUNE SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Share values are based on the Company&rsquo;s
share price of $12.80 (CHF 12.65). Equity awards are comprised of options and non-vested stock (restricted shares and restricted
share units) awards. The fair value of our options is determined using the Black-Scholes Merton Model and our non-vested stock
awards are valued using a reasonable estimate of market value of the common stock on the date of the award. Total shares are derived
from our transfer agent&rsquo;s records as at 31 December 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The table below presents beneficial ownership
of executive officers and directors, including affiliated entities, if applicable, in accordance with Article 663c CO as at 31
December 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>Beneficial ownership of executive officers and directors</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Number of Shares</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Number of Equity&nbsp;Awards</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 78%; text-align: left">Andrea Pfeifer, Ph.D., Chief Executive Officer and Director</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">2,596,809</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">339,352</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">J&ouml;rg Hornstein, Chief Financial Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113,981</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Andreas Muhs, Ph.D., Chief Scientific Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">475,050</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">373,867</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Jean-Fabien Monin, Chief Administrative Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">275,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,923</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Martin Velasco, Chairman and Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">469,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,125</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Detlev Riesner, Ph.D., Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">759,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,875</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Friedrich von Bohlen und Halbach, Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,875</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Peter Bollmann, Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,875</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Thomas Graney, Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,023</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,875</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">15.</TD><TD>Post balance sheet events</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February 2, 2018, we entered into an
additional lease with the EPFL Innovation Park to expand our premises by more than 4,300 square feet effective March 1, 2018. As
part of this expansion, the Company agreed to purchase CHF 750 thousand of the previous tenant&rsquo;s lab equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Proposal of the Board of Directors to the
annual Shareholders&rsquo; Meeting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Proposal of the Board for the accumulated
losses to be carried forward, subject to the approval of the Annual Shareholders&rsquo; Meeting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As at 31 December,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">in CHF thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 78%; text-align: left">Accumulated losses carried forward</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(32,558</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">(24,930</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Loss for the year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(25,868</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,628</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total accumulated losses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(58,426</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(32,558</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
</TABLE>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROSPECTUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$350,000,000<BR>
Common Shares<BR>
Debt Securities<BR>
Warrants<BR>
Purchase Contracts<BR>
Units<BR>
Subscription Rights</P>

<P STYLE="font: bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt">AC IMMUNE
SA </FONT><BR>
(incorporated in Switzerland)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may offer, from time to time, in one
or more offerings, common shares, senior debt securities, subordinated debt securities, warrants, purchase contracts, units or
subscription rights, which we collectively refer to as the &ldquo;securities.&rdquo; The aggregate initial offering price of the
securities that we may offer and sell under this prospectus will not exceed $350,000,000. We may offer and sell any combination
of the securities described in this prospectus in different series, at times, in amounts, at prices and on terms to be determined
at or prior to the time of each offering. This prospectus describes the general terms of these securities and the general manner
in which these securities will be offered. We will provide the specific terms of these securities in supplements to this prospectus.
The prospectus supplements will also describe the specific manner in which these securities will be offered and may also supplement,
update or amend information contained in this prospectus. You should read this prospectus and any applicable prospectus supplement
before you invest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The securities covered by this prospectus
may be offered through one or more underwriters, dealers and agents, or directly to purchasers. The names of any underwriters,
dealers or agents, if any, will be included in a supplement to this prospectus. For general information about the distribution
of securities offered, please see &ldquo;Plan of Distribution&rdquo; beginning on page 26.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our common shares are listed on the NASDAQ
Global Market under the symbol &ldquo;ACIU.&rdquo; On May 22, 2018, the last sale price of our common shares as reported by the
NASDAQ Global Market was $10.23 per common share. As of May 22, 2018, the aggregate market value of our outstanding common shares
held by non-affiliates was approximately $238,164,456 based on approximately 57,400,565 shares of outstanding common shares, of
which approximately 23,280,983 shares were held by non-affiliates. We have not offered any securities pursuant to General Instruction
I.B.5 of Form F-3 during the prior 12 calendar month period that ends on, and includes, the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Investing in our securities involves
risks. See &ldquo;<U>Risk Factors</U>&rdquo; beginning on page 4 of this prospectus. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Neither the U.S. Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is June 8,
2018.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not authorized anyone to provide you with information
different or additional to the information contained in or incorporated by reference in this prospectus or any related prospectus
supplement we provide to you. We are not making an offer of securities in any jurisdiction where the offer is not permitted. You
should not assume that the information contained in or incorporated by reference in this prospectus is accurate as of any date
other than the date on the front of this prospectus. Unless otherwise noted or the context otherwise requires, references in this
prospectus to &ldquo;AC Immune,&rdquo; &ldquo;the Company,&rdquo; &ldquo;our company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo;
&ldquo;our&rdquo; or similar terms refer to AC Immune SA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">_______________________________</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-variant: small-caps"><U>Page</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD STYLE="width: 94%">About This Prospectus</TD>
    <TD STYLE="width: 6%; text-align: right">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Where You Can Find More Information</TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Special Note Regarding Forward-Looking Statements</TD>
    <TD STYLE="text-align: right">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>AC Immune SA</TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Risk Factors</TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Ratio of Earnings to Fixed Charges</TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Use of Proceeds</TD>
    <TD STYLE="text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Description of Share Capital and Articles of Association</TD>
    <TD STYLE="text-align: right">4</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Comparison of Swiss Law and Delaware Law</TD>
    <TD STYLE="text-align: right">14</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Description of Debt Securities</TD>
    <TD STYLE="text-align: right">20</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Description of Warrants</TD>
    <TD STYLE="text-align: right">21</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Description of Purchase Contracts</TD>
    <TD STYLE="text-align: right">22</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Description of Units</TD>
    <TD STYLE="text-align: right">23</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Description of Subscription Rights</TD>
    <TD STYLE="text-align: right">24</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Plan of Distribution</TD>
    <TD STYLE="text-align: right">25</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Incorporation of Certain Information By Reference</TD>
    <TD STYLE="text-align: right">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Enforcement of Judgments</TD>
    <TD STYLE="text-align: right">26</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Expenses</TD>
    <TD STYLE="text-align: right">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(213,234,234)">
    <TD>Legal Matters</TD>
    <TD STYLE="text-align: right">27</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Experts</TD>
    <TD STYLE="text-align: right">27</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>


<!-- Field: Page; Sequence: 59; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 11pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">About This
Prospectus</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus is part of a registration
statement that we filed with the Securities and Exchange Commission, or the SEC, utilizing a &ldquo;shelf&rdquo; registration process.
Under this shelf process, we may sell any combination of the securities described in this prospectus in one or more offerings.
This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide
a prospectus supplement that will contain specific information about the terms of that offering. The prospectus supplement may
also add, update or change information contained in this prospectus. You should read both this prospectus and any prospectus supplement
together with additional information described under the headings &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation
of Certain Information by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have filed or incorporated by reference
exhibits to the registration statement of which this prospectus forms a part. You should read the exhibits carefully for provisions
that may be important to you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Neither the delivery of this prospectus
nor any sale made under it implies that there has been no change in our affairs or that the information in this prospectus is correct
as of any date after the date of this prospectus. You should not assume that the information in this prospectus, including any
information incorporated in this prospectus by reference, the accompanying prospectus supplement or any free writing prospectus
prepared by us, is accurate as of any date other than the date on the front of those documents. Our business, financial condition,
results of operations and prospects may have changed since that date. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">You should not assume that the information
contained in this prospectus is accurate as of any other date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Where You
Can Find More Information</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We file or furnish certain information
with the SEC, including annual reports on Form 20-F and reports on Form 6-K under the Securities Exchange Act of 1934, as amended,
or the Exchange Act. You may read and copy this information at the following location of the SEC: Public Reference Room, 100 F
Street, N.E., Washington, D.C. 20549.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">You may obtain information on the operation
of the SEC&rsquo;s Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet site that contains
reports and other information about issuers like us who file electronically with the SEC. The address of the site is <I>http://www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As a foreign private issuer, we are exempt
under the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and our
managing directors, supervisory directors and principal shareholders are exempt from the reporting and short-swing profit recovery
provisions contained in Section 16 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Special
Note Regarding Forward-Looking Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This prospectus contains statements that
constitute forward-looking statements. All statements other than statements of historical facts contained in this prospectus, including
statements regarding our future results of operations and financial position, business strategy, product candidates, product pipeline,
ongoing and planned clinical studies, including those of our collaboration partners, regulatory approvals, research and development
costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking
statements. Many of the forward-looking statements contained in this prospectus can be identified by the use of forward-looking
words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;should,&rdquo;
&ldquo;plan,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; &ldquo;will&rdquo; and &ldquo;potential,&rdquo; among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Forward-looking statements appear in a
number of places in this prospectus and include, but are not limited to, statements regarding our intent, belief or current expectations.
Forward-looking statements are based on our management&rsquo;s beliefs and assumptions and on information currently available to
our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed
or implied in the forward-looking statements due to various factors, including, but not limited to, those identified under the
section entitled &ldquo;Risk Factors&rdquo; in this prospectus. These risks and uncertainties include factors relating to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The success of our and our collaboration partners&rsquo; clinical studies, and our and their ability to obtain regulatory approval
and to commercialize crenezumab, our anti-Tau antibody candidate, ACI-24, ACI-35 and our Tau-PET Imaging tracer candidate&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The ability of our competitors to discover, develop or commercialize competing products before or more successfully than we
do&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our Morphomer proprietary technology platform and its success in building additional product candidates for our pipeline&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The identification of serious adverse, undesirable or unacceptable side effects related to our product candidates&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to maintain our current strategic relationships with our collaboration partners&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Failure to protect our, and not infringe on third parties&rsquo;, intellectual property rights throughout the world&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our ability to raise capital when needed in order to continue our product development programs or commercialization efforts&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The FDA&rsquo;s and applicable foreign regulatory authorities&rsquo; acceptance of data from studies we conduct outside the
United States in the future&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our foreign private issuer status, the loss of which would require us to comply with the Exchange Act&rsquo;s domestic reporting
regime and cause us to incur significant legal, accounting and other expenses&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our incorporation in Switzerland, the laws of which govern our corporate affairs and may differ from those applicable to companies
incorporated in the United States&#894; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The other risk factors discussed in our most recent Annual Report on Form 20-F.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">AC Immune
SA</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a clinical stage biopharmaceutical
company focused on neurodegenerative diseases with four product candidates in clinical trials. We leverage our two proprietary
technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative
diseases associated with protein misfolding. Misfolded proteins are generally recognized as the leading cause of neurodegenerative
diseases, such as Alzheimer&rsquo;s disease, or AD, and Parkinson&rsquo;s disease, or PD, with common mechanisms and drug targets,
such as Abeta, Tau and alpha-synuclein and Tar Binding Protein (TDP-43). We believe that our large and diverse pipeline of nine
therapeutic candidates and three diagnostic candidates has the potential to drive a paradigm shift in the treatment of a broad
spectrum of neurodegenerative and other diseases related to protein misfolding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a Swiss stock corporation (<I>soci&eacute;t&eacute;
anonyme</I>) organized under the laws of Switzerland. We were formed as a Swiss limited liability company (<I>soci&eacute;t&eacute;
&agrave; responsabilit&eacute; limit&eacute;e</I>) on February 13, 2003 with our registered office and domicile in Basel, Switzerland.
We converted to a Swiss stock corporation (<I>soci&eacute;t&eacute; anonyme</I>) under the laws of Switzerland on August 25, 2003.
Our Swiss enterprise identification number is CHE-109.878.825. Our domicile and registered office is in Ecublens, near Lausanne,
Canton of Vaud, Switzerland. Our common shares were admitted to trading on NASDAQ Global Market on September 23, 2016. Our shares
are traded under the symbol &ldquo;ACIU.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our registered and principal executive
offices are located at EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland, our general telephone number is (41) 21 345
91 21 and our internet address is www.acimmune.com. Our website and the information contained on or accessible through our website
are not part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Risk Factors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Before making a decision to invest in our
securities, you should carefully consider the risks described under &ldquo;Risk Factors&rdquo; in the applicable prospectus supplement
and in our then most recent Annual Report on Form 20-F, and in any updates to those risk factors in our reports Form 6-K incorporated
herein, together with all of the other information appearing or incorporated by reference in this prospectus and any applicable
prospectus supplement, in light of your particular investment objectives and financial circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Ratio of
Earnings to Fixed Charges</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth our ratio
of earnings to fixed charges for each of the periods indicated. You should read this table in conjunction with the consolidated
financial statements and notes incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="3">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">Fiscal
Year Ended December 31,&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 64%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 12%">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">2017&nbsp;</P></TD>
    <TD STYLE="width: 12%; padding-right: 5pt; padding-left: 5pt">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">2016&nbsp;</P></TD>
    <TD STYLE="width: 12%">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">2015&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD>Ratio of earnings to fixed charges&#9;</TD>
    <TD STYLE="layout-grid-mode: char; text-align: center">*</TD>
    <TD STYLE="layout-grid-mode: char; text-align: center">*</TD>
    <TD STYLE="layout-grid-mode: char; text-align: center">1,062</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">* Our earnings were insufficient to cover
fixed charges of CHF 174 thousand and CHF 27 thousand for the years ended December 31, 2017 and 2016, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For purposes of calculating the ratios
in the table above, earnings consist of pre-tax income/(loss) from continuing operations plus fixed charges. Fixed charges consist
of relevant interest expenses and an estimate of the interest expense (5% for all periods) within rental expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Use of Proceeds</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Unless otherwise indicated in a prospectus
supplement, the net proceeds from our sale of the securities will be used for general corporate purposes and other business opportunities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Description
of Share Capital and Articles of Association</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a Swiss stock corporation (<I>soci&eacute;t&eacute;
anonyme</I>) organized under the laws of Switzerland. We were formed as a Swiss limited liability company (<I>soci&eacute;t&eacute;
&agrave; responsabilit&eacute; limit&eacute;e</I>) on February 13, 2003 with our registered office and domicile in Basel, Switzerland.
We converted to a Swiss stock corporation (<I>soci&eacute;t&eacute; anonyme</I>) under the laws of Switzerland on August 25, 2003.
Our domicile and registered office is in Ecublens, near Lausanne, Canton of Vaud, Switzerland. Our head office is currently located
at EPFL Innovation Park, Building B, Lausanne, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Share Capital</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of the date of this prospectus, our
issued share capital is CHF&nbsp;1,147,253.80, consisting of 57,362,690&nbsp;common shares. We have no dividend rights certificates
(<I>bons de jouissance</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Articles of Association</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On March 26, 2018, we adopted the articles
of association and when we refer to our articles of association in this prospectus, we refer to the articles of association as
filed as Exhibit 4.1 hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Purpose</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Under our articles of association, our
purpose is the research, study, development, manufacture, promotion, sale and marketing of products and substances within the pharmaceutical
and nutrition industry as well as the purchase, sale and exploitation of patents and licenses in this field. We may engage in any
activities which are apt to favor our purpose directly or indirectly. We may also acquire and sell real estate. We may open branch
offices in Switzerland and abroad and may also acquire participations in other companies. We may provide securities to its subsidiaries
and supply guarantees. Ordinary Capital Increase, Authorized and Conditional Share Capital</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under Swiss law, we may increase our share
capital (<I>capital-actions</I>) with a resolution of the general meeting of shareholders (ordinary capital increase) that must
be carried out by the board of directors within three months of the general meeting in order to become effective. Under our articles
of association, in the case of subscription and increase against payment of contributions in cash, a resolution passed by a simple
majority of the shares represented at the general meeting of shareholders regardless of abstentions or empty or invalid votes is
required. In the case of subscription and increase against contributions in kind or to fund acquisitions in kind, when shareholders&rsquo;
statutory pre-emptive subscription rights are withdrawn or where transformation of reserves into share capital is involved, a resolution
passed by two-thirds of the shares represented at a general meeting of shareholders and the absolute majority of the nominal amount
of the shares represented is required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Furthermore, under the Swiss Code of Obligations,
or the CO, our shareholders, by a resolution passed by two-thirds of the shares represented at a general meeting of shareholders
and the absolute majority of the nominal amount of the shares represented, may empower our board of directors to issue shares of
a specific aggregate nominal amount up to a maximum of 50% of the share capital in the form of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>conditional capital (<I>capital conditionnel</I>) for the purpose of issuing shares in connection with, among other things,
(i) option and conversion rights granted in connection with warrants and convertible bonds of the Company or one of our subsidiaries
or (ii) grants of rights to employees, members of our board of directors or consultants or our subsidiaries or other persons providing
services to the Company or a subsidiary to subscribe for new shares (conversion or option rights)&#894; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>authorized capital (<I>capital-actions autoris&eacute;</I>) to be utilized by the board of directors within a period determined
by the shareholders but not exceeding two years from the date of the shareholder approval.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Pre-Emptive Rights</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the CO, shareholders have pre-emptive
subscription rights (<I>droits de souscription</I>) to subscribe for new issuances of shares. With respect to conditional capital
in connection with the issuance of conversion rights,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">convertible bonds or similar debt instruments,
shareholders have advance subscription rights (<I>droit de souscrire pr&eacute;alablement</I>) for the subscription of conversion
rights, convertible bonds or similar debt instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A resolution passed at a general meeting
of shareholders by two-thirds of the shares represented and the absolute majority of the nominal value of the shares represented
may authorize our board of directors to withdraw or limit pre-emptive subscription rights or advance subscription rights in certain
circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If pre-emptive subscription rights are
granted, but not exercised, the board of directors may allocate the pre-emptive subscription rights as it elects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The authorization previously granted to
the board of directors to issue share capital has expired. A valid authorization to issue share capital in the articles of association
of a Swiss stock corporation would typically provide for the withdrawal or limitation of preemptive subscription rights of shareholders,
and their allocation to third parties or to the company, in the event that the newly issued shares are used for the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if the issue price of the new registered shares is determined by reference to the market price&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>for the acquisition of an enterprise, part(s) of an enterprise or participations, or for the financing or refinancing of any
of such transactions, or in the event of share placement for the financing or re-financing of such transactions&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>for purposes of broadening the shareholder constituency of the company in certain financial or investor markets, for purposes
of the participation of strategic partners, or in connection with the listing or registration of new registered shares on domestic
or foreign stock exchanges&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>for purposes of granting an over-allotment option of up to 20% of the total number of registered shares in a placement or sale
of registered shares to the respective initial purchaser(s) or underwriter(s)&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>for raising of capital (including private placements) in a fast and flexible manner which probably could not be reached without
the exclusion of the statutory pre-emptive right of the existing shareholders&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>for other valid grounds in the sense of Article 652b para. 2 of the CO.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Our Authorized Share Capital</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under Article 3a of our articles of association,
the authorization granted to our board of directors to increase our nominal share capital has expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Our Conditional Share Capital</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Conditional Share Capital for Bonds and Similar
Debt Instruments</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under Article 3b of our articles of association,
our nominal share capital may be increased by a maximum aggregate amount of CHF 91,867.50 through the issuance of not more than
4,593,375 common shares, which would have to be fully paid-in, with a nominal value of CHF 0.02 each, by the exercise of option
and conversion rights granted in connection with warrants and convertible bonds of the Company or one of our subsidiaries. Shareholders
will not have pre-emptive subscription rights in such circumstances. The holders of convertible bonds are entitled to the new shares
upon the occurrence of the applicable conversion feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">When issuing convertible bonds, the board
of directors is authorized to withdraw or to limit the advance subscription right of shareholders to subscribe to the convertible
bond issuance:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>for the purpose of financing or refinancing the acquisition of enterprises, divisions thereof, or of participations or of newly
planned investments of the Company&#894; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if the issuance occurs in domestic or international capital markets, including private placements.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To the extent that the advance subscription
rights are withdrawn, (i) the convertible bonds are to be issued at market conditions&#894; (ii) the term to exercise the option
or conversion rights may not exceed ten years as of the date of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">the convertible bond issue and twenty years
for conversion rights&#894; and (iii) the exercise price for the new shares must at least correspond to the market conditions at
the time of the convertible bond issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Conditional Share Capital for Employee Benefit
Plans</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under Article 3c of our articles of association,
our nominal share capital may, to the exclusion of the pre-emptive subscription rights of shareholders, be increased by a maximum
aggregate amount of CHF 57,073.04 through the issuance of not more than 2,853,652 common shares, which would have to be fully paid-in,
with a nominal value of CHF 0.02 each, by the exercise of option or conversion rights that have been granted to employees, members
of the board of directors or consultants of the Company or of one of our subsidiaries or other persons providing services to the
Company or a subsidiary through one or more equity incentive plans created by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Uncertificated Securities</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our shares are uncertificated securities
(<I>droits-valeurs</I>, within the meaning of Article 973c of the CO) and, when administered by a financial intermediary (<I>d&eacute;positaire</I>,
within the meaning of the Federal Act on Intermediated Securities, &ldquo;FISA&rdquo;), qualify as intermediated securities (<I>titres
interm&eacute;di&eacute;s</I>, within the meaning of the FISA). In accordance with Article 973c of the CO, we will maintain a non-public
register of uncertificated securities (<I>registre des droits-valeurs</I>). We may at any time convert uncertificated securities
into share certificates (including global certificates), one kind of certificate into another, or share certificates (including
global certificates) into uncertificated securities. Following entry in the share register, a shareholder may at any time request
from us a written confirmation in respect of the shares held by such shareholder, as reflected in the share register. Shareholders
are not entitled, however, to request the printing and delivery of certificates. We may print and deliver certificates for shares
at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">General Meeting of Shareholders</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Ordinary/Extraordinary Meetings, Powers</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The general meeting of shareholders is
our supreme corporate body. Under Swiss law, ordinary and extraordinary general meetings of shareholders may be held. Under Swiss
law, an ordinary general meeting of shareholders must be held annually within six months after the end of a corporation&rsquo;s
financial year. In our case, this generally means on or before June 30.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following powers are vested exclusively
in the general meeting of shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>adopting and amending the articles of association, including change of a company&rsquo;s purpose or domicile&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>electing the members of the board of directors, the chairman of the board of directors, the members of the compensation committee,
the auditors and the independent proxy&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>approving the annual report, the annual statutory financial statements and (to the extent required) the financial statements,
and deciding on the allocation of profits as shown on the balance sheet, in particular with regard to dividends&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>approving the compensation (basis, bonus and equity) of members of the board of directors and executive management, which under
Swiss law is not necessarily limited to the executive officers&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>discharging the members of the board of directors and executive management from liability with respect to their tenure in the
previous financial year&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>dissolving a company with or without liquidation&#894; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>deciding matters reserved to the general meeting of shareholders by law or the articles of association or presented to it by
the board of directors.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">An extraordinary general meeting of shareholders
may be called by a resolution of the board of directors or, under certain circumstances, by a company&rsquo;s auditor, liquidator
or the representatives of convertible bond holders, if any. In addition, the board of directors is required to convene an extraordinary
general meeting of shareholders if shareholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">representing at least 10% of the share capital
request such general meeting of shareholders in writing. Such request must set forth the items to be discussed and the proposals
to be acted upon. The board of directors must convene an extraordinary general meeting of shareholders and propose financial restructuring
measures if, based on a company&rsquo;s stand-alone annual statutory balance sheet, half of the share capital and reserves are
not covered by its assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Voting and Quorum Requirements</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Shareholder resolutions and elections (including
elections of members of the board of directors) require the affirmative vote of the simple majority of shares represented at the
general meeting of shareholders regardless of abstentions or empty or invalid votes, unless otherwise stipulated by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A resolution of the general meeting of
the shareholders passed by two-thirds of the shares represented at the meeting, and the absolute majority of the nominal value
of the shares represented is required for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>amending a company&rsquo;s corporate purpose&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>creating or cancelling shares with preference rights or amending rights attached to such shares&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>cancelling or amending the transfer restrictions of shares&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>creating authorized or conditional share capital&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>increasing the share capital out of equity, against contributions in-kind or for the purpose of acquiring specific assets and
granting specific benefits&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>limiting or suppressing shareholder&rsquo;s pre-emptive subscription rights&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changing a company&rsquo;s domicile&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>alleviating or withdrawing of restrictions upon the transfer of registered shares and the removal of the voting cap of 33<FONT STYLE="font-size: 10pt">1</FONT>&#8725;<FONT STYLE="font-size: 10pt">3</FONT>%&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>removing the indemnification provision for the board of directors and executive management&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>converting registered shares into bearer shares and vice versa&#894; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>dissolving or liquidating a company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The same voting requirements apply to resolutions
regarding transactions among corporations based on Switzerland&rsquo;s Federal Act on Mergers, Demergers, Transformations and the
Transfer of Assets, or the Merger Act (including a merger, demerger or conversion of a corporation) see &ldquo;&mdash;Compulsory
Acquisitions&#894; Appraisal Rights.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In accordance with Swiss law and generally
accepted business practices, our articles of association do not provide quorum requirements generally applicable to general meetings
of shareholders. To this extent, our practice varies from the requirement of NASDAQ Listing Rule 5620(c), which requires an issuer
to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding
voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Notice</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">General meetings of shareholders must be
convened by the board of directors at least 20 days before the date of the meeting. The general meeting of shareholders is convened
by way of a notice appearing in our official publication medium, currently the Swiss Official Gazette of Commerce. Registered shareholders
may also be informed by ordinary mail or e-mail. The notice of a general meeting of shareholders must state the items on the agenda,
the proposals to be acted upon and, in case of elections, the names of the nominated candidates. Except in the limited circumstances
listed below, a resolution may not be passed at a general meeting without proper notice. This limitation does not apply to proposals
to convene an extraordinary general meeting of shareholders or to initiate a special investigation. No previous notification is
required for proposals concerning items included in the agenda or for debates that do not result in a vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All of the owners or representatives of
our shares may, if no objection is raised, hold a general meeting of shareholders without complying with the formal requirements
for convening general meetings of shareholders (a universal meeting). This universal meeting of shareholders may discuss and pass
binding resolutions on all matters within the purview of the ordinary general meeting of shareholders, provided that the owners
or representatives of all the shares are present at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Agenda Requests</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to Swiss law, one or more shareholders,
whose combined shareholdings represent the lower of (i) one tenth of the share capital or (ii) an aggregate nominal value of at
least CHF 1,000,000, may request that an item be included in the agenda for an ordinary general meeting of shareholders. To be
timely, the shareholder&rsquo;s request must be received by us generally at least 120 calendar days in advance of the meeting.
The request must be made in writing and contain, for each of the agenda items, the following information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a brief description of the business desired to be brought before the ordinary general meeting of shareholders and the reasons
for conducting such business at the ordinary general meeting of shareholders&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the name and address, as they appear in the share register, of the shareholder proposing such business&#894; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>all other information required under the applicable laws and stock exchange rules.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, if the shareholder intends
to solicit proxies from the shareholders of a company, such shareholder shall notify the company of this intent in accordance with
Securities and Exchange Commission Rule 14a-4 and/or Rule 14a-8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our business report, the compensation report
and the auditor&rsquo;s report must be made available for inspection by the shareholders at our registered office no later than
20 days prior to the general meeting of shareholders. Shareholders of record may be notified of this in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Voting Rights</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each of our shares entitles a holder to
one vote, regardless of its nominal value. The shares are not divisible. The right to vote and the other rights of share ownership
may only be exercised by shareholders (including any nominees) or usufructuaries who are entered in our share register at cut-off
date determined by the board of directors. Those entitled to vote in the general meeting of shareholders may be represented by
the independent proxy holder (annually elected by the general meeting of shareholders), another registered shareholder or third
person with written authorization to act as proxy or the shareholder&rsquo;s legal representative. The chairman has the power to
decide whether to recognize a power of attorney.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our articles of association contain provisions
that prevent investors from acquiring voting rights exceeding 33<FONT STYLE="font-size: 10pt">1</FONT>&#8725;<FONT STYLE="font-size: 10pt">3</FONT>%
of the outstanding share capital. Specifically, no individual or legal entity may, directly or indirectly, control voting rights
with respect to 33<FONT STYLE="font-size: 10pt">1</FONT>&#8725;<FONT STYLE="font-size: 10pt">3</FONT>% or more of the registered
share capital recorded in the Commercial Register. In the event that a shareholder should exceed the 33<FONT STYLE="font-size: 10pt">1</FONT>&#8725;<FONT STYLE="font-size: 10pt">3</FONT>%
ownership threshold, the registered shares exceeding the limit of 33<FONT STYLE="font-size: 10pt">1</FONT>&#8725;<FONT STYLE="font-size: 10pt">3</FONT>%
shall be entered in our share registered as shares without voting rights. The board of directors may in special cases approve exceptions
to the above regulations. Additional voting caps apply to shareholders acquiring shares for other persons (nominees).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Dividends and Other Distributions</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our board of directors may propose to shareholders
that a dividend or other distribution be paid but cannot itself authorize the distribution. Dividend payments require a resolution
passed by a simple majority of the shares represented at a general meeting of shareholders regardless of abstentions or employ
or invalid votes. In addition, our auditors must confirm that the dividend proposal of our board of directors conforms to Swiss
statutory law and our articles of association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under Swiss law, we may pay dividends only
if we have sufficient distributable profits brought forward from the previous business years (<I>report des b&eacute;n&eacute;fices</I>),
or if we have distributable reserves (<I>r&eacute;serves &agrave; libre disposition</I>), each as evidenced by our audited stand-alone
statutory balance sheet prepared pursuant to Swiss law, and after allocations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">to reserves required by Swiss law and the
articles of association have been deducted. We are not permitted to pay interim dividends out of profit of the current business
year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Distributable reserves are generally booked
either as &ldquo;free reserves&rdquo; (<I>r&eacute;serves libres</I>) or as &ldquo;reserve from capital contributions&rdquo; (<I>apports
de capital</I>). Under the CO, if our general reserves (<I>r&eacute;serve g&eacute;n&eacute;rale</I>) amount to less than 20% of
our share capital recorded in the Commercial Register (i.e., 20% of the aggregate nominal value of our issued capital), then at
least 5% of our annual profit must be retained as general reserves. The CO permits us to accrue additional general reserves. Further,
a purchase of our own shares (whether by us or a subsidiary) reduces the distributable reserves in an amount corresponding to the
purchase price of such own shares. Finally, the CO under certain circumstances requires the creation of revaluation reserves which
are not distributable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Distributions out of issued share capital
(i.e. the aggregate nominal value of our issued shares) are not allowed and may be made only by way of a share capital reduction.
Such a capital reduction requires a resolution passed by a simple majority of the shares represented at a general meeting of shareholders
regardless of abstentions or empty or invalid votes. The resolution of the shareholders must be recorded in a public deed and a
special audit report must confirm that claims of our creditors remain fully covered despite the reduction in the share capital
recorded in the Commercial Register. The share capital may be reduced below CHF 100,000 only if and to the extent that at the same
time the statutory minimum share capital of CHF 100,000 is reestablished by sufficient new fully paid-up capital. Upon approval
by the general meeting of shareholders of the capital reduction, the board of directors must give public notice of the capital
reduction resolution in the Swiss Official Gazette of Commerce three times and notify creditors that they may request, within two
months of the third publication, satisfaction of or security for their claims. The reduction of the share capital may be implemented
only after expiration of this time limit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our board of directors determines the date
on which the dividend entitlement starts. Dividends are usually due and payable shortly after the shareholders have passed the
resolution approving the payment, but shareholders may also resolve at the ordinary general meeting of shareholders to pay dividends
in quarterly or other installments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Transfer of Shares</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Shares in uncertificated form (<I>droits-valeurs</I>)
may only be transferred by way of assignment. Shares that constitute intermediated securities (<I>titres interm&eacute;di&eacute;s</I>)
may only be transferred when a credit of the relevant intermediated securities to the acquirer&rsquo;s securities account is made
in accordance with the relevant provisions of the FISA. Article 5 of our articles of association provides that in the case of securities
held with an intermediary such as a registrar, transfer agent, trust corporation, bank or similar entity, any transfer, grant of
a security interest or usufructary right in such intermediated securities and the appurtenant rights associated therewith requires
the cooperation of the intermediary in order for such transfer, grant of a security interest or usufructary right to be valid against
us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Voting rights may be exercised only after
a shareholder has been entered in our share register (<I>registre des actions</I>) with his or her name and address (in the case
of legal entities, the registered office) as a shareholder with voting rights. Our articles of association contain provisions that
prevent investors from acquiring voting rights exceeding 33<FONT STYLE="font-size: 10pt">1</FONT>&#8725;<FONT STYLE="font-size: 10pt">3</FONT>%
of the outstanding share capital. Specifically, no individual or legal entity may, directly or indirectly, control voting rights
with respect to 33<FONT STYLE="font-size: 10pt">1</FONT>&#8725;<FONT STYLE="font-size: 10pt">3</FONT>% or more of the registered
share capital recorded in the Commercial Register except if such individual or legal entity has submitted a tender offer to all
shareholders. In the event that a shareholder should exceed the 33<FONT STYLE="font-size: 10pt">1</FONT>&#8725;<FONT STYLE="font-size: 10pt">3</FONT>%
ownership threshold, the registered shares exceeding the limit of 33<FONT STYLE="font-size: 10pt">1</FONT>&#8725;<FONT STYLE="font-size: 10pt">3</FONT>%
shall be entered in our share registered as shares without voting rights. Additional voting caps apply to shareholders acquiring
shares for other persons (nominees).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Inspection of Books and Records</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the CO, a shareholder has a right
to inspect our share register with respect to his own shares and otherwise to the extent necessary to exercise his shareholder
rights. No other person has a right to inspect our share register. Our books and correspondence may be inspected with the express
authorization of the general meeting of shareholders or by resolution of the board of directors and subject to the safeguarding
of our business secrets. See &ldquo;Comparison of Swiss Law and Delaware Law&mdash;Inspection of Books and Records.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Special Investigation</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If the shareholders&rsquo; inspection rights
as outlined above prove to be insufficient in the judgment of the shareholder, any shareholder may propose to the general meeting
of shareholders that specific facts be examined by a special</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">commissioner in a special investigation. If
the general meeting of shareholders approves the proposal, we or any shareholder may, within 30 calendar days after the general
meeting of shareholders, request a court sitting in Lausanne, Switzerland, our registered office, to appoint a special commissioner.
If the general meeting of shareholders rejects the request, one or more shareholders representing at least 10 percent of the share
capital or holders of shares in an aggregate nominal value of at least CHF 2,000,000 may request that the court appoint a special
commissioner. The court will issue such an order if the petitioners can demonstrate that the board of directors, any member of
the board of directors or our executive management infringed the law or our articles of association and thereby caused damages
to the Company or the shareholders. The costs of the investigation would generally be allocated to us and only in exceptional cases
to the petitioners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Compulsory Acquisitions&#894; Appraisal
Rights</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Business combinations and other transactions
that are governed by the Swiss Merger Act (i.e. mergers, demergers, transformations and certain asset transfers) are binding on
all shareholders. A statutory merger or demerger requires approval of two-thirds of the shares represented at a general meeting
of shareholders and the absolute majority of the nominal value of the shares represented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If a transaction under the Swiss Merger
Act receives all of the necessary consents, there are no appraisal rights and all shareholders are compelled to participate in
such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Swiss corporations may be acquired by an
acquirer through the direct acquisition of the share capital of the Swiss corporation. The Swiss Merger Act provides for the possibility
of a so-called &ldquo;cash-out&rdquo; or &ldquo;squeeze-out&rdquo; merger if the acquirer controls 90% of the outstanding shares.
In these limited circumstances, minority shareholders of the corporation being acquired may be compensated in a form other than
through shares of the acquiring corporation (for instance, through cash or securities of a parent corporation of the acquiring
corporation or of another corporation). For business combinations effected in the form of a statutory merger or demerger and subject
to Swiss law, the Swiss Merger Act provides that if equity rights have not been adequately preserved or compensation payments in
the transaction are unreasonable, a shareholder may request the competent court to determine a reasonable amount of compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, under Swiss law, the sale
of &ldquo;all or substantially all of our assets&rdquo; by us may require the approval of two-thirds of the number of shares represented
at a general meeting shareholders and the absolute majority of the nominal value of the shares represented. Whether a shareholder
resolution is required depends on the particular transaction, including whether the following test is satisfied:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a core part of our business is sold without which it is economically impracticable or unreasonable to continue to operate the
remaining business&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our assets, after the divestment, are not invested in accordance with our statutory business purpose&#894; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the proceeds of the divestment are not earmarked for reinvestment in accordance with our business purpose but, instead, are
intended for distribution to our shareholders or for financial investments unrelated to our business.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A shareholder of a Swiss corporation participating
in certain major corporate transactions may, under certain circumstances, be entitled to appraisal rights. As a result, such shareholder
may, in addition to the consideration (be it in shares or in cash) receive an additional amount to ensure that the shareholder
receives the fair value of the shares held by the shareholder. Following a statutory merger or demerger, pursuant to the Swiss
Merger Act, shareholders can file an appraisal action against the surviving company. If the consideration is deemed inadequate,
the court will determine an adequate compensation payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Board of Directors</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our articles of association provide that
the board of directors shall consist of at least three and not more than nine members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The members of the board of directors and
the chairman are elected annually by the general meeting of shareholders for a period until the completion of the subsequent ordinary
general meeting of shareholders and are eligible for re-election. Each member of the board of directors must be elected individually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Powers</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The board of directors has the following
non-delegable and inalienable powers and duties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the ultimate direction of the business of the Company and issuing of the relevant directives&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>laying down the organization of the Company&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>formulating accounting procedures, financial controls and financial planning&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>nominating and removing persons entrusted with the management and representation of the Company and regulating the power to
sign for the Company&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the ultimate supervision of those persons entrusted with management of the Company, with particular regard to adherence to
law, our articles of association, and regulations and directives of the Company&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>issuing the annual report and the compensation report, and preparing for the general meeting of shareholders and carrying out
its resolutions&#894; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>informing the court in case of over-indebtedness.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The board of directors may, while retaining
such non-delegable and inalienable powers and duties, delegate some of its powers, in particular direct management, to a single
or to several of its members, managing directors, committees or to third parties who need be neither members of the board of directors
nor shareholders. Pursuant to Swiss law and Article 25 of our articles of association, details of the delegation and other procedural
rules such as quorum requirements must be set in the organizational rules issued by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Indemnification of Executive Management and
Directors</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Subject to Swiss law, Article 29 of our
articles of association provides for indemnification of the existing and former members of the board of directors, executive management
and their heirs, executors and administrators, against liabilities arising in connection with the performance of their duties in
such capacity, and permits us to advance the expenses of defending any act, suit or proceeding to our directors and executive management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, under general principles of
Swiss employment law, an employer may be required to indemnify an employee against losses and expenses incurred by such employee
in the proper execution of their duties under the employment agreement with the employer. See &ldquo;Comparison of Swiss Law and
Delaware Law&mdash;Indemnification of directors and executive management and limitation of liability.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have entered into indemnification agreements
with each of the members of our board of directors and executive management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Conflict of Interest, Management Transactions</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Swiss law does not have a general provision
regarding conflicts of interest. However, the CO contains a provision that requires our directors and executive management to safeguard
the Company&rsquo;s interests and imposes a duty of loyalty and duty of care on our directors and executive management. This rule
is generally understood to disqualify directors and executive management from participation in decisions that directly affect them.
Our directors and executive officers are personally liable to us for any breach of these provisions. In addition, Swiss law contains
provisions under which directors and all persons engaged in the Company&rsquo;s management are liable to the Company, each shareholder
and the Company&rsquo;s creditors for damages caused by an intentional or negligent violation of their duties. Furthermore, Swiss
law contains a provision under which payments made to any of the Company&rsquo;s shareholders or directors or any person associated
with any such shareholder or director, other than payments made at arm&rsquo;s length, must be repaid to the Company if such shareholder
or director acted in bad faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our board of directors has adopted a Code
of Business Conduct and Ethics that covers a broad range of matters, including the handling of conflicts of interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Principles of the Compensation of the
Board of Directors and the Executive Management</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to Swiss law, beginning at our
first annual meeting as a public company in 2016 our shareholders must annually approve the compensation of the board of directors
and the persons whom the board of directors has, fully or partially, entrusted with the management of the Company. The board of
directors must issue, on an annual basis, a written compensation report that must be reviewed together with a report on our business
by our auditor. The compensation report must disclose all compensation, loans and other forms of indebtedness granted by the Company,
directly or indirectly, to current or former members of the board of directors and executive management to the extent related to
their former role within the Company or not on customary market terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The disclosure concerning compensation,
loans and other forms of indebtedness must include the aggregate amount for the board of directors and the executive management,
as well as the particular amount for each member of the board of directors and executive officer, specifying the name and function
of each person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Certain forms of compensation are prohibited
for members of our board of directors and executive management, such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>severance payments provided for either contractually or in the articles of association (compensation due until the termination
of a contractual relationship does not qualify as severance payment)&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>advance compensation&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>incentive fees for the acquisition or transfer of corporations, or parts thereof, by the Company or by companies being, directly
or indirectly, controlled by the us&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>loans, other forms of indebtedness, pension benefits not based on occupational pension schemes and performance-based compensation
not provided for in the articles of association&#894; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>equity securities and conversion and option rights awards not provided for in the articles of association.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Compensation to members of the board of
directors and executive management for activities in entities that are, directly or indirectly, controlled by the Company is prohibited
if the compensation (i) would have been prohibited if it was paid directly by the Company, (ii) is not provided for in the articles
of association or (iii) has not been approved by the general meeting of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Beginning in 2016, the general meeting
of shareholders will annually vote on the proposals of the board of directors with respect to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the maximum aggregate amount of compensation of the board of directors for the subsequent term of office&#894; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the maximum aggregate amount of compensation of the executive management for the subsequent financial year.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The board of directors may submit for approval
at the general meeting of shareholders deviating or additional proposals relating to the same or different periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the event that, at the general meeting
of shareholders, the shareholders do not approve a proposal of the board of directors, the board of directors must form a new proposal
for the maximum aggregate compensation and the particular compensation for each individual, taking into account all relevant factors,
and submit the new proposal for approval by the same general meeting of shareholders, at a subsequent extraordinary general meeting
or the next ordinary general meeting of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition to fixed compensation, members
of the board of directors and executive management may be paid variable compensation, depending on the achievement of certain performance
criteria. The performance criteria may include individual targets, targets of the Company or parts thereof and targets in relation
to the market, other companies or comparable benchmarks, taking into account the position and level of responsibility of the recipient
of the variable compensation. The board of directors or, where delegated to it, the compensation committee shall determine the
relative weight of the performance criteria and the respective target values.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Compensation may be paid or granted in
the form of cash, shares, financial instruments, in kind, or in the form of other types of benefits. The board of directors or,
where delegated to it, the compensation committee shall determine grant, vesting, exercise and forfeiture conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Borrowing Powers</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Neither Swiss law nor our articles of association
restrict in any way our power to borrow and raise funds. The decision to borrow funds is made by or under the direction of our
board of directors, and no approval by the shareholders is required in relation to any such borrowing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Repurchases of Shares and Purchases of
Own Shares</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The CO limits our right to purchase and
hold our own shares. We and our subsidiaries may purchase shares only if and to the extent that (i) we have freely distributable
reserves in the amount of the purchase price&#894; and (ii) the aggregate nominal value of all shares held by us does not exceed
10 percent of our share capital. Pursuant to Swiss law, where shares are acquired in connection with a transfer restriction set
out in the articles of association, the foregoing upper limit is 20 percent. We currently do not have any transfer restriction
in our articles of association. If we own shares that exceed the threshold of 10 percent of our share capital, the excess must
be sold or cancelled by means of a capital reduction within two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Shares held by us or our subsidiaries are
not entitled to vote at the general meeting of shareholders but are entitled to the economic benefits applicable to the shares
generally, including dividends and pre-emptive subscription rights in the case of share capital increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, selective share repurchases
are only permitted under certain circumstances. Within these limitations, as is customary for Swiss corporations, we may purchase
and sell our own shares from time to time in order to meet imbalances of supply and demand, to provide liquidity and to even out
variances in the market price of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Notification and Disclosure of Substantial
Share Interests</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The disclosure obligations generally applicable
to shareholders of Swiss corporations under the Swiss Act on Stock Exchanges and Securities Trading do not apply to us since our
shares are not listed on a Swiss exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to Article 663c of the CO, Swiss
corporations whose shares are listed on a stock exchange must disclose their significant shareholders and their shareholdings in
the notes to their balance sheet, where this information is known or ought to be known. Significant shareholders are defined as
shareholders and groups of shareholders linked through voting rights who hold more than five percent of all voting rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stock Exchange Listing</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our common shares are listed on the NASDAQ
Global Market under the symbol &ldquo;ACIU.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Transfer Agent and Registrar of Shares</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Computershare Trust Company, N.A. acts
as transfer agent and registrar for our common shares. The share register reflects only record owners of our shares. Swiss law
does not recognize fractional share interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Comparison
of Swiss Law and Delaware Law</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Swiss laws applicable to Swiss corporations
and their shareholders differ from laws applicable to U.S. corporations and their shareholders. The following table summarizes
significant differences in shareholder rights between the provisions of the Swiss Code of Obligations (<I>Code des Obligations
Suisse</I>) and the Swiss Ordinance against excessive compensation in listed stock corporations applicable to our Company, as implemented
by the Company in its articles of association, and the Delaware General Corporation Law applicable to companies incorporated in
Delaware and their shareholders. Please note that this is only a general summary of certain provisions applicable to companies
in Delaware. Certain Delaware companies may be permitted to exclude certain of the provisions summarized below in their charter
documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">DELAWARE
CORPORATE LAW&nbsp;</P></TD>
    <TD STYLE="width: 50%; padding-left: 6pt">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">SWISS
CORPORATE LAW&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><I>Mergers and similar arrangements</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Under the Delaware General Corporation Law, with certain exceptions, a merger, consolidation, sale, lease or transfer of all or substantially all of the assets of a corporation must be approved by the board of directors and a majority of the outstanding shares entitled to vote thereon. A shareholder of a Delaware corporation participating in certain major corporate transactions may, under certain circumstances, be entitled to appraisal rights pursuant to which such shareholder may receive cash in the amount of the fair value of the shares held by such shareholder (as determined by a court) in lieu of the consideration such shareholder would otherwise receive in the transaction. The Delaware General Corporation Law also provides that a parent corporation, by resolution of its board of directors, may merge with any subsidiary, of which it owns at least 90.0% of each class of capital stock without a vote by the shareholders of such subsidiary. Upon any such merger, dissenting shareholders of the subsidiary would have appraisal rights.</TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">Under Swiss law, with certain exceptions, a merger or a demerger of the corporation or a sale of all or substantially all of the assets of a corporation must be approved by two-thirds of the voting rights represented at the respective general meeting of shareholders as well as the absolute majority of the nominal value of shares represented at such shareholders&rsquo; meeting. A shareholder of a Swiss corporation participating in a statutory merger or demerger pursuant to the Swiss Merger Act (<I>Loi sur la fusion</I>) can file a lawsuit against the surviving company. If the consideration is deemed &ldquo;inadequate,&rdquo; such shareholder may, in addition to the consideration (be it in shares or in cash) receive an additional amount to ensure that such shareholder receives the fair value of the shares held by such shareholder. Swiss law also provides that if the merger agreement provides only for a compensation payment, at least 90.0% of all members in the transferring legal entity, who are entitled to vote, shall approve the merger agreement.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><I>Shareholders&rsquo; suits</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Class actions and derivative actions generally are available to shareholders of a Delaware corporation for, among other things, breach of fiduciary duty, corporate waste and actions not taken in accordance with applicable law. In such actions, the court has discretion to permit the winning party to recover attorneys&rsquo; fees incurred in connection with such action.</TD>
    <TD STYLE="padding-left: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Class actions and derivative actions as such
        are not available under Swiss law. Nevertheless, certain actions may have a similar effect. A shareholder is entitled to bring
        suit against directors for breach of their duties and claim the payment of the company&rsquo;s losses or damages both to the corporation
        and, subject to certain conditions, to the individual shareholder and creditors. Likewise, an appraisal lawsuit won by a shareholder
        may indirectly compensate all shareholders. In addition, to the extent that US laws and regulations provide a basis for liability
        and US courts have jurisdiction, a class action may be available.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Under Swiss law, the winning party is generally
        entitled to recover or to partially recover attorneys&rsquo; fees incurred in connection with such action, provided, however, that
        the court has broad discretion to permit the shareholder whose claim has been dismissed to recover attorneys&rsquo; fees incurred
        to the extent he or she acted in good faith.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">DELAWARE
CORPORATE LAW&nbsp;</P></TD>
    <TD STYLE="width: 50%; padding-left: 6pt">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">SWISS
CORPORATE LAW&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><I>Shareholder vote on board and management compensation</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Under the Delaware General Corporation Law, the board of directors has the authority to fix the compensation of directors, unless otherwise restricted by the certificate of incorporation or bylaws.</TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">Pursuant to the Swiss Ordinance against excessive compensation in listed stock corporations (<I>Ordonnance contre les r&eacute;mun&eacute;rations abusives dans les soci&eacute;t&eacute;s anonymes cot&eacute;es en bourse</I>), the general meeting of shareholders has the non-transferable right, amongst others, to vote on the fixed and on the variable compensation of the members of the board of directors, of the executive management and of the advisory boards.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><I>Annual vote on board renewal</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Unless directors are elected by written consent
        in lieu of an annual meeting, directors are elected in an annual meeting of stockholders on a date and at a time designated by
        or in the manner provided in the bylaws. Re-election is possible.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Classified boards are permitted.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P></TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">The general meeting of shareholders elects annually (i.e. term of office until the end of the following general meeting of shareholders) the members of the board of directors and the members of the compensation committee individually for a term of office of one year. Re-election is possible.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><I>Indemnification of directors and executive management and limitation of liability</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The Delaware General Corporation Law provides
        that a certificate of incorporation may contain a provision eliminating or limiting the personal liability of directors (but not
        other controlling persons) of the corporation for monetary damages for breach of a fiduciary duty as a director, except no provision
        in the certificate of incorporation may eliminate or limit the liability of a director for:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;any
        breach of a director&rsquo;s duty of loyalty to the corporation or its shareholders&#894;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;acts
        or omissions not in good faith or which involve intentional misconduct or a knowing violation of law&#894;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;statutory
        liability for unlawful payment of dividends or unlawful stock purchase or redemption&#894; or</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;any
        transaction from which the director derived an improper personal benefit.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">A Delaware corporation may indemnify any person
        who was or is a party or is threatened to be made a party to any proceeding, other than an action by or on behalf of the corporation,
        because the person is or was a director or officer, against liability incurred in connection with the proceeding if the director
        or officer acted in good faith and in a manner reasonably believed to be in, or not opposed to, the best interests of the corporation&#894;
        and the director or officer, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct
        was unlawful.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P></TD>
    <TD STYLE="padding-left: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Under Swiss corporate law, an indemnification
        by the corporation of a director or member of the executive management in relation to potential personal liability is not effective
        to the extent the director or member of the executive management intentionally or negligently violated his or her corporate duties
        towards the corporation (certain views advocate that at least a grossly negligent violation is required to exclude the indemnification).
        Furthermore, the general meeting of shareholders may discharge the directors and members of the executive management from liability
        from actions taken during the past financial year. Such discharge is effective only, however, for disclosed facts and only as against
        the company and those shareholders who approved the discharge or who have since acquired their shares in full knowledge of the
        discharge. Most violations of corporate law are regarded as violations of duties towards the corporation rather than towards the
        shareholders. In addition, indemnification of other controlling persons is not permitted under Swiss corporate law, including shareholders
        of the corporation.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The articles of association of a Swiss corporation
        may also set forth that the corporation shall indemnify and hold harmless, to the extent permitted by the law, the directors and
        executive managers out of assets of the corporation against threatened, pending or completed actions.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Also, a corporation may enter into and pay
        for directors&rsquo; and officers&rsquo; liability insurance which may cover negligent acts as well.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P></TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">DELAWARE
CORPORATE LAW&nbsp;</P></TD>
    <TD STYLE="width: 50%; padding-left: 6pt">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">SWISS
CORPORATE LAW&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><I>Directors&rsquo; fiduciary duties</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">A director of a Delaware corporation has a
        fiduciary duty to the corporation and its shareholders. This duty has two components:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;the
        duty of care&#894; and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;the
        duty of loyalty.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The duty of care requires that a director
        act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty,
        a director must inform himself or herself of, and disclose to shareholders, all material information reasonably available regarding
        a significant transaction.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The duty of loyalty requires that a director
        act in a manner he or she reasonably believes to be in the best interests of the corporation. He or she must not use his or her
        corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest
        of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder
        and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed basis,
        in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption
        may be rebutted by evidence of a breach of one of the fiduciary duties.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Should such evidence be presented concerning
        a transaction by a director, a director must prove the procedural fairness of the transaction, and that the transaction was of
        fair value to the corporation.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P></TD>
    <TD STYLE="padding-left: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The board of directors of a Swiss corporation
        manages the business of the corporation, unless responsibility for such management has been delegated to the executive management
        (for example by organizational rules and comparable bylaws). However, there are several non-transferable duties of the board of
        directors:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;the
        overall management of the corporation and the issuing of all necessary directives&#894;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;determination
        of the corporation&rsquo;s organization&#894;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;the
        organization of the accounting, financial control and financial planning systems as required for management of the corporation&#894;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;the
        appointment and dismissal of persons entrusted with managing and representing the corporation&#894;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;overall
        supervision of the persons entrusted with managing the corporation, in particular with regard to compliance with the law, articles
        of association, operational regulations and directives&#894;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;compilation
        of the annual report, preparation for the general meeting, the compensation report and implementation of its resolutions&#894;
        and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;notification
        of the court in the event that the company is overindebted.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The members of the board of directors must
        perform their duties with all due diligence and safeguard the interests of the corporation in good faith. They must afford the
        shareholders equal treatment in equal circumstances.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The burden of proof for a violation of
        these duties is with the corporation or with the shareholder bringing a suit against the director.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><I>Shareholder action by written consent</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">A Delaware corporation may, in its certificate of incorporation, eliminate the right of shareholders to act by written consent.</TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">Shareholders of a Swiss corporation may only exercise their voting rights in a general meeting of shareholders and may not act by written consents. The articles of association must allow for (independent) proxies to be present at a general meeting of shareholders. The instruction of such (independent) proxies may occur in writing or electronically.</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">DELAWARE
CORPORATE LAW&nbsp;</P></TD>
    <TD STYLE="width: 50%; padding-left: 6pt">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">SWISS
CORPORATE LAW&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><I>Shareholder proposals</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">A shareholder of a Delaware corporation has the right to put any proposal before the annual meeting of shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings.</TD>
    <TD STYLE="padding-left: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">At any general meeting of shareholders any
        shareholder may put proposals to the meeting if the proposal is part of an agenda item. No resolution may be made on proposals
        relating to the agenda items that were not duly notified. Unless the articles of association provide for a lower threshold or for
        additional shareholders&rsquo; rights:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;shareholders
        together representing at least 10% of the share capital may demand that a general meeting of shareholders be called for specific
        agenda items and specific proposals&#894; and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;shareholders
        together representing shares with a nominal value of at least CHF 1.0 million may demand that an agenda item including a specific
        proposal be put on the agenda for a regularly scheduled general meeting of shareholders, provided such request is made with appropriate
        notice.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any shareholder can propose candidates
        for election as directors provided that the election of board members and the names of the candidates have been included as an
        agenda item.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">In addition, any shareholder is entitled,
        at a general meeting of shareholders and without advance notice, to (i) request information from the Board on the affairs of the
        company (note, however, that the right to obtain such information is limited), (ii) request information from the auditors on the
        methods and results of their audit, (iii) request to convene an extraordinary general meeting or (iv) to carry out a special audit
        and to appoint an auditor at the request of a shareholder.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-left: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><I>Cumulative voting</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation&rsquo;s certificate of incorporation provides for it.</TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">Cumulative voting is not permitted under Swiss corporate law. Pursuant to Swiss law, shareholders can vote for each proposed candidate, but they are not allowed to cumulate their votes for single candidates. An annual individual election of (i) all members of the board of directors, (ii) the chairman of the board of directors, (iii) the members of the compensation committee, (iv) the election of the independent proxy for a term of office of one year (i.e. until the following annual general meeting) as well as the vote on the compensation for the members of the board of directors and the executive committee as well as for the members of the advisory board, if applicable, is mandatory for listed companies. Re-election is permitted.</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">DELAWARE
CORPORATE LAW&nbsp;</P></TD>
    <TD STYLE="width: 50%; padding-left: 6pt">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">SWISS
CORPORATE LAW&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><I>Removal of directors</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">A Delaware corporation with a classified board may be removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise.</TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">A Swiss corporation may remove, with or without cause, any director at any time with a resolution passed by a simple majority of the shares represented at a general meeting of shareholders concerned.&nbsp;&nbsp;The articles of association may require the approval by a qualified majority of the shares represented at a meeting for the removal of a director.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><I>Transactions with interested shareholders</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">The Delaware General Corporation Law generally prohibits a Delaware corporation from engaging in certain business combinations with an &ldquo;interested shareholder&rdquo; for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or group who or which owns or owned 15.0% or more of the corporation&rsquo;s outstanding voting stock within the past three years.</TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">No such rule applies to a Swiss corporation.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><I>Dissolution&#894; Winding up</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Unless the board of directors of a Delaware corporation approves the proposal to dissolve, dissolution must be approved by shareholders holding 100.0% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation&rsquo;s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board.</TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">A dissolution of a Swiss corporation requires the approval by two-thirds of the shares represented as well as the absolute majority of the nominal value of the share capital represented at a general meeting of shareholders passing a resolution on such dissolution. The articles of association may increase the voting thresholds required for such a resolution.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><I>Variation of rights of shares</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">A Delaware corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise.</TD>
    <TD STYLE="padding-left: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The general shareholder meeting of a Swiss
        corporation may resolve that preference shares be issued or that existing shares be converted into preference shares with a resolution
        passed by a simple majority of the shares represented at the general meeting of shareholders. Where a company has issued preference
        shares, further preference shares conferring preferential rights over the existing preference shares may be issued only with the
        consent of both a special meeting of the adversely affected holders of the existing preference shares and of a general meeting
        of all shareholders, unless otherwise provided in the articles of association.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Shares with preferential voting rights are
        not regarded a special class for these purposes.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-left: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><I>Amendment of governing documents</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">A Delaware corporation&rsquo;s governing documents may be amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise.</TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">The articles of association of a Swiss corporation may be amended with a resolution passed by a simple majority of the shares represented at such meeting, unless otherwise provided in the articles of association. There are a number of resolutions, such as an amendment of the stated purpose of the corporation, the introduction of authorized and conditional capital and the introduction of shares with preferential voting rights that require the approval by two-thirds of the votes and an absolute majority of the nominal value of the shares represented at a shareholders&rsquo; meeting. The articles of association may increase the voting thresholds.</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">DELAWARE
CORPORATE LAW&nbsp;</P></TD>
    <TD STYLE="width: 50%; padding-left: 6pt">
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">SWISS
CORPORATE LAW&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><I>Inspection of Books and Records</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Shareholders of a Delaware corporation, upon written demand under oath stating the purpose thereof, have the right during the usual hours for business to inspect for any proper purpose, and to obtain copies of list(s) of shareholders and other books and records of the corporation and its subsidiaries, if any, to the extent the books and records of such subsidiaries are available to the corporation.</TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">Shareholders of a Swiss corporation may only inspect books and records if the general meeting of shareholders or the board of directors approved such inspection. The information may be refused where providing it would jeopardize the corporation&rsquo;s trade secrets or other interests warranting protection. A shareholder is only entitled to receive information to the extent required to exercise such shareholders&rsquo; rights, subject to the interests of the corporation. The right to inspect the share register is limited to the right to inspect that shareholder&rsquo;s own entry in the share register.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><I>Payment of dividends</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The board of directors may approve a dividend
        without shareholder approval. Subject to any restrictions contained in its certificate of incorporation, the board may declare
        and pay dividends upon the shares of its capital stock either:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;out
        of its surplus, or</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;in
        case there is no such surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding
        fiscal year.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.15in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Stockholder approval is required to authorize
        capital stock in excess of that provided in the charter. Directors may issue authorized shares without stockholder approval.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P></TD>
    <TD STYLE="padding-left: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Dividend payments are subject to the approval
        of the general meeting of shareholders. The board of directors may propose to shareholders that a dividend shall be paid but cannot
        itself authorize the distribution.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Payments out of the Company&rsquo;s share
        capital (in other words, the aggregate nominal value of the Company&rsquo;s registered share capital) in the form of dividends
        are not allowed&#894; however, payments out of share capital may be made by way of a capital reduction only. Dividends may be paid
        only from the profits brought forward from the previous business years or if the Company has distributable reserves, each as will
        be presented on the Company&rsquo;s audited annual stand-alone balance sheet. The dividend may be determined only after the allocations
        to reserves required by the law and the articles of association have been deducted.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><I>Creation and issuance of new shares</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">All creation of shares require the board of directors to adopt a resolution or resolutions, pursuant to authority expressly vested in the board of directors by the provisions of the company&rsquo;s certificate of incorporation.</TD>
    <TD STYLE="text-indent: 0in; padding-left: 6pt">All creation of shares require a shareholders&rsquo; resolution. An authorized or contingent capital increase requires at least two-thirds of the voting rights represented at the general meeting of shareholders and an absolute majority of the nominal value of shares represented. Authorized shares can be, once created by shareholder resolution, issued by the board of directors (subject to fulfillment of the authorization). Conditional shares are created and issued through the exercise of options and conversion rights related to debt instruments issued by the board of directors or such rights issued to employees.</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Description
of Debt Securities</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The debt securities will be either senior
debt securities or subordinated debt securities and may be secured or unsecured and may be exchangeable for and/or convertible
into other securities, including our common shares. The debt securities will be issued under one or more separate indentures between
us and a designated trustee. We will include in a prospectus supplement the specific terms of each series of senior or subordinated
debt securities being offered, including the terms, if any, on which a series of senior or subordinated debt securities may be
convertible into or exchangeable for other securities. In addition, the material terms of any indenture, which will govern the
rights of the holders of our senior or subordinated debt securities will be set forth in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Description
of Warrants</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may issue warrants to purchase debt
securities, common shares or other securities. We may issue warrants independently or together with other securities. Warrants
sold with other securities may be attached to or separate from the other securities. We will issue warrants under one or more warrant
agreements between our company and a warrant agent that we will name in the applicable prospectus supplement. The terms of any
warrants to be issued and a description of the material provisions of the applicable warrant agreement will be set forth in the
applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Description
of Purchase Contracts</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may issue purchase contracts for the
purchase or sale of equity securities issued by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each purchase contract will entitle the
holder thereof to purchase or sell, and obligate us to sell or purchase, on specified dates, such equity securities issued by us
at a specified purchase price, which may be based on a formula, as set forth in the applicable prospectus supplement. The applicable
prospectus supplement will also specify the methods by which the holders may purchase or sell such securities and any acceleration,
cancellation or termination provisions or other provisions relating to the settlement of a purchase contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any purchase contracts we issue will be
physically settled by delivery of the securities. The purchase contracts may require the holders thereof to secure their obligations
in a specified manner to be described in the applicable prospectus supplement. Alternatively, purchase contracts may require holders
to satisfy their obligations thereunder when the purchase contracts are issued. Our obligation to settle such pre-paid purchase
contracts on the relevant settlement date may constitute indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Description
of Units</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As specified in the applicable prospectus
supplement, we may issue units consisting of one or more common shares, debt securities, warrants or any combination of such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Description
of Subscription Rights</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following is a general description
of the terms of the subscription rights we may issue from time to time. Particular terms of any subscription rights we offer will
be described in the prospectus supplement or free writing prospectus relating to such subscription rights, and may differ from
the terms described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may issue subscription rights to purchase
our securities. These subscription rights may be issued independently or together with any other security offered hereby and may
or may not be transferable by the shareholder receiving the subscription rights in such offering. In connection with any offering
of subscription rights, we may enter into a standby arrangement with one or more underwriters or other purchasers pursuant to which
the underwriters or other purchasers may be required to purchase any securities remaining unsubscribed for after such offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The applicable prospectus supplement will
describe the specific terms of any offering of subscription rights for which this prospectus is being delivered, including the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether common shares or warrants for those securities will be offered under the shareholder subscription rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the price, if any, for the subscription rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the exercise price payable for each security upon the exercise of the subscription rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the number of subscription rights issued to each shareholder;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the number and terms of the securities which may be purchased per each subscription right;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the extent to which the subscription rights are transferable;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other terms of the subscription rights, including the terms, procedures and limitations relating to the exchange and exercise
of the subscription rights;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the date on which the right to exercise the subscription rights shall commence, and the date on which the subscription rights
shall expire;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the extent to which the subscription rights may include an over-subscription privilege with respect to unsubscribed securities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if appropriate, a discussion of material U.S. federal income tax considerations; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if applicable, the material terms of any standby underwriting or purchase arrangement entered into by us in connection with
the offering of subscription rights.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The description in the applicable prospectus
supplement of any subscription rights we offer will not necessarily be complete and will be qualified in its entirety by reference
to the applicable subscription rights certificate or subscription rights agreement, which will be filed with the SEC if we offer
subscription rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">Standby Arrangements</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If fewer than all of the subscription rights
issued in any rights offering are exercised, we may offer any unsubscribed securities directly to persons other than shareholders,
to or through agents, underwriters or dealers or through a combination of such methods, including pursuant to standby arrangements,
as described in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Plan of
Distribution</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may sell the securities in one or more
of the following ways (or in any combination) from time to time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through underwriters or dealers;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>directly to a limited number of purchasers or to a single purchaser;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through agents; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through any other method permitted by applicable law and described in the applicable prospectus supplement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The prospectus supplement will state the
terms of the offering of the securities, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the name or names of any underwriters, dealers or agents;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the purchase price of such securities and the proceeds to be received by us, if any;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any underwriting discounts or agency fees and other items constituting underwriters&rsquo; or agents&rsquo; compensation;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any initial public offering price;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any discounts or concessions allowed or reallowed or paid to dealers; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any securities exchanges on which the securities may be listed.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any initial public offering price and any
discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If underwriters are used in in the sale,
the securities will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>negotiated transactions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at a fixed public offering price or prices, which may be changed;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at market prices prevailing at the time of sale;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at prices related to prevailing market prices; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at negotiated prices.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Unless otherwise stated in a prospectus
supplement, the obligations of the underwriters to purchase any securities will be conditioned on customary closing conditions
and the underwriters will be obligated to purchase all of such series of securities, if any are purchased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The securities may be sold through agents
from time to time. The prospectus supplement will name any agent involved in the offer or sale of the securities and any commissions
paid to them. Generally, any agent will be acting on a best efforts basis for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may authorize underwriters, dealers
or agents to solicit offers by certain purchasers to purchase the securities at the public offering price set forth in the prospectus
supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. The contracts
will be subject only to those conditions set forth in the prospectus supplement, and the prospectus supplement will set forth any
commissions paid for solicitation of these contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Underwriters and agents may be entitled
under agreements entered into with us to indemnification by us against certain civil liabilities, including liabilities under the
Securities Act, or to contribution with respect to payments which the underwriters or agents may be required to make.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The prospectus supplement may also set
forth whether or not underwriters may over-allot or effect transactions that stabilize, maintain or otherwise affect the market
price of the securities at levels above those that might otherwise prevail in the open market, including, for example, by entering
stabilizing bids, effecting syndicate covering transactions or imposing penalty bids.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Underwriters and agents may be customers
of, engage in transactions with, or perform services for us and our affiliates in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each series of securities will be a new
issue of securities and will have no established trading market, other than our common shares, which are listed on the NASDAQ Global
Market. Any underwriters to whom securities are sold for public offering and sale may make a market in the securities, but such
underwriters will not be obligated to do so and may discontinue any market making at any time without notice. The securities, other
than our common shares, may or may not be listed on a national securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Incorporation
of Certain Information By Reference</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The SEC allows us to incorporate by reference
information into this document. This means that we can disclose important information to you by referring you to another document
filed separately with the SEC. The information incorporated by reference is considered to be a part of this document, except for
any information superseded by information that is included directly in this prospectus or incorporated by reference subsequent
to the date of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We incorporate by reference herein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our 2017 Annual Report on Form 20-F for the fiscal year ended December 31, 2017;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our reports on Form 6-K furnished to the SEC on March 20, 2018 (only with respect to &ldquo;Item 1.C&mdash;2017 Board Compensation&rdquo;
and &ldquo;Item 2.C&mdash;2017 Executive Compensation&rdquo; of Exhibit 99.3), March 22, 2018, March 26, 2018, April 27, 2018,
and May 2, 2018 (only with respect to Exhibits 99.1 and 99.2); and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our registration statement on Form 8-A filed with the SEC on September 23, 2016, including any amendments or reports filed
for the purpose of updating such description.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All annual reports we file with the SEC
pursuant to the Exchange Act on Form 20-F after the date of this prospectus and prior to termination or expiration of this registration
statement shall be deemed incorporated by reference into this prospectus and to be part hereof from the date of filing of such
documents. We may incorporate by reference any Form 6-K subsequently submitted to the SEC by identifying in such Form that it is
being incorporated by reference into this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Documents incorporated by reference in
this prospectus are available from us without charge upon written or oral request, excluding any exhibits to those documents that
are not specifically incorporated by reference into those documents. You can obtain documents incorporated by reference in this
document by requesting them from us in writing or at AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland,
or via telephone at +41 21 345 91 21.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Enforcement
of Judgments</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are organized under the laws of Switzerland
and our registered office and domicile is located in Ecublens, Switzerland. Moreover, a number of our directors and executive officers
are not residents of the United States, and all or a substantial portion of the assets of such persons are located outside the
United States. As a result, it may not be possible for investors to effect service of process within the United States upon us
or upon such persons or to enforce against them judgments obtained in U.S. courts, including judgments in actions predicated upon
the civil liability provisions of the federal securities laws of the United States. We have been advised by our Swiss counsel that
there is</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">doubt as to the enforceability in Switzerland
of original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent solely predicated
upon the federal and state securities laws of the United States. Original actions against persons in Switzerland based solely upon
the U.S. federal or state securities laws are governed, among other things, by the principles set forth in the Swiss Federal Act
on Private International Law. This statute provides that the application of provisions of non-Swiss law by the courts in Switzerland
shall be precluded if the result would be incompatible with Swiss public policy. Also, mandatory provisions of Swiss law may be
applicable regardless of any other law that would otherwise apply. Switzerland and the United States do not have a treaty providing
for reciprocal recognition of and enforcement of judgments in civil and commercial matters. The recognition and enforcement of
a judgment of the courts of the United States in Switzerland is governed by the principles set forth in the Swiss Federal Act on
Private International Law. This statute provides in principle that a judgment rendered by a non-Swiss court may be enforced in
Switzerland only if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the non-Swiss court had jurisdiction pursuant to the Swiss Federal Act on Private International Law&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment of such non-Swiss court has become final and non-appealable&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment does not contravene Swiss public policy&#894;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the court procedures and the service of documents leading to the judgment were in accordance with the due process of law&#894;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>no proceeding involving the same parties and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland,
or was earlier adjudicated in a third state and this decision is recognizable in Switzerland.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Expenses</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth the expenses
(other than underwriting discounts and commissions or agency fees and other items constituting underwriters&rsquo; or agents&rsquo;
compensation, if any) expected to be incurred by us in connection with a possible offering of securities registered under this
registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount<BR> To Be Paid</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="width: 89%; text-align: left">SEC registration fee&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">43,575.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">FINRA filing fee&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,000.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Transfer agent&rsquo;s fees&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Printing and engraving expenses&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="text-align: left">Legal fees and expenses&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounting fees and expenses&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(213,234,234)">
    <TD STYLE="padding-bottom: 1pt">Miscellaneous&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">*</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total&#9;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 16.05pt">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;</P></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">_______________</P>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><P STYLE="margin-top: 0; margin-bottom: 0">*</P></TD><TD>To be provided by a prospectus supplement or as an exhibit to a Report on Form 6-K that is incorporated by reference into this
prospectus.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Legal Matters</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The validity of our common shares and certain
other matters of Swiss law will be passed upon for us by Vischer AG, Zurich, Switzerland. Certain matters of U.S. federal and New
York State law will be passed upon for us by Davis Polk &amp; Wardwell LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">Experts</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The financial statements of AC Immune SA
appearing in AC Immune SA&rsquo;s Annual Report (Form 20-F) for the year ended December 31, 2017 have been audited by Ernst &amp;
Young AG, Switzerland, an independent registered public accounting firm, as set forth in their report thereon, included therein,
and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Such financial statements are incorporated
herein by reference in reliance upon such report given the authority of such firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The current address of Ernst &amp; Young
AG is Route de Chancy 59, 1213 Petit-Lancy, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Subscription Rights</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus Supplement</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>July 20,
2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
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MSK/ 5JE.G&UW*I.C&I&G%=7-Q2ZL]5KM/CPH * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@"&>>*UB:65MJ+T'=B>BJ.,L?R R6(4$CS<WS?
M 9%@*V8YC65##4$EHG*I6JS?+2P^'I1]^MB*T[0I4H)RG)]$FU=.G.I-0IK7
M[DEU;?1+J_U,LV]YJ W3RO8VS?=MH<"9ER"#,SJ0-R@AHV0C#8*(Z[C\%4R7
MBCC.+JYYCL9PGD52[H9!E=2-/-\50;3A4SG,'&2P]2I&_/E]"%2G3A/V=9NM
M!R.Q5</A-*4(UZJWJU%^[B];JG!/75Z3NG=73L[$%QX:L)XO+S(C* $8^6<8
MZ @(K;?41M&<=&%>3C? [@ZMAIT\%/,\NQ7*_9XM8MXFU3I*MAZ\73J1O\4(
M.BW?W9Q>II3S7$PE=J$H]8V<=][-/1^;3]&>;W\<NAW$ZO.+>.VW2O*[A(8X
MXU\PR2LV(PJ1D2[V PC*Y6-B57^7\[RC'\+YWC,JQ4G1QV5XB/)B,/*=+FBX
MQK8;%X>HG&I"-:E*%:#O&<+\LK2BSZ+#R6,A2]E3=1UFH0I1CS3E.;Y/9QBK
MMR<O=25[O:^Y\4_M)?M1>/=.L-/T/X?W7]B:/?BZM+[Q5;AEUVZN82K>182N
M,Z7:26[%XKR(#4Y]A87%L$<7'[_P#XCYIQ!E5;*L96_X4LKC3Y\?HL1C\%4;
MA2JS=DH5Z4X^RKU(KGJITJK:G.HY?OWAIX1\/^VK9EQ+AUC\?2]E6P^2U'?+
ML-"=USXJ,'?&UHS5I8>36$I<R4H5].3\V;R^O=0N9[R_N[F]N[F1IKBYNII)
MYYYF^]+-+*S/)(V!N=V+-W)KZIMW<I-N3=W*3;DV]VV]?Q/Z5I4Z>&I0P^'I
MT\/0I14:5"A3A0H4HI64:=&E&-.$;=(Q2\BJI*GY25/L2.OT]:1HFX_"W'T=
MM_3N?I/^Q/\ M!:Y+KUO\(?%^I3ZEI]_;W#^#KV]E>:[TV]LH)+N713<2$LV
MFW-G#.]C'(_^A7,$=I;*8KQ8[?ZOA[,ZBJK 5YN4)1?U>4G>4)15W2N]7"44
MW!/X6N5:-)?S+XZ>'67K+:G&N2X6E@\7A*M*.>X?#4U2H8K#XBHJ4,Q5&G%0
MIXFEB)TZ>*E!1C7IU56FO:4IRJ?J17V1_)H4 % !0 4 % !0 4 % !0 4 %
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M-N3[2ND\$* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
% * /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_s1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_s1.jpg
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M;ZW5<E&;KTZ?L?X=:I0A1JS<:=.<I3C?DK^%?$>#X;K<28BOE=&C1Q6/PD<
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M!GO_ $)<V_\ #=C/_E(?\)IX._Z&SPS_ .#W2_\ Y*H^LX;_ *"*'_@VG_\
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M'NE__)5=7UG#?]!%#_P;3_\ DCQ/[ SW_H2YM_X;L9_\I#_A-/!W_0V>&?\
MP>Z7_P#)5'UG#?\ 010_\&T__D@_L#/?^A+FW_ANQG_RDX;P+9_#7X?1>*H=
M%\::7.GB[QQXF\?:E_:7B31)S!K'BJZ2\U&WLO(-L(=.CE0"T@E$\\:DB6YF
M)W5R8&&!R_#1PE#$P=.%3$U4ZE:DY\V*Q-;%5%>/*K*I7FH+ENHV3<G>3]S/
M?]:>(*N6UL9D..I2RO),IR##K#95CZ<98/)L+'"8:I54XU'+$SI13KSBX0G+
M6%."]T\@E^ _P&N/#7AOPI<^.YYM)\,6?Q7L;-?^$S\/PW-S;_&%-03Q0MY<
M6]M$Q:V74I_[':V%M]FVQB[%\N]9/.>4Y2\'3P3Q<E2HY14R:+6)HJ?U:IC,
M-CO:-J/*Z\:^%I6;C[*5/GIU*,XR:/KH<:^(%'-<TSBEP[[/&9KCN%<PK_\
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M4MKF9=/TRU?3[_3[MI(H[J!;B!I[:6*>-HIX))9E.^.2.0AF1#V%#_GS2_\
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MX+A_D']L9O\ ]#7,O_"[%?\ RT/^$6\,?]"YH/\ X*-/_P#D>CV%#_GS2_\
M!</\@_MC-_\ H:YE_P"%V*_^6A_PBWAC_H7-!_\ !1I__P CT>PH?\^:7_@N
M'^0?VQF__0US+_PNQ7_RT/\ A%O#'_0N:#_X*-/_ /D>CV%#_GS2_P#!</\
M(/[8S?\ Z&N9?^%V*_\ EH?\(MX8_P"A<T'_ ,%&G_\ R/1["A_SYI?^"X?Y
M!_;&;_\ 0US+_P +L5_\M#_A%O#'_0N:#_X*-/\ _D>CV%#_ )\TO_!</\@_
MMC-_^AKF7_A=BO\ Y:'_  BWAC_H7-!_\%&G_P#R/1["A_SYI?\ @N'^0?VQ
MF_\ T-<R_P#"[%?_ "T/^$6\,?\ 0N:#_P""C3__ )'H]A0_Y\TO_!</\@_M
MC-_^AKF7_A=BO_EH?\(MX8_Z%S0?_!1I_P#\CT>PH?\ /FE_X+A_D']L9O\
M]#7,O_"[%?\ RT/^$6\,?]"YH/\ X*-/_P#D>CV%#_GS2_\ !</\@_MC-_\
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MO_EH?\(MX8_Z%S0?_!1I_P#\CT>PH?\ /FE_X+A_D']L9O\ ]#7,O_"[%?\
MRT/^$6\,?]"YH/\ X*-/_P#D>CV%#_GS2_\ !</\@_MC-_\ H:YE_P"%V*_^
M6A_PBWAC_H7-!_\ !1I__P CT>PH?\^:7_@N'^0?VQF__0US+_PNQ7_RT/\
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MXA'XX+3_ %?XB5NG]KX96^7]IZ"_\--?LA_]#IX&_P#"8U#_ .9^C^V^'?\
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M[X7_ .>8?\--?LA_]#IX&_\ "8U#_P"9^C^V^'?^@G"_^")__*0_XA'XW_\
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MC^V^'?\ H)PO_@B?_P I#_B$?C?_ -"#B+_P[X7_ .>8?\--?LA_]#IX&_\
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M7/:U.24JJQ'^UQPU*%5<EJ4(XRI4JWBYSJJ,(N-!0IP^]:DD* "@ H * "@
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MYQ;<Z=-8EI_\^J^:3P<5)72IT[1E&E/G=256T714$F_KBL30* "@ H * "@
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MQ*_[@45_[<1_Q-EQ!TX)R!?]U7-%;_RD4W_X)]^#X^!\3_%O_@@T(?RN*/\
M4G"K_F88G3_IS16_S#_B;+B%?\T1D"_[JV:*W_E(IO\ L">$8^!\3/%??_F
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M4O3]ZYIPG4A3M.-.KB,.I7Y5*MAZ&)K-)+F2A*6$KTN=OFC-0;@XR;C[8""
M1T(!'T/2AJSMVT^XF+32DMFDUZ-70M PH * "@ H * "@ H * "@ H * "@
MH \R^+_P[\+?$_P'JOA;QA<WFGZ0DMEKBZII\ZVU[H^H:!=1:MI^JV[R13PN
MUE=6J3-!<6\\$\8>*2)@^1Z64YIB,FQM/&X6-.<XQJ4I4JT6Z52E6@Z=6G-1
M<9)3A)VE"491=FGH>=FF6T,UP53!5Y5:4)N,XU*,E&I2J4WS0G#FC*+L]XRB
MXRBVFM;KYN\7_L[> _&NHWFH?%'XG:MXC\5:QX5L]&T+6(-!\-^&(K#1[_58
M];BU"6PTK2%L=:FN+S1E%[/K#RV\=@LMJ\%LMS"X^@PG%]?+(4:&5Y?A\)A:
M>*>*JT)U\7B75FZ,\.H1JU:O/0A&G5DXJCRR53EFYRY;/Y_%<(4<PE6JYEF&
M(Q.)J8>.&I5H4,)A52C&M&NIRI4:/)6J.I!*3JWBZ;E#D2::U_#/P/\ AKX<
M\9^%_%L_CZTN]=T/Q-<Z]:0:'H_A'PMX<$T'A74/#YL+C3=!L8TM@;34+J\>
M6YO7N;F] 6(QQAH#CB^*\5B,'B<"L-&-'$858:4Z^*Q>+Q*7UNGBW/VU>JU=
M2I1IQBH1BJ=[J4K26V#X4PN$QF'QOUENMAL2\3"G0PN$P>&_W6IA>3V.'I1:
M7+5E4E)SE*4]G&-XO U/]EOX9G5+C7-+\<M_:OBJ[\6VTJZEH/A/QFEQ'XR\
M5W.NW(T/3M6L)X]-O]*U.ZNH+75XEE,=L&2\CF\IC752XUQL*-'#SPL/98>.
M"]FL/B<7@I-X+"PPB5:="K&56E6IPC*K2?*N>[A*-SDJ<$8)UJM>GBJBJUY8
MWVGUC"X3%QBL;BIXJ3HPK4G&C5HU*DHTJJ4GR.TXRM<ZG2_@1\+/^$0\;^#=
M.\:ZO+IWB'QCX6\7:A(9M*%_;7G@6T\.WUO%8Q06%O#+87$'AZVFO)(K383+
M<K;&(*BIQRXKQKQF#QKPV&53!X+'8&$5[;DE#'O%>TG.]64^>'UN:A[]O=CS
M<SYK]D.$\%3P6,P,,3B?98O&X'&RD_8J<)X'ZK[.$5&G&')/ZK#VGN+XI<G+
M[MN;O/@#\/)]&T.=?B0\^E^%/%7BKQ?X,LM;\.^'-=MM(A^(U_<S>(+'6-'U
M&T4Z_8SZA>?:=,OK^&WN=,$<;QW$L1!/1#B_$0G7J?4H0J8S!X+"8VIA\5BL
M-5J?V?"$,-6H5*<^;"S5.')6A#FIU5)WC$PGP?AY0H4_KDY4\%C,;B\%2KX7
M"XBE268SG4Q5&M3J0Y<3%U)\]*<U&I2<5:4C4TSX ^'O!<CW7@OXPZYX6U+6
M/"5QX8\3ZMI^D>$9X[W28]=U+4'U'3HH-*M]+\*75EJ.KW]G:W5E$\42>4KP
MSW%F]P(K<5O%J,,;E6%Q5&AC%C<+2G7QB5.I[&C0<*TW6E4Q5*<:%.52-22<
MI<UI1C+E54.%%@KRP.:XK!U:F#>"Q-2GA\&G.DZU6NIT81HPAA:L)5ZD:<J<
M7&,>6\93CS/H6^!OPT/AWQ'X8;Q]J4\'BKXI>&?B1>7=SJNDW&I?V_H-UH,M
MG8F;[.HEAU"?0+?[6\L7VB62XG9)$+(%Y_\ 6?%K$X7$K"86,L)E6)RFG3A&
MI"E[#%+$J4^55+QE36)DJ:B^1*,4T];]*X8PL,/BL,L5BG'%YIA\UJ3FZ<JB
MK8?ZO:'-R).-3ZO%SDUSN4I--:6^K*^8/I@H Y;4U;[7+@'&$Q_WPM%O(5TM
M+VM\K7,*5&Y^4_YS3MY!S1[E"5&Y^4_Y!HMY!S1[HSI4;GY3U_J:+>0<T>Z,
M^5&Y^4_YS1;R#FCW,YT;GY3_ )%*WD'-'N9\B-D_*>]%@YH]S/F1AVQ^G>BP
M<R[E&16].Y_G18.9=S.F5L'CM_0T6\@YEW/JSPV-OA[0QTQI&G<=,9M(J-O*
MWX7&O(VJ "@ H * "@ H * "@#F=75OM P#CRE_F]%A72TO:WX7.:F1L'Y3_
M )S3MY!S1[F5,C<_*>I_E1;R#FCW1D3(V#\I_P YHMY!S1[F3.C?W3U_K2L'
M-'N9$Z-CH>O^-%@YH]S+E5MIX_SS18.9=ST7X4*1JNL\8_T"V_\ 2B2BW];
MFNA[G0,* "@ H * "@"EJ'_'E/\ [H_]#6@#B9^_UH R9NHH R9N_P!3_*@#
M(F[_ $/\Z ,J7O\ 5J ,F7_/YT 9<OWE_P!X?SH ^PD^XG^ZO\A0 ^@ H *
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MA#7=)T#Q-I,]N^DKK2:CIMSK5E<1E=-DM=2MFS83S.\:MR0RBK*F\1',L-'
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M7?*XOG>;YU37+"*J<KG#6RHNKA:]/$4IMW5:<\97>*A6E%Z4:2]R48QC:OO
M6LVUI=1V<AU&TO7":CH\WCW4@]QI:^.3K5OIMA>7]W.MG+8>'[2"UM)TDM6D
MGU"]@FO%C"2Q9P<HPIJ2YK+"5*D%RI>UIT,9.I&/PWA#$U,'AH^]%3P=!2:=
M5-SU=N:KR-T[O%0IS3U5.J\)0BW%J23K4:>*Q4[QFX8BNX+W)7C3UCPG\1/^
M$<GT_3;^TE%R!';Z-)XNNYAI=G+<^)=4M-.^WRZGILE[%I=Q=>'=,NKV6Z-S
M):6ERUI'=1PV\$BFIN,8<_OQ48^V4>5<]*BXTJR7Q*'/B:\6W&=6;P6!JU(.
M<ZK@4O9PFI<DHP3YG3NI/V=6I1]K3M\+J6P_/;FC2Y<9B*4:B4(^T[;P5X8U
MW2-8TC6-=\0/=W,5A?VFJM-XGN[Z"2.+3?#^F:3;06$DXL56:6QU'5[ZX%N+
MEK^59'G<S2+71*5-3KN"DHU%5DHRY6O:5,;*<+.RE!4<-3@H*+45+%XB'*^5
M,YXQE&%*,E9TIT4FINWLZ>$G3J-QTO*OB*RE*[EIAJ;['%7>E^,O$>M>)-=T
MR6XT^U_MG6K42-XUNK)_$OANUO-,TK_A'=)TTS+:^&9)8](U2Y766MHIOM-W
M!=65]Y6H74UOSTDHT:<I1E*-7FE7PTG[THU,9*M1J*I>#A"GAE!.@IPE*%>M
M0;C;FETUOXDX4VJ<Z:BJ56WN4YQR_P!G)\BNIRK8BMSJ;4XPE0IU)J4H^S,V
MPT#QQ-JUS9V4KV#Z#/:3:'?77CG4I=-\+I<3:CKTWAUK0SC_ (2>5].U#2=$
M?5)TO[. &^A654L+7S::FZ<Y\UII5</)JR^M06$J07L$[/#\E?&**K5(J53Z
MA3JZ5%RN5&G&48VE&+E2K1CTA%XRGS.M;F<G*G@*L_90J?NWCW32E3E*9N3^
M'O'M[IYNYC9P7]KIR6&GV$_BV.]O88X]-\/Z%<W,=W#<65NFJW]B_BV\9TOX
M(GGN;%+F^W,[Q.IR\U5P34:U2?-'3W:%7$T)RHK6'NQIY=@925U&^*Q\8*7N
M.<04HQA'X94:<5&7-)1E6I4,2HU&K2DE.IF%9)M<R^IX64DE-JGF:%X!\;6X
MM+JZU"PL/$5OH$6FV6O+XHGN5TJ!_$7BG79='^S->7+3V\+-X4A5Y/MJ-:1W
M-JTDT4 229<T8S<9?O'3PZJ25E]8='+ZU/E<G%>SC]:Q590?)&452HUG>3FB
MUR*4>:,G2C6Q$Z<'HZ*JXK S51I2][FH8:4)T54Y??J14ESIENU\">*[FSO%
MEU&YTBU-E-<:7HTGQ#U*^GA\3?9],TXZQJFHV]T#=Q74G]IZZEA'.UE%=06$
MKVJ75Q<P1Z_NXSC[.].G&M3]@DKO#82KB,/.K3M*ZJ5\-3PK=.<^=2>.Q-)2
MFDID+F2M-<S]D_;N+4/K.(A0Q,5-:?NJ6(GBX1E&/)R_4J4^5<R2^F4O;)55
M?MULVU0NYKF$LV !N8[^IZGWJ&[MNRC=MV6B5WLO);(<5RQC%MR<4DY/=M*U
MWYO=B_;K'_G\M?\ P(A_^+I##[=8_P#/Y:_^!$/_ ,70 ?;K'_G\M?\ P(A_
M^+H /MUC_P _EK_X$0__ != !]NL?^?RU_\  B'_ .+H /MUC_S^6O\ X$0_
M_%T 'VZQ_P"?RU_\"(?_ (N@#(N+#P]=:UIGB"XEMI=4T:TU&RTR5K[]U:1:
MJ;7[>\=L)A;_ &B=+."+[2T9G2#S(8W6.:97(^Y*I*/NNI3C1E_U[C457E2^
MRI5(PE.UG)TZ?-?D0/6,(O14ZCJQ6UJCISI*3M:]J=2I&*=U'VDVDG)LX;4_
MA9\.-3UB_P!>E^U6FI:H=0&HR:7XIU;2X;R'5X=,M]9M9K6QU*"V-MK$6CZ<
M-2B6)1<O;^<Q$TLLCS",:<90BO<G=3IR]Z$XNO4Q3A*+NG3=>K5J.'PMU:D6
MN2<HMSDY.,F^6<.5PG'W9PE&E["%2,HV:J1H\M*,U[RC"GK>G!K9'@KP9%JG
M]IVMQ<V"MY#7&D:;XCU'3O#][-:V$>F6]Q?:%9W\.F74T>GPVUKF6W9)8[2T
M\Y)7M8&1RBI*M&:YU7=:4U/WES8E25>44_@=7GFY\MESSG4252<IM12IJFJ:
M]G[*%*G!P]V7)0GST8-JS:IRVN[N-J<FZ=H'/P_"7X;V_P#9PCDU!8]*ET"Y
MLX?^$NUGR5OO"[1#P]J$\7]I[;F]TJU@@TZVGN!*QTZ&&TF$L<4>VU.:G&?,
MW*%7VT7+WN6M+#QPE:JD].?$X>*IXEV_?)R<O>G)M2BI1G!KW:E-T9I>[>E]
M8GBZ=.ZLU"CB9RK4(K^%.W)9127J_P!NL?\ G\M?_ B'_P"+J1A]NL?^?RU_
M\"(?_BZ #[=8_P#/Y:_^!$/_ ,70 ?;K'_G\M?\ P(A_^+H /MUC_P _EK_X
M$0__ != !]NL?^?RU_\  B'_ .+H /MUC_S^6O\ X$0__%T 'VZQ_P"?RU_\
M"(?_ (N@ ^W6/_/Y:_\ @1#_ /%T 'VZQ_Y_+7_P(A_^+H /MUC_ ,_EK_X$
M0_\ Q= !]NL?^?RU_P# B'_XN@ ^W6/_ #^6O_@1#_\ %T 'VZQ_Y_+7_P "
M(?\ XN@ ^W6/_/Y:_P#@1#_\70 ?;K'_ )_+7_P(A_\ BZ /R=G_ &-OB_H?
MQ(USQ]X4^)/PUTS4;KQ%XIUG2)[A-6NY]/A\27.ILK>7-H\]LFH6]EJ;I'<1
M;FM;L"XM91)''(/@_P#5?-*>)Q6(P^-P=)XGZ[3NU5YXT,:JD*L4_9/DJ.C4
ME#VD&I1NW"2=F?V4OI#^'N,X6R[AC.N%N*L9A</EF2X+&TZ%7+J%'$U,II8-
MVYH9C2K2PM3$82,IT9\L:]&]*M!PG*+UO#7[.W[2?A#1XO#^F?%3X1WFCP6%
M]I8L?$?AYO%44FFZAJT&NW%C<CQ!X;U#[5:KJ]M'?VL5QYBV=PTS6PC\Z3.]
M+(L^HT(8:..RR=&%*E1C3KX;VZ]G0JXBO2C+VV'FY.G5Q5><9.\DZEKV4;>9
MFWC1X/9SCYYGB^#>.,-CIXJAC7B,IS>EDLX8O#X&>6PQ-'^S,YPOL:T\!4>&
MKSI<CKTHTU5Y^2-L-?V4_C/=_$KP_P#$KQ5\0?A[X@U+1-?\-:O):PMJVDP/
M8>&;VSN++0],@LM!2QT;3X;6S6RL;>TM!;6,; I V&#+!\.9IALTHYI6Q>%Q
M%:G7]O4]^O"=27LG2C:7L6H<D>2,$H\L84XQC%)([:GC_P"'&'X1S3A')>%^
M*LJP>/RK-\OA5D\LQE2GB,WP^(I8C,<7.OFKQ&/Q-2MB)8G$U:]?VV(G=2J*
MZ:Z/Q=\$/VD/%%_KTDGQ-^&=CI&LZ=XMT(:)9Z.]K:PZ#XRU2VU/68IUL/#%
MG%=ZY>FPTV*^\320C6+M;)"]S\\@:*W#V>XBC5H5L?EWLJV'AA:E.G0E1I^P
MIXCZVHTX4Z$8TI3Q%JM:=/EE6FDZC:22\G)?&#P?R7#Y;&GP;QE6QN78O)<S
M6/K9A0K5YYGD6!K8' U(2Q.=5ZE'+Z$<5C)X;*8S^HT'B9<M'W8VY'6OV:_V
M@M=\(:9X&U?XE_#6]T+1X+"SL)6T:==?CL=*9VTS3I/%">'5U^;3[#<%M;.2
M_:&)(H(PI2)5I8CAS/,3"C3K9A@7]7]FZ=14YPKMTHJ-&56O&@JM65**BH2J
M3DURPW<4UZ^ \>/";*L[Q?$& X-XRPV88ZIBJ^)IQS##/+'B,=;ZYBH9/+.'
MEM+$XJSE7KPPT9SE4JR;YJDF:9^"7[30\6_\)Q-\6? -WX@/AR+PC</>Z1<W
MNEW_ (=BPXTS4M#NO#TFDZA'+<@:A<275K)-<:GG4)I&N29#JLCX@6+Q.->8
MX"5?%PA#$\]&4J-6%)05)2P\J#HKV3A&=-Q@G"?-.+3E*_!_Q&3P7CD<>':7
M ?%N'RNGFD\ZH1PV.PN&QF$S2I>+Q>$S&CF\,;AIQHMX6G&C6C"G@[86$512
MBL^#X$?M%V5_9ZC;?$GX=076F^+=5\<6 @T&6&UM/$>LZ'#X;O[F"RA\.QVD
M5FVBP0V4&F)"+"VV">&!9RTAR7#F>14$LPP*5.GCZ4?W<U:&9IK&K2A_R]3:
MC_SZ5E2Y4D;U?&WP@JX;$82KP7QG.CBLEP'#^)Y\RPTZM;*\MS&IF^$I5*\\
MWE6E7CF%6IB*N+<WB:_.Z=6I*FE!-7X)_M(VVCZ7H=M\3? EE:Z+IWAK2M-N
M[#1KFTUF"Q\':O%KGAB)];A\/IJ5PVC:G"DUG)<7$KK$9;8EK>:6-]GD?$'[
MGES+ TY8=X*5.=.C*G43R^A/#81SG&@I5?9X>I.B_:.7M*;Y*G-%)$2\:O!R
M>.QN85>!N+Z];'XK.<9BZ&(QV$K8">(XAP<\OSJ<<OJ9N\+16886I*->-&E"
M+FH5HJ-6$))GB'X,_M'>)8M3M]6^(WP^^Q:MX<U+PK>Z9IOAQM&TO^Q]9UBQ
MU[5_LVFZ5X<M+.TU+5=7TVQO=0U>WB34KIX%66Y9&93G5X>SRHIQEC\OC"<<
M-!4J=&5*C2AA*\L30IT*5.A&%"$:\YU9QIQBJLI/VG-I8ROQJ\'LFG@ZN!X*
MXT6(P&:X;.L/B\5F=#'8UX_!9?B<KP;KXO&9S6KXC#8/ 8S$X?"X*K.6%HQJ
MMPI*2BUP'BK]E?XO>,->U#Q/XB\9^#;[6M3^R?;;J*SU>S2;[#86NFVVVVM=
M(BMX_+LK*WB/EQKO9#(^9'9CR5N$<TKUJU>KC<%*K7JU*U625:*E4JR<YR48
MT5&*<FW9));)'T.3_24\.N'\LPF3Y3PGQ;ALOP4:T<-0E5RNM*FJ^)K8NJG5
MK9E.K/FQ&(JS]Z3LI**M&,4MBT_X)[_$R[M;:Z7XA_#.%;FWAN%BEG\0++$)
MHUD$<J_V7\LB;MKKV8$5E_J9F"_YBL'I_P!?UO\ ]PSU5]*K@G_HF^*EY?\
M"0K?^7Q8_P"'=_Q-_P"BC_"__P "/$'_ ,JZ/]3,P_Z"L'_Y7_\ E8?\35<$
M_P#1.<4_^8G_ .;@_P"'=_Q-_P"BC_"__P "/$'_ ,JZ/]3,P_Z"L'_Y7_\
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MO1_J7F'3%X+_ ,K_ /RH:^E7P3_T37%<?7^Q]/NQ[.E_X=W_ !-_Z*/\+_\
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ME'_W[7_"@ \F'_GE'_W[7_"@ \F'_GE'_P!^U_PH /)A_P">4?\ W[7_  H
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M-][)J]O1'MWDP_\ /*/_ +]K_A2*#R8?^>4?_?M?\* #R8?^>4?_ '[7_"@
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M._Z#<8O^YJNO_;P_U.X0_P"B2X77_=OY0O\ W3&_\+"^(/\ T/OC;_PK-?\
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MR_[H#T_\O3L[3]@O]H*[M;>[@M_ _DW,$5Q#N\5S!O+F19$W!=&90VUAD!B
M<C)ZTO\ 5'.%IRX33_J(?7_N$6OI+^%]DU5XCMNKY)3B_FGF":]&DR?_ (8!
M_:'_ .?;P+_X5<__ ,I*/]4LX_EPO_A0_P#Y4/\ XF6\+_\ G[Q'_P"&6G_\
M\ _X8!_:'_Y]O O_ (5<_P#\I*/]4LX_EPO_ (4/_P"5!_Q,MX7_ //WB/\
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M+A?_  H?_P J#_B9;PO_ .?O$?\ X9:?_P \ _X8!_:'_P"?;P+_ .%7/_\
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M2PV&I)\M#"T(^Y1HPM&,5=\TY2E+L:Z3P@H * "@ H I:A_QY3_[H_\ 0UH
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M>BX5.MHU*;^TCW86<HR/[0OO_)08^G^B4?A_7ZAZ:!]CE_Z"-]_Y)_\ R'0
M?8Y?^@C??^2?_P AT 'V.7_H(WW_ ))__(= !]BDQ@ZA>D="#]C((]"#9X(]
M0: _KL'V.7_H(7W_ ))C_P!LZ #['+_T$;[_ ,D__D.@ ^QR_P#01OO_ "3_
M /D.@ ^QR_\ 01OO_)/_ .0Z #['+_T$;[_R3_\ D.@ ^QR_]!&^_P#)/_Y#
MH /L<O\ T$;[_P D_P#Y#H /L<O_ $$;[_R3_P#D.@ ^QR_]!&^_\D__ )#H
M /L<O_01OO\ R3_^0Z #['+_ -!&^_\ )/\ ^0Z #['+_P!!&^_\D_\ Y#H
M/L<O_01OO_)/_P"0Z #['+_T$;[_ ,D__D.@ ^QR_P#01OO_ "3_ /D.@ ^Q
MR_\ 01OO_)/_ .0Z #['+_T$;[_R3_\ D.@ ^QR_]!&^_P#)/_Y#H /L<O\
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M$=<^D(H RY8V7/[Z7C/_ #S[C_KF* V,J9#@_.__ ([[^BB@#,F&.YZ^WK[
M4 94Q _A'7OGW]Z ,R5@!_JTX_WQUSZ.* /0/A>AFU35U21[0K8VY+6^P,^;
MB3Y6\])UP.HVJISU)'% 'M/V.7_H(WW_ ))__(= !]CE_P"@C??^2?\ \AT
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MF\L5EM.I6QE+$8"=&C*A*E0I3KV=24G1M4MR-,X3Q'^TW^U)X<\8VG@.?3_
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MCIJ>&+!M1U6*6XTO3D^'6LF_U."$NLT^G60N#<WT,+1R+++:Q2QQM&ZNRE6
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M\T/_ )VA_P / /VA/[W@+_PEKS_Y?T?ZVYQWPG_@B7_RT/\ B6;PQ_EXD_\
M#S0_^=H?\/ /VA/[W@+_ ,):\_\ E_1_K;G'?"?^")?_ "T/^)9O#'^7B3_P
M\T/_ )VA_P / /VA/[W@+_PEKS_Y?T?ZVYQWPG_@B7_RT/\ B6;PQ_EXD_\
M#S0_^=H?\/ /VA/[W@+_ ,):\_\ E_1_K;G'?"?^")?_ "T/^)9O#'^7B3_P
M\T/_ )VA_P / /VA/[W@+_PEKS_Y?T?ZVYQWPG_@B7_RT/\ B6;PQ_EXD_\
M#S0_^=H?\/ /VA/[W@+_ ,):\_\ E_1_K;G'?"?^")?_ "T/^)9O#'^7B3_P
M\T/_ )VA_P / /VA/[W@+_PEKS_Y?T?ZVYQWPG_@B7_RT/\ B6;PQ_EXD_\
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MK_W*'_$L7A?VXH_\/T5_[H$#?MC?&9NI\&?AX9<?^Y2C_6_./^H/_P )G_\
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MHZMC4K3^W)+F_P#$EQ:Z-H8%GJ6E:='H?@K5-.TR6"]U2PTS4)&_MVYFAO\
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M-X_5_8RA=)5+K,E@Y*2=KTZ]&3JP?LXV<ERRJ*,*L_I*D2% !0 4 % !0 4
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M )];O_P%N/\ XW19_P LO_ 7_D'M:7_/ZC_X.I__ "0?9[G_ )];O_P%N/\
MXW19_P LO_ 7_D'M:7_/ZC_X.I__ "0?9[G_ )];O_P%N/\ XW19_P LO_ 7
M_D'M:7_/ZC_X.I__ "0?9[G_ )];O_P%N/\ XW19_P LO_ 7_D'M:7_/ZC_X
M.I__ "0?9[G_ )];O_P%N/\ XW19_P LO_ 7_D'M:7_/ZC_X.I__ "0?9[G_
M )];O_P%N/\ XW19_P LO_ 7_D'M:7_/ZC_X.I__ "0?9[G_ )];O_P%N/\
MXW19_P LO_ 7_D'M:7_/ZC_X.I__ "0?9[@<?9;I<=OLTXQG_MG1RR_EE_X#
M+_(/:4O^?U'_ ,'4O_DP\BX_Y]KK_P !I_\ XW1RR_EE]S_R#VE+_G]1_P#!
MU+_Y,3R+@?\ +M<C'_3O,,9_[9T<LOY9?^ O_(/:T?\ G]1_\'4O_DP\B?\
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MG_\ DV@ V:E_SWLO_ 2?_P"3: #9J7_/>R_\!)__ )-H -FI?\][+_P$G_\
MDV@ V:E_SWLO_ 2?_P"3: #9J7_/>R_\!)__ )-H -FI?\][+_P$G_\ DV@
MV:E_SWLO_ 2?_P"3: #9J7_/>R_\!)__ )-H -FI?\][+_P$G_\ DV@ V:E_
MSWLO_ 2?_P"3: #9J7_/>R_\!)__ )-H -FI?\][+_P$G_\ DV@ V:E_SWLO
M_ 2?_P"3: #9J7_/>R_\!)__ )-H Y?4HKG[5+N-B3\F2MDPSE%.?FN&.?7D
MT62Z+3R74=Y+[4_E.27W)I(Q)(YN?^//_P !<>O_ $UHLNR^Y!S2_GG_ .!R
M_P RC+')Z6OX6V.Q_P"FE%EV7W(.:7\\_P#P.?\ F4)8V'\-MQZ6X'4G_:HL
MNR^Y!S27VYJW]^2M?YE&1#S\L'X0J/7W-%EV7W(+R_FG_P"!R_S,]T&#\D7_
M 'Z3T^E%EV7W(.:7\T__  .7^91D1 3^[CXSTC0=?^ T679?<D%Y?S37_;\E
M;\2A*L0_Y9)^"1CO_N462Z)?)(.:7\\__ Y?YE-UA'_+(=?[L0[_ /7.BR[+
M[D'-+^>:_P"WYZ?B9\HM^?W/;MY0['_IC19=E]R"\OYIK_M^:M^)].>'X+K^
MP=&,;6"Q_P!E6!17LI&=5^RQ;0S+=1JS8QN940,<D*,XHLNR7RM8?/-:<TE;
M^\]/Q-C[/>_W]._\ 9?_ ),I679!SS_FE_X$_P#,/L][_?T[_P  9?\ Y,HL
MNR#GG_-+_P "?^8?9[W^_IW_ ( R_P#R919=D'//^:7_ ($_\P^SWO\ ?T[_
M , 9?_DRBR[(.>?\TO\ P)_YA]GO?[^G?^ ,O_R919=D'//^:7_@3_S#[/>_
MW]._\ 9?_DRBR[(.>?\ -+_P)_YA]GO?[^G?^ ,O_P F4679!SS_ )I?^!/_
M ##[/>_W]._\ 9?_ ),HLNR#GG_-+_P)_P"9SNJPW(N &-@2(E^[9,O4O_>N
M&.?Q]*=EV7W(7-+^:?RG)?@F<Y+'+@\6GX6N/7_IK19=E]R#FE_//_P.?^9F
M2QOSQ;#KTMP,<?[]%EV7W(.:2^W/_P #E_F9<J'!^6#\(5'K[FBR[+[D@O+^
M:?\ X'+_ #,N=%'\$7'I$@ZGZ4679?<D%Y?S3_\  Y?YF5,L>/\ 5)U[)&/7
M_8HLNR^Y!S2_FG_X'+_,SI!$H.(RO&/D\M#@YR,B///>C;9)6[*UK@V]KR:6
MJ3E)JZZV;L>@?"\2?VIJ_P!E*1,+&WW&X1IE*_:'P%6-[<J<]268$=AUH$>T
M[-2_Y[V7_@)/_P#)M !LU+_GO9?^ D__ ,FT &S4O^>]E_X"3_\ R;0 ;-2_
MY[V7_@)/_P#)M !LU+_GO9?^ D__ ,FT &S4O^>]E_X"3_\ R;0!4OTU 6D^
MZ>SVA1D"UG!Y9>A^V$#\J _KL<;,MU_STM^O:"0?^W% &7,)P1\\/X1./_:U
M ;>7X&9,)>?FCZGHC#M_UTH#;RM\K7,J4-SRO?& 1W_WJ ,N7O\ 4].* ,N7
M8.S<>C =3_N\4 9LABRORR?>'1U'?_KG0!]8HFH[%Q/98VKC_1)_0?\ 3[0!
M:A$ZJ?/>%FS\ODQ/"H7 X(>:8DYSR"!C QWH FH * /Q/^-O_)8?B9_V.&J_
M^A1T =!\&)X9)/%>DKX=\%WLLGA?5[R_U?QAJOB?2[7^Q VFVMQH3S:%J5G:
M6MO>W<MM*NH7L)%K-^\>XBC1"ER7^S5$HQ]RIAHN'-RRKU:N)A]6@G)JG"<*
MT8^S=X*3?+*5I,A-0K4Y<THK]Y9\MXT8QP]>5>JXQ7/.+HN<9Q2DTK2C&Z=^
M9^*?AZ?PWXATVVN/#FD^$YM0\-:1K$F@:-<ZO=VVGM?/=J8YKG6K[4;F>[_<
M_O9;:[DL)$\I[3Y69FQ3M4KP4I/V<Z:M*/)R.="E4<.5I3BXN=IQJ+F53G7P
M\J-FOW5&7*H*3KQ34G+G5*M*FJG,FX2A-+FIRIZ2IRBW=NY]'?L/_P#(Z>._
M^Q7TO_T[359!^A_B/7]*\)^']<\3ZY<K8Z+X<TC4M=U:[? 6UTW2;.:_OIR"
M1Q%;02OC(W8P.365>M##4:E::ERTHN7+!7G)_9ITXW7/4J2:A3@M9SE&*U:-
M:-*5>K2H4[*=2<:<7)\L8N;2YIRVA!7YIR>D8IR>B/)/AK^T9\*_B9\--+^*
MMGKJ>#O#&IZMJ>@>5\1)=/\ !NJZ;KVE7%Y#=Z+JEIJ-^8;35/*LIK^*S%U+
M-)IQ6[VA-X3IKT_JOL/:3II5Z#Q%*TTN:$'4C65GRM2P]2E6IUU;]W*E.[<$
MI/GHS]LZT:4*G^SU(4Y^Y)+]ZJ$J,XM+6G76*P_L9Z*HZU.,?>DDZ/B_]J#X
M*^#;KP_I\WC31]=U#Q9X/\8>-_"5KX;U?0M13Q-HW@NW$VI)HNI2ZM::-=7]
M_-YECHEJ=2C&IWMM?1QR)'IU_-;8WDJU>@J=3VN&PM#&58<O*XX?$XFCAJ,U
M&;BY<_MGB$H*3^JT*]=^Y!<VT(<T,/44X1I8G&O 4ZEVX+$0I5*M3G<%+DA3
MY(TJDVO=KUJ%*W/52.N\<_%2V\#_  ^M?B(G@GX@>,;"YMM-O6T#P)HECKWB
M>UL=1LFOVOKC3WUBQM/LFGP+_P 3&:#49UB9E\C[0K!Z6-G' 5)PK7Y*56O3
MK5H)^QH1P].M4J5ZLI<DH4;47%2Y.;GG3BX+F;BL+!XN$)45RRJ4Z4Z5&32J
MU)5ITH0I4XQYHRJWJJ3CS<O+&;4G9)\+\*?VHOAM\4M T#Q"T6N?#*S\97%G
M%\/[7XMCP]X*U3XBV]_:VEU:ZAX%TY_$5_<>(;&5;ZUB5[11.9YXHQ;GS$9N
MF5"<)QHOE^LRC*H\&G?%TZ*ITZL:\Z"7/"C5C4;IU-FZ=5/EY&8*M#EJ5+2C
M0I2]G+$R7)AO;*I5I5*"JMJ/MJ,Z356#LX\\+7YM/:8_&?@YY((8O%GAIY;K
MQ!>>$[:*/7=+:2X\5:>D\M_X:@1;HM-X@L8[:YDO-&C#:C;);SO-;(L4A7&'
MO^S]G[WM*52O2Y/>]I0HRY:U:GRWYZ5*7NU*D;PA+233-I)T^;G3IJG*E"?,
MN7V<\1"-2A"5[<DJ\)PG2B[.I"<904E)-MUKQMX,\,ZGHFB>(O%OACP_K/B6
MX-IX;TC6M>TK2M3U^[#Q1&VT2POKN"ZU6X\V>&,PV$4\F^:)-NZ102%IU/8T
M_>K*#JNE#WJBIKFO4]G&\E!<LKSMR^[+71BE^ZINK/\ =T8RY'5E[E-2=K1<
MW:*D[K2]W=::F'<?%OX66EWJNG2_$?P-_:FA6.N:EJ^D1>*]"FU?3K'PR+@^
M(;FZTJ&^>_ABT0VMRFJL]N/L$D$L=SY3HRC*=>E##UL5SIX?#T?K%6I3_>1A
M1YG!5'R<WNSJ+V<&OCJ6IQO-J)I&C4=:CAU%QK5ZL*%&G/\ =RG6J0C4C3BI
M<OO.E.%6W_/J2J/W&I'AT?[:7P1N/#>D>,=/O]6U+PEK47PV>T\1:?'HDVGP
M2?$_Q3?^$=(M=44Z\E[HUUHFI:?--XKBU6TL_P"Q+-T+-<7D=U9V^ZA)5,+2
MJ1^KRQ>*PF$I.LU"G&>+RS^U85)U(N4(4:=#FHUI\S=/$PG3Y90C[0R;2I5Z
MD$ZBPV'S#$5(THR=3DR_&4<'4C"G93G4KSQ%*MAE%-5</.-64H*45+WB;XI_
M#&V\*P>.I_B-X#M_!%S<"TMO&,WB_P /Q>%;BZ:62 6T'B%]172);@SQ2PB&
M.[:0RQR1A=Z, I)TI4H33IRK).C&2Y)55).2=*+LYIQ3DG%.Z3:T3'%I^TY+
M/V#<:W+K[&2<8RC4M_#:E**:E9IRBGJT<[\5OCI\,?@SX0OO&7C3Q1I5O9V^
M@:CXCTS2+35-'?Q%XIT[2K07UY_PB.D7>I64GB&9+1EG"6$CIY3K(\B(P8Q.
M7LZL:'+-UO;8:C*C"$I5J;Q>+I8*G4J4HKVD*4:]6*JS<;02GHY1Y2Z5-U(>
MTA*"I<E6<:TI*-&7LJ$L0X0J?!*I.$?W<4[SE*"7Q)G7Z7X^\%ZOIVE:G8^*
M?#[VFM:F-"TT_P!M:7NN/$/E22R^&XPEVZR>(;807"W6BQ-)J$#VUPLD ,,F
MW:=-TZJHWC*;]NZ7LWS1K0PSJJO5H-?Q:5/V-5SJ03C&-.;DURRMA3JQG159
M*5."CAY351>SE1>*C1GAX5D_X52JL11Y(2LYNK34>;GC?KZS- H * "@ H *
M "@#S[XC>)O$/@_0I->T32]%U2VLV@2_@U75+_3)LWM_96%L;-K/2=320"2Z
M:2?SO)VH@$>]G.TBI.M1I+EBJU:A0@];QJ5ZT:2;27P1YU)V=VDTE>UZLE3J
MRNTZ-*O7:LDG"A0J5I).^DY>SY8Z<MW=O0HV_P 3]#L7N=.\37$>G:QIUAX@
MU"\:QLM<N-"N(_"X,VO1Z)JUWI5DNKW.D6S1MJ-M:Q-/#-YL*)(87PG*"A.<
M>90IPC4ES1Y7R.K3P\JL(J[E1CB:D*/M%I>46[*29*C+VD*5ES5*L:4%%Z*I
M5I.O2IU'I&%2I1C*JHMVY%>]]#M-,\1:1J][J&GZ=<F:[TJ'2[B^B,$\0ABU
MFT:]TY@\L:))Y]LID*QL[1'Y)0C_ "UI.G.FZD9+E='$5<+45U[M>C"C4J0T
M>O+#$4GS*\7S63;4K*,DXTY1^&K1A7I]+TJDJD(RMO&\J4U9VEI=JS5]NH&%
M !0 4 % !0 4 ?,/[7GC3Q3X#^"]]K'A'5KG0-2N_%/@K0+G6;(1K>:9H^O>
M)+#3-6NK2YE22.PN!9SR)%J#(?L;2"9"L@1U^HX/P6%QV=4Z.*H1Q-.&%QE>
M-"=W"I6H8>=2E&<(N,JD>9<SII^^E9WC=/YOBO%XC!9-5JX:O+"SE6H495Z;
MC"=*%6HHR<)R3C3D](J=KKF]UJ3BUX!\0?B]>?L]_$C4X=+U'XEZY:+X">\T
M_P '>+O$-GXM\+^*IG\0:3HUGXSL_$3ZWJ_B/PY-#=:D8+C2#ID+:V8RD4=J
M7BE'TN79-#B++*,JM+*\//\ M'V=3&8'"SP6+P<8X6OB)X&>%CAZ&$Q*E"ES
M1K>UE["Z;<TI(^7S#.)\-9E7C1J9I7A'+U.E@\;BX8O"8J4\52H0QL,1+$5\
M5AFI5.65%4HJKRM)0<XL[2S_ &E_BI=^,=&^&;>"/#6D>*=>\5VV@V&O:ZGB
M'2](6TG\)ZEXIEGN/"<TG_"2P7,"Z9)91"XO8+:^-Q#>6\H@611P5.%LII8&
MOFBQ^)K87#8.6(GA\,\-6J\ZQM'"1C'&17U64)>V51\L)3IN,J<ES-,[J?%&
M;3QU#*U@,-0Q5?%QH0Q&)CB:%)0E@ZN+E*6"D_K491]DZ<>:<85.>,XOENCG
MHOVO_B#J%_J?AO1_A]H]SXB\):=XXOO$T]FOB'6=*U!_!GBV^\+%=*AL8H+O
M0K'4GL3=-JNNS36^G><D,R3;6E/3_J7EU.G1Q5;,:U/#8NK@(86-3ZMAZU)8
M[!4\6_:.I)PQ%6FJG)&CAXQE6Y7*+C=(YEQGF,ZE7"T<MHRQ.#IX^>)=-8FO
M1F\%C*F$7LHTXQGAJ57V?.Z^(;A2YE&2E;F->T_:M\?:AH?B/QW;^#?"%AX3
M\)>,O 7@[5O#]YK&I7?BFYN?&T?AK==6>KV$9T&)=,G\2Q 1M:W27L5G.Z7$
M)EB%83X1R^CB,-E[QN,GB\7@<RQU'$0H4H82$<!+&6A.C4:Q#]M'"2;?-!TW
M4BN65F;PXMS&IA\3CXX'!T\)@\;EN"JX:=:K+%2EF"PEYPKTU]72HO%K3DDJ
MBIR:E&Z,CP]^TS\8(/#O@2+5-$\*>)?$/Q$\;_%'P]HM[HVG^(+IM/L?AUJ^
MJV][_:'AK2HDN[Z>6."U@L#IUW$$M(Y+_4CYQ:*M\3PKDWUK,?8U\5A,/EF!
MRK$UJ=>KAZ<9SS.C1E3Y,76?)2BG*<JGM(/FJ-4J2Y;,QP_%&<0PN7*IA\+B
M<1F6-S3#T9T:>(G*G#+*M:-1RPE"*G4<N6"I*E)6I)U*K<KI]#X7_:>^)/CA
M]8L=%\&>!?#.J>#/ ]WXS\4IXT\3W=I8WXMO$.O:''9:5>VD8AT**X707NY[
M[7I)1I37D=K?6^ZVGE/-BN%<KP'L9UL;F&)HXW,88#"/ X2$JE/GPV&Q#J5:
M<I7Q$HO$J$*>'2]LH.=.7OQB=&%XIS3&^VA0P.7X6K@LNGC\4L;BZE.E/EQ&
M(H*G2J1BHX=-8=RG4Q#DJ+FHSB^5R?(^$?CS\3- _P"%F>-[Z30O$G@@?M :
M!X071+_6]2U#7M#M/&<7A*RBL_"^M6CR^'9-#T>XUH75FB6ABU&,74T<\ G@
MKKQG#^65O[+P,%B,)CO]7<3C?;TL/3I4*\\%/&S<\70GRXF->M&@X5'SWI>Y
M%QDXR.7 Y]F=#^U,:W0Q.!_UAH81T*M>K4KX>&,IX->SP=>FY89X>BZRG3]S
MEJ7J2YHQE%GZ+U^;'Z0% 'Y7^*/^"@=YIGBOQ#H$7PDANWTCQ%JWA^*9?&,R
M27CZ7JEQI44RP)X=?RWNVMUD$"M)L:01AY"-[?$SXOJ1Q,\+3RQ5)QQ,L-32
MQ+4IS55TH)1]CO.5K*^[M=[G]=Y;]%K#X_*,MS:7'53"PQV58',YTGD%.4,-
M'%X*EC)P=66;1YHT54<74<8<RCS<L;\J[:W_ &F/BO=^)?%7A%O@3H>F:UX)
ML-.U3Q0FM_%O0M#TW2K#5S NG7,FM:K86FDRI=/=P1IY-XY\V3RB!(&4=<,_
MS"4\9!930@\OQ$<)BW5S.A1A3Q$W-0@IU(0A/GY).$H.49JSBVI*_P M6\$>
M"J.4Y)G<?$S,L3E_$5?%87)GE_ N8YABL97P2J2Q5..7X+%UL;3E1C2J3G[2
MA'W(N?PV9P7B7]M'QGX5\3/X.USX%_9?$8DLHX--M?&AU)M074T1]+GTF?3=
M!N;?5;75(Y8Y-.NM/EGAO$=3"[<@<DN+,73Q,L%+)IK%PJJB\.J\G5]I)1E&
M*A&@W+GC.$X.-U*$HR3L[GT&5_1KR#.,HCGN7>)OM,IY,1.IBZO#D<)'"_5'
M..,IXVGBLUHU<%6PDH3CBJ.)A2J4)1:J11SFI?MUZYIEW>V&I?!>73KS3KJ:
MRO[:Y\3WD<EG>6\IAGM;C/AS;'-%-^Z="V1(0O)89Q_UUFKK^R[<LI0?^TRT
MG&;IN/\  LY<\90LMY)I7/1PWT5LNQ=&AB,)XCQKT,31AB,-5I9%AY1K4*L/
M:4ZU/_A83E3G3]]2M;ENWHF9I_;SOV=HE^$?[U!EX5\47AFC7 .YX1X<\Q%P
MP.YE PP.>11_KK)7ME:]W=+$R]W_ !+V'N[];;FO_$IV%C&,O^(@N,).T9O(
M<.H2>ND9_P!LJ,G=/2+;T98NOVU?$=K9:7J-S\%;RWT_7(;BXT:\D\07RV^J
M6]K<&TN)[!_^$<Q<0170:!IH\QF4%$9B#5RXQK4_9J642A[2DJU)/$33G1E.
M<(U8KZOK"4Z=2,9;2Y6U=:G-2^BWE-:OC,+1\2Z-3$Y=4IT<?0ADN&=3!5JU
M)5Z=+$Q_MG]U5G1DJJIRM-0:<DKF*?VYKQF15^%2[I,F)%\3W1>4<Y,2#P_N
MD VMDQA@"K9QM.(7&L]$LK5VKI+$RNTU>Z2H7<;:W6EKNYU/Z)N&BI/_ (B!
M.,:>DF\@H*,&[:3E_;*4&[JRDTWS+NBN?VW[QU9D^%B[$W[F7Q-=,L?EX,N]
MET#:GEY!EW$>6""^W(H_UUE:ZRQ<MKW6*E:W>_L+6OU[@_HFX9-1?B!.,GR\
ML7D%"+?/\'+%YPF^?7DM?GUY;V99U/\ ;#U[1_L']K?""XTO^U-/M]7TT7_B
M"ZM#?:7=E_LNH6RS:"C26EQY;F&8#;(HWKE&5FJIQC6H3]G5RETJBA3J>SGB
M)0FJ=:'/2FXN@FE4@U.-[7BT^IS83Z+.5XWZQ]1\288M8/%5<#BGALBH5EA\
M90Y?;X6JZ><-0KT7)*I"]XR?*_>4DL5_VU)VR/\ A6T"\8_Y&F7C_P HE1_K
MM+_H6Q_\*G_\H.O_ (E*H_\ 1>UO_$<IK_WKGJ6G?\%(;O3M/L; ?!^"065I
M;VHD_P"$W=-X@B2+?L/A=]F[;NV[VQG&X]:/]=9?]"U+_N:>G_E I?1,H+3_
M %[JZ?\ 5.QZ^F<)%W_AY;>?]$<@_P#"Y?\ ^96C_767_0M7_A5_]P#_ (E,
MH?\ 1=U/_$=C_P#/D/\ AY;>?]$<@_\ "Y?_ .96C_767_0M7_A5_P#< _XE
M,H?]%W4_\1V/_P ^0_X>6WG_ $1R#_PN7_\ F5H_UUE_T+5_X5?_ ' /^)3*
M'_1=U/\ Q'8__/D/^'EMY_T1R#_PN7_^96C_ %UE_P!"U?\ A5_]P#_B4RA_
MT7=3_P 1V/\ \^0_X>6WG_1'(/\ PN7_ /F5H_UUE_T+5_X5?_< _P")3*'_
M $7=3_Q'8_\ SY#_ (>6WG_1'(/_  N7_P#F5H_UUE_T+5_X5?\ W /^)3*'
M_1=U/_$=C_\ /D/^'EMY_P!$<@_\+E__ )E:/]=9?]"U?^%7_P!P#_B4RA_T
M7=3_ ,1V/_SY#_AY;>?]$<@_\+E__F5H_P!=9?\ 0M7_ (5?_< _XE,H?]%W
M4_\ $=C_ //DS;O_ (*.W5S)O_X4_;)A0N#XWE/3//'AI!SGTH7&LE_S+8Z?
M]136_I0)?T2Z/3CVK'R7#L-/OS<SG_X*&7+<?\*DME_[G2;C_P MVC_767_0
MMC_X5/\ ^4!_Q*51_P"B]K?^(Y3_ /GN5'_X*!7+?\TGME_[G*;O_P!R]1_K
MM)?\RR/_ (5/_P"4!_Q*717_ #7M;_Q'*:_]ZY4?]OBX8$?\*JMU_P"YPFX_
M\M^C_7:7_0LC_P"%3_\ E ?\2ET?^B]K?^(Y3_\ GN57_;ON&X_X5=;K_P!S
M=+_\H11_KM)?\RR.G_44UO\ ]P _XE+H_P#1>UE_W;E/3_S+E1_VY)V_YIC;
MC_N;)3Z_]0*C_7:7_0LC_P"%3_\ E ?\2ET?^B]K?^(Y3_\ GN56_;;G(Q_P
MK2!?^YJEX_\ *)1_KM+_ *%L?_"I_P#R@/\ B4JC_P!%[6_\1RG_ //<Z'PK
M^WU<^%[J\N5^%<%W]J@BAV?\)A);^7Y<C2;MQ\/3!MV[&-JXQG/44?ZZR6V6
MQ5O^HIK?_N "^B707_->5?*_#L%^6;H[?_AY;>?]$<@_\+E__F5H_P!=9?\
M0M7_ (5?_<"O^)3*'_1=U/\ Q'8__/D?#_P4MF$L7VCX.JMOYL?GM!XVWSK
M7'G-!')X9BC>81[C$CRQ([[5:1%)8"XU::OENB:O;%:V>]DZ"5[;)M)OJMR9
M_1,I\D_8\=/VO)+V2J</\E-U.5\BJ2CF\Y0@Y64Y1A.48W:A)JS_ $?^'OQ"
M\*?$_P *:9XQ\&ZG'J6C:E'D$8CNK&Z0+]ITW4;8DO9ZA9R-Y=S;2<J=LD;2
M0R12O]G@\9A\;AX8C#34J4UZ2A+[4)QWC.+TE%^JNFF_Y4XGX8SG@W.<7D.>
MX26#Q^#EM\5'$49-^RQ>%JI*-?"UXKGI58Z-7C)1J1G"/;5U'SX4 % %+4/^
M/*?_ '1_Z&M '$S]_K0!DS=10!DS=_J?Y4 9$W?Z'^= &5+W^K4 9,O^?SH
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MKFI5,;E6&J8+*5"JE&$I3PM=5\2DZE55\OPOUB-*4*48_I17.=(4 % !0 4
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MOP;,&OM3N[>U,L%G<ZM'-?10:<MW,MI9O%:O<,=[5C3S-0X@P^;*C7AAJ%7
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MQ-6_NR5K_(/K&&7_ #$X56_ZB:"M?_N('V&__P"@?J'_ ( 7G_QFCEE_)/\
M\!E_D'UC#?\ 05A?_"FA_P#+ ^PW_P#T#]0_\ +S_P",T<LOY)_^ R_R#ZQA
MO^@K"_\ A30_^6!]AO\ _H'ZA_X 7G_QFCEE_)/_ ,!E_D'UC#?]!6%_\*:'
M_P L#[#?_P#0/U#_ , +S_XS1RR_DG_X#+_(/K&&_P"@K"_^%-#_ .6!]AO_
M /H'ZA_X 7G_ ,9HY9?R3_\  9?Y!]8PW_05A?\ PIH?_+ ^PW__ $#]0_\
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MY\KW_P  [G_XU1R2_DG_ . 2_P @^L8;_H)PO_A30_\ E@?9+O\ Y\KW_P
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M_P!Q_P#(] !NU3_GE8?]_P"X_P#D>@ W:I_SRL/^_P#<?_(] !NU3_GE8?\
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M'_R/0 ;M4_YY6'_?^X_^1Z #=JG_ #RL/^_]Q_\ (] !NU3_ )Y6'_?^X_\
MD>@ W:I_SRL/^_\ <?\ R/0 ;M4_YY6'_?\ N/\ Y'H -VJ?\\K#_O\ W'_R
M/0!SVJM?"<;TLE(B7A9)C@$OW, HV^7ZBMZKYM6^1SLK76#\EL/HTG'7_IE0
M%O7[W_F9<QGY^6 <GH7]/^N= 6]?O?\ F94QDP>(Q],\=?\ 8% 6]?O?^9ES
M%O11] /7Z"@+>OWM&5-C!SGKV5?>@=O7[V9LICP?O_@J>_\ M4!;U^]G??#
MRC4]7^R",M]BM]XN28E"^?)@H84D).>H8*,8P31MY!;Y'M.[5/\ GE8?]_[C
M_P"1Z #.J?\ /*P_[_W'_P CT!MY6^5KANU3_GE8?]_[C_Y'H -VJ?\ /*P_
M[_W'_P CT &[5/\ GE8?]_[C_P"1Z #=JG_/*P_[_P!Q_P#(] %2^.I?9)MT
M=B%VC)$UP2/F7H/LX_F* _KL<?-]J'\-KU[/-_+RA0!ES?:,CY8![!Y?_C=
M;>7X&7+YO/$0Y/ 9^./]R@/P_ R9=W/"CKT)]?I0!F2]^W)Z?K0!ER[!_?\
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MG'#T[IQPV#HX522:<Y4J^+J.HHZ\D)1KT^6+;DFIW>QZM6!H% !0 4 % !0
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M+)V2_)?UL&WE^!^Q X &<D#KTSCO@<?E68CF=8_X^?\ MDG\WH YF;H?\^M
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MW_S4T '_  D&M?\ 0B^)?_ [P=_\U- !_P )!K7_ $(OB7_P.\'?_-30 ?\
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MAQO<KN; !. ,+^NP;>7X&O\ \)!K7_0B^)?_  .\'?\ S4T <YJVO:P;@?\
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M?]32/Y4 ;.EW]Y>K,;O1-1T0QL@C74)](F-P&#%FB.DZGJ2J(R '$[0L2Z[
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MT_3_ !H ]&^$_P#R%M9_Z\+;_P!*)* /=* "@ H * "@ H I:A_QY3_[H_\
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M<G2_UBKJT+WSKD510Y?:>PQ?LM*GN7]IR\O-IS6/],N*WB(>!^,EA76CB(\
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M?^GC_P  KW_Y'H /[1M?^GC_ , KW_Y'H /[1M?^GC_P"O?_ )'H /[1M?\
MIX_\ KW_ .1Z #^T;7_IX_\  *]_^1Z #^T;7_IX_P# *]_^1Z #^T;7_IX_
M\ KW_P"1Z #^T;7_ *>/_ *]_P#D>@ _M&U_Z>/_  "O?_D>@ _M&U_Z>/\
MP"O?_D>@ _M&U_Z>/_ *]_\ D>@ _M&U_P"GC_P"O?\ Y'H /[1M?^GC_P
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MVC&;.\4#YE[F  ?C0!QLUS#S@R#G_GA<#_VD* ,N6>+(P7'MY,PQ_P"0Z _
MS)I$[;N__+.0=O=10!E2L.<9'7^%AW^@H RY>^/4^W^% &7*C>P_X$H[_44
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M49MJ,)W27-%F1X4_9K^ GAZTT/Q'IJ^*==O- ^(UKX^7QIXB\7>,/%OB>_\
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MXO\ XJ@ ^V6G_/U;_P#?^+_XJ@ ^V6G_ #]6_P#W_B_^*H /MEI_S]6__?\
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MZEV6R;<)C; N/N+TPE &)+;#G_1Q_P!^1[_[- %"6WQ_RP QT_= 8R#_ +-
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M .%)N),D!LA2>Y&,T >W_9;;_GW@_P"_4?\ \30 ?9;;_GW@_P"_4?\ \30
M?9;;_GW@_P"_4?\ \30 ?9;;_GW@_P"_4?\ \30 ?9;;_GW@_P"_4?\ \30
M?9;;_GW@_P"_4?\ \30!3O[:W6SGVV\ (48(BC&/F7_9XH#;RM\K7.,FBB_Y
MY1CG_GF@_P#9: ,F:.-2,1HN/1%&,_A0&WD9<RKS\JCK_"H[?2@-O(R)@!G
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M57Q9\*^ O%_@V33/B0'_ .$6L]>\*:\_E7=_9.-9\/>)M*UGPV4?3&6\F?\
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MH R9N_U/\J ,B;O]#_.@#*E[_5J ,F7_ #^= &7+]Y?]X?SH ^PD^XG^ZO\
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M+>D:GJ6A^'+K2X+R\/AOX@>!O$]_IVGI++=ZAI.C^(+2;488;:'Y[IX+=VU
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M,P_LW3_^?&T_\!XO_B* #^S=/' L;0>WV>(?IMHV\K?*UPV\K?*UP_LW3_\
MGQM/_ >+_P"(H /[-T__ )\;3_P'B_\ B* #^S=/_P"?&T_\!XO_ (B@ _LW
M3_\ GQM/_ >+_P"(H /[-T__ )\;3_P'B_\ B* #^S=/_P"?&T_\!XO_ (B@
M _LW3_\ GQM/_ >+_P"(H /[-T__ )\;3_P'B_\ B* #^S=/_P"?&T_\!XO_
M (B@ _LW3_\ GQM/_ >+_P"(H /[-T__ )\;3_P'B_\ B* #^S=/_P"?&T_\
M!XO_ (B@ _LW3_\ GQM/_ >+_P"(H /[-T__ )\;3_P'B_\ B* #^S=/_P"?
M&T_\!XO_ (B@ _LW3QTL;0?]N\0_]EH /[-T_P#Y\;3_ ,!XO_B* #^S=/\
M^?&T_P# >+_XB@ _LW3_ /GQM/\ P'B_^(H /[-T_P#Y\;3_ ,!XO_B* $;3
M]-169K.S55!9F:"%555&2S$J   ,DG@#DTFTDVVDDKMO1)+=M]$@2V26NR2_
M!)$:6FD/"MQ';Z>UNT0G2=([=H6A9=XF6504,10[Q(&V%?F!QS3?N7YO=4;N
M5_=Y;;WO:WG<%T4>]DEWO:RMUOIZBQ66E311S06MC+#*BR12Q10/%)&ZADDC
M=%*NCJ0RNI*LI!!(--IQ=FG%QT:>C3].@*W3;R)/[-T__GQM/_ >+_XBD ?V
M;I__ #XVG_@/%_\ $4 ']FZ?_P ^-I_X#Q?_ !% !_9NG_\ /C:?^ \7_P 1
M0 ?V;I__ #XVG_@/%_\ $4 ']FZ?_P ^-I_X#Q?_ !% !_9NG_\ /C:?^ \7
M_P 10 ?V;I__ #XVG_@/%_\ $4 ']FZ?_P ^-I_X#Q?_ !% !_9NG_\ /C:?
M^ \7_P 10 ?V;I__ #XVG_@/%_\ $4 ']FZ?_P ^-I_X#Q?_ !% !_9NG_\
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M]FZ?_P ^-I_X#Q?_ !% !_9NG_\ /C:?^ \7_P 10 ?V;I__ #XVG_@/%_\
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MA_:8_:![_%WQC_X$V/\ \@5C_;V=?]#/%?\ @4/_ ) ];_B#7A3_ -$#P_\
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M@ H * .8UC_CY_[9)_-Z .9FZ'_/K0!DS=_J?Y4 9,W0_P"?6@#)G_K_ %H
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MZ #^ST_Y^;__ ,#;C_XN@#FM1M52ZE43WF $^]=3$\HO<MF@#$DMUY_>W/\
MX$2>_O0!1EA Z23\?]-W[@^] ;>5OPN9\L8'1Y>.QE<]2?>@"C*G7YG_ !=O
M?WH SW7&>6X]SW% %&3@D?6@"C*<=E_[Y'K0!2D?'\*<9_@7U'M0!GS2$9PD
M7 [Q*>H/M0!].^'K)'T'17\^\0MI5@VV.[FC1=UK$=J(K!449PJJ  , <4!_
M78V/[/3_ )^;_P#\#;C_ .+H /[/3_GYO_\ P-N/_BZ #^ST_P"?F_\ _ VX
M_P#BZ #^ST_Y^;__ ,#;C_XN@ _L]/\ GYO_ /P-N/\ XN@ _L]/^?F__P#
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M;B,_M=_M!'KXVM?_  EO#(_EI='^M&=_]!<?_";#_P#RL/\ B7OPD_Z)FO\
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M^?6@#)G_ *_UH R)NG^?>@#+E^Z?I_C0!Z-\)_\ D+:S_P!>%M_Z424 >Z4
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MB2.Q%1*$7&4&O=DI)I>[\2:E:UK-IO5:Z[E1DXR4HNTHM-/MRNZ^2[;'"_\
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M?@J;D\/@<)#>-"@I/63<ZM24ZM1N<V=++_G\Z[#Y<HR?U/\ .@#.F[_3^AH
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M::=TUHT54ISI3G2J0E3J4Y2A.G-.,H3BVI1E%V<9)IIIV:9)_8GC'_H=T_\
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M/!?:BK>:5K_,RYM*\3C/_%6#O_S*FF#M_P!?5'LJG_/N?_@$O\@YX?S1_P#
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M3GB,ZSO)'>2Y:-?(L/7Q.)KSDM'0J1P\U2<;SU3G&*O;!U8*AB*\%)T\/D>
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MHJ^/SRA#%27U;ZQA,OGET<%B8X.I^]B\5#%U9U&GR1Y(2Y8PK4T>_?&7QO\
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M4XS<E3C34X\G)!5^:K&K+#]5A&HTXT>>4YRG"K6YW2JTE'W6LB@H * "@ H
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M1G(VJ2 -O*WRM<6.:*8,898Y1'))"YC=7"2Q,4EB8H2%DC<%)$.&1@58 C%
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M_P!2[!JU_P#N"._X27Q)_P!#%KW_ (.=2_\ DFC_ %OXL_Z*?B#_ ,/.8_\
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MS_HI^(/_  \YC_\ - ?V)DO_ $)\J_\ #=@O_E ?\)+XD_Z&+7O_  <ZE_\
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MO_#=@_\ Y2)_:&H=/M][]/M=Q_\ '*7^M_%G_13\0_\ AYS'_P":0_L/)?\
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M]3_*@#(F[_0_SH RI>_U:@#)E_S^= &7+]Y?]X?SH ^PD^XG^ZO\A0 ^@ H
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M(:O^0?ZZ<)?]%%E?_A1_]J'_  K;Q_\ ]"AKO_@&?_BZ/^(3>)'_ $1F??\
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MDOEX^Z_X,H]?]B@#T#X7B3^U-7^R,D3"QM]QN$:92OVB3 58WMRISU)9@1T
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MU5-XCV"<)2BGS*%*NXN<4[R47%/6YP$OP7\0Z'XCLM6\+ZSI6MZ5:7%AJ?\
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M^@>G_@:G_P 9H //U#_H'I_X&I_\9H //U#_ *!Z?^!J?_&: #S]0_Z!Z?\
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M ]/_  -3_P",T 'GZA_T#T_\#4_^,T 'GZA_T#T_\#4_^,T 'GZA_P! ]/\
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M+_F:9FK?]3#&*U_^XQ0DTVP'_,'TQ<>EK9#&3_U[T?ZO</?]$]D'_ADRM?\
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MUV,R18\K^]*_,/\ EDWK_O4!_78^L$GO]BXT],;5Q_IJ>@_Z8T 7('F93YT
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MR0"PO, L,X!.3@XZ&A?27\.N5S6#XJY(R47)97@5%2:;4;_VM:]DW;>VH?\
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MPX_Z!>*%_P!TS :?^98/^(0<5K_E]DW_ (68C_YB*<GC31SD!+[IQF",=O\
MKO1_Q,WX<?\ 0+Q1_P"&S ?_ #V#_B$'%?\ S^R9?]SF(T_\LCW#2/CUX(T_
M2M-L9K?Q 9K.PM+:4QZ?;,AD@@2-RC&_4E=RG:2H)&#@=*7_ !,UX==,+Q-;
MI_PFX%?A_:N@UX0<5?\ /[)E_P!SM?3_ ,LS1_X:%\"?\^WB+_P6VO\ \L:/
M^)FO#K_H%XF_\-V!_P#GJ'_$(.*O^?V3?^%M?_YC#_AH7P)_S[>(O_!;:_\
MRQH_XF:\.O\ H%XF_P##=@?_ )ZA_P 0@XJ_Y_9-_P"%M?\ ^8P_X:%\"?\
M/MXB_P#!;:__ "QH_P")FO#K_H%XF_\ #=@?_GJ'_$(.*O\ G]DW_A;7_P#F
M,/\ AH7P)_S[>(O_  6VO_RQH_XF:\.O^@7B;_PW8'_YZA_Q"#BK_G]DW_A;
M7_\ F,/^&A? G_/MXB_\%MK_ /+&C_B9KPZ_Z!>)O_#=@?\ YZA_Q"#BK_G]
MDW_A;7_^8P_X:%\"?\^WB+_P6VO_ ,L:/^)FO#K_ *!>)O\ PW8'_P">H?\
M$(.*O^?V3?\ A;7_ /F,]&\(>./#_C:SEN]#N),VTGEW-G=(MO?6Q.?+>6!9
M) (I@"T4J.\;X9=P=71?U'@CQ!X:X_P-;&</XFIS82I[+%X'%PAA\?A>:_LZ
ME7#PJUH^QK)-TJU.I.G)J4')583A'X[B+A?-^%\33P^9T815:'/0Q&'E*IA:
MR7QQIU7"'OTV[5*<HQG&ZE9QE&3Z^OMCYTYC6/\ CY_[9)_-Z .9FZ'_ #ZT
M 9,W?ZG^5 &3-T/^?6@#)G_K_6@#(FZ?Y]Z ,N7[I^G^- 'HWPG_ .0MK/\
MUX6W_I1)0![I0 4 % !0 4 % %+4/^/*?_='_H:T <3/W^M &3-U% &3-W^I
M_E0!D3=_H?YT 94O?ZM0!DR_Y_.@#+E^\O\ O#^= 'V$GW$_W5_D* 'T % !
M0!\3>-O^1P\3?]AB[_FM %K1M4TJ#0KC2KO5-;T:>35EOVN-&M$G-S;QV8@B
MMYW^WV+JL4S2RH@9URV<9/#E;EII-KD]K>.T7*;CRRWW48N.W704?=E/1>]&
MFD]FN64Y225M%)RBW9ZVUV*'B?4;+4KZTFL9KRY2WTJPL9KS4($M[R\N+1'C
M>YGC2:X&]X_*7>TSLP0;B<9,_;J2LHJ4U)):)7A",G:R2<I)R:7>_4K2,*<;
MN\>=-O324Y2C%:[14N5>1Z5\#_\ D-:[_P!@NU_]*VIB.D_:&^&_C'XJ_#'4
M/"'@/Q;9^#?$4FM>&=7M]2U&UOY]/O+?0M=L=6N]%OIM'O-.UW3+;5X;1K1]
M5T"_L=:L"RS:?=P3#S%QJTY2JX.<>7DP^*C6K492J4XXBE[*M2E1E4HRA5A%
MNK&HU"<?:JFZ$Y*E5F:TYJ%/%4US1E7PU2A3JP4'+#SG*$O:QIU(RI3?+&5.
MU2,HQ51U.64H13^>/A?^Q9=^#OA=J/@/6_B'J<5W)KWQ=U6UL?"FH>)X?AOK
M%K\4XY%%A\0O OB'7=6D^(-GH?G/;16WB37+V>[LT_TC4FO+FXNSIB8^TP6'
MPM-J<\/E3RQ/%0C.@W'&8[$PQ4*%'V,</B)1Q4;U</[.I1JTXU*$HNG3:G#S
M='%U,2^:'M,RP^9)T)RIUZ4J5#!TY4(5YN<Y454PTG%5>>-6$[5H.,I0/G/5
M/V2/C-\(?@=XKT30=4U'QU\3=?\ B=\,=<^#5I\.[;4Y_#?PB\2^%3=VX\7:
MEJ?Q%\3:EK]CX6O--OM3TS7;,7^JV>C:7)9V.E6$L=S=.E57.N\JPT*E2A66
M.Q]3$8^JU*EA\#F>#AEV98>K57+7KN6!J8FK0J5%4KU<;[&_*Z-.3BE3HT)9
MEB)4X2PW]G4J4<'14HU\7B<'BEC\OJ4J3G&A1G1QM'"\U&E.GAUAU6<XU7/D
M/H77OV*I9-.\4:'X8\0Z'INC:I^QK)^S!H\>HZ;=75[::[-K&L:O=>,=0N8W
M GMM0N=4%WJ,,2K?76HB6ZDD9BF(QL%B)9FJ2C2HXO,^',3A*3BO9X7 </R<
M:&"=-67NX=4J5&TN6*IQNM+O3!5)8:GEGMOWE?"1XBJXNIHU7QO$%#!1K8B"
MM%12Q-#$5:D5&'-"OR04(W1M^/\ ]C*Q\>6GPULM;\6:KXHTCP_XZ^&?B7QM
MX'\=:KJWBCX;:AHG@/PEJ_AR_P!%\&^"[R1],\,G6Y]1AO+@A'MYQ#)]K21W
M!KHK2IU<TEC)4_:4/K&>8J,:UJF)C5S6E7CAX^W:_@X2I6C4C25HITJ3A9TT
MGAAU4P^72P<)^SJO Y9@E*E>G1<<%C\NQ5><Z<6FYUZ."J4>?XK5Y\VDI&?\
M>OV--*\8V'P<TKX0^#_@1H'AKX5>(/&6NR_#?Q]X#N]0^&NO3>+M%CTIY[SP
M_P"%KG1VDOK*<-J4-Q),&-Y%:NY=(3$W._:O%TJ\I1J0I8#$8&%.JG)T8UL1
MAJZE0N^6FXNA46BU=:<OBDY&Z=.."Q&%A&5&=?,,#CI5:3C#G>$I8NE.%;2\
MU5CB*<6[W]G24+V44NEUO]G'Q?XG_93UWX!3I\'O &M:E=61TY?A;X4US0?A
MOI-E9^--)\58M?#U]J=[J<=W>+978O72\$4M_=?:%14WJW1.=\5DV(YJLO[-
MQN7XJK&I)/FA@L4ZOL</9+V<'2Y(P4^9*ISOX6DLL.E06/BH4X+%8;,*$/9Q
MY&IX[+ZF%]K6Z3FJU24Y.-N:E&,?B3;]1^/'PL\5?$C3_AG<^"M<T#0_$OPR
M^*GA;XD6#>)].U#4=#U--%L=8TJ^TN\@TN[L;^,W-CK=S):SP7"^7=0P^8#&
MSXYTIPS#!XVFXI8=9C2JTY)MRH9EE^)P-5TVI14*T%74Z;DI4[I\T)72""4<
MMQ.!?Q5:6 ]G-/EC&O@,=@\=2<TTVZ,YX50J1C:;A+W91?O+Y,\3?L0?$C4?
M@M\)_A)HOQ+\*V%MX.7XK6?C2WN-(\4VFC>)H?B3J>HZC::Q:S>%_$7AWQ&-
M4\,27B7$.E7NL'P]KE[EM>M+ZT@CM)(KT?:JG24G"A2X?PN448ZWP^)PE'"1
MCBZ=._U>K&M4PWOT\32K0I1DZE.FZLI,ZWB6L1B\5&/)4Q6?5\WG&+M&K1Q'
MUE2PM62_>PY(XF7+4H3IU)64744%9]=\/OV3OBG\--:T=/#7CWX;#PIKWA;X
M&:3\4(-:\!ZAKWB&'5/@GX1L_"4$WPTO+K68-,TBT\06=C%+%-KNG:A>^&+V
M6;4M(\RX(C/?BZM/&U\Q595(8/%YCFN:4HT'&GBX5\XPD,-B,/4Q+4OW-)TX
MRI5Z<8U_92GAG:#YGPT54PU#!QHN+Q&%P4,N<ZR<J%2A1S+$YA2Q$J"<8NM-
M8J<<1AG_ ++4JI5K<ST\8\-_\$V=6\.^%?B%X6C\6> Y#JNA:?X1\'>(#H_C
MJZUVX\/)\4M ^(.I2^-EUCQIJV@075S8>'[31SI7@K0=#T6ZO6.LW<1N-R/C
MA*CHPR_V\8RJ87&Y#7Q$:-XT*M#(Y.2Y8U?:556Q4N2K&,ZKHX*49TL.G2K3
M1O4:>)Q4X\_L:V%XAA256;E6I8C/<#B<(G)QY*4J6$6)E%U/9?6,73Y76DJD
M$W^LZ*$55  "J%  P %    X &.!V%2W=MZW;;UU>KZON90CR0A!62C&,4DK
M)<J2T71::+H.I%!0 4 % !0 4 % 'E_Q+\%:WXQATB#2-3M;.WM3JT&IV-Y<
M:M8P7UOJNG/8I*]WH5Q::C*M@[-,^CO<1:;K*2-;:BRHD3IC4H^T56#?+3JX
M2OA[[NE.K*C*-94G^ZK.*IRC[.K[J<U4C[\(FM.I[+D:3YH8BC6Y4^13A3C6
MC*BZB7/1YW5A+VM+WU[/E^&<C"@^%VIV_@71?#ESJ=KK%]H^@^&-)72[Z:_L
M?"BW?AHV7DZOI+Z2+7Q'H.K.;)+FTU*VU*YDTZZ;=%!*JC/36FYUG6C'EDZL
M*VLY*=&3HNG4CAZL.5QBW*:?-%^UI2G3GRJHW'GH0]A2]C?2-.M2LH1]G6A4
MJN<?;TI<RD^5I6C*/LZBC4BY.FE+G(OAGXAE\2^"TU75+W4GT;2/$]SK^H72
MWE]I]RMS?W5SX&T8:SJ,K:CJL_A*\OKR6"ZO-^H7%O#'<WKQR7"J^$J7-1QE
M-3<92RR.$C4G"--U,?*G7PZQBA3LERX'%XW#U.56;J4IN3K;:*7+*C[ON_V@
M\1R1E)^SP<?85JF&E.3NU6QF$P5>*DG91K4XI4DB[_PJ/Q#87'@K5=*U?1&U
M/P7X<\":-#;WUK>1V.HS^%[?Q18:BTLUNSW%K;W5IXE::P\N*:2*YM DZM%.
MS)NIRAB<57@DOK%:I)1E=*%.KE]7!RORVYIQG.-2*3C&4%*#<6U)1R+V2I.\
M>5UY)QLKRGCL%C:<7?:/^RRIS>K7M%.*?*XR/!_PM\9^#+6[L+/6?#%Y#XCT
MNPM?$MU=6&IQ36MY8P7]K)+H=O#/B6UO;:ZB$<%_=H=-N(YIU-\DQ@&%6GSX
M.I@8OEI.ARTYM?O/:RRO"8"?.E:*INI@Z=:,DI34)SI.+Y836JFUB8XJR]I[
M6;G':"IO,,3C8<MM7.,,55I33M&I*,*O-&\X/&T7X#ZEHWDZ>U_IFI:6UQIV
MM3SWNJ^,HI;'7['PU::*9-/\/V6LVOANX47EC!>66HZA;27-K;2RVL]G>M%!
M,+Q"=:&(C']VVLP6&E\3BL?'$J7.I>[!P>,KQE*FFJE)J'+"I*54F-HSC*UU
M)X1UX?!%_5*U*HK<CC*<90H47&$G%0KIU.:4'[,Z/3/A#J=C;VD+ZOITC6VJ
M_";4&9;2==R?#O2]/L+V,9?(?49+.26S;I;K(!*&;<3O4J*5=54G%1S+,<<H
M]5#&Y5'+HT[_ ,T)Q=2;VE!\JUU$_P"%.GUE@:.$OTYJ>85<;SM?RN-112W4
MUS;6/>:Q * "@ H Q[OP_H]Y))--8P+/,$6>>!1;W$Z1#;&EQ-!Y<LR(.$21
MF5!PH%<..R["9C&E'&0G4C1O[./M:L8PN^:248345S/5M*[ZL48QA)RA&,)2
MMS2C%1D[:)2DE=I=$WIT/E;]JMK71+#X)-!X@M/ MO9?&#1G3Q-+;VD]KX<"
MZ+KA.J2VU\193K#DETNSY3E]TI[U^B>'^$I4HY_A,-EZQ-*/#^(A#+:+G2>)
M3Q.&;HQE2_>1E-ZN4+S;N]6V?$\:S5-9!-XN. Y,]H2^N3C"4<+;#XC]]*-2
MU-J/53]UWU/ESQ-XE\R_^,EUIGCS_A9MS/!\%'N?B]HD?]A"SA7X@:?9_P#"
M!"/1)(]'5!#--J9DTUQ-<I--%J/F%0%^YP>"Y*>04ZN6?V-",^(E#(<2_K/M
M)/*JM3^T[XA/$7;4:-JJY8N,72Y;N_QV+Q=ZN>SHYBLUE)</N6=X=?5E3BLS
MITWEML.U02LY5KTFI34I*I>VG0^)M7M_+^)>O7GB?6K?]IC2OC=%H_@'0(]<
MU6'41H8\0:5;^&]&TOPO'<+977A#5?#<MW<ZC="PFMIU::XNKE9$%<F#P\T\
MGPU+!4'P=6X=>(S3%2PU!T5B?JE>>,Q%;&N'M*>/HXR,(4J?M8SB^6$*;3.K
M%UXJ.;8BIBZ\.+*'$"H9;A8XFM&JL/\ 6J,<)0HX-35.>!K864YU9^RE&2YI
MSE=(P-3G\'^+_''BK1/&GC3P?HVHW?QN>YN=>\9>(/$L/B[3] T76;*$^!(O
M"B6K>%?[!U&6UFL],N)]:AT_^SKE;R^L_MPB"=-&&/R_+,#B,NR['UZ5/AQ0
MCALOPF#E@*N*Q.'J269RQWM%COK-)5(U*T8X9U?;0=.G/V5V^:K+ XW,<9A\
M=C\%AJDN()3EB<=BL7#'4L-0KTXO+HX)0>"^K57"5.C*6(5/V,O:5(>TM;9\
M+7>L:OX@L=<U7Q[X6\+_ !8'QIN=-GM;S5/'%]X^-M#XDFMX?!G_  AFG/-H
M_P#PAM_X:6*.VN4T\:1;6#Q:K/?).LD@Y\;3H8;"SPN'RS&8O(UP[3JPG3HY
M=2RQ3E@XSEF']H55'$?VA3QKE*<'5^L3K*5"--Q:1T8*=:OB*>(K9CA,%G7]
MOSI2A4K9A4S+ECBY1C@/J%)RH?4:N#24)*G["%-QK2J<RDR72+.6R\"^#?BA
M#KWB/_A++3]J&X\):?>/XAU:2TM/"NH?$35=-O?#ITTWC:=<V-W%)*\YGMI)
MGD= )A##%$JJSC/,<?DTL-A%@:G!D<?5IK"4(U)8VEE-&M2Q?M5356%6$E%1
MY9J*C=N+E*4G5*$J>7X#-X8G%+&4^+W@:<WBJSIPP=7,ZU&KA?9<_LI4YIR<
MN:+DVU[W+&*7ZA(Z,H:-E9#RK(P*GGL5.#SZ=Z_'&FM+--='I;Y=#]=35KIZ
M=&MAU(#X!\/7%O9_%J"YNIXK6V@\8:K)+//*D$4*"ZO\N\LA6./D@!G(7<1F
MO\WN%<9A<M\::N,QF*IX+"X?B/B:=7%5:]+"QHKV>:J+C7K2C2IU93<8T93=
MO;2@K-NS_K7-Z-7$>'U6A0I5*U:KP[@(4Z-*$JE2I)T,)[L:<$YSNKMQBFW&
MYU=EKOA_QKJFEV6IL9[#0+/5+F:^\?:JD^J:D+VZM=UI;7-A=Z% RZ?&CS64
M%Q? ;7N&5)9-D;?8Y9Q!PIQ_G64T,YG2JY7PQE./EB,?X@YS[;/<WCF.98:K
M5A2Q>!QW#N'JRRBDI2P5"OC*DHX>KC94<-B:WLJ3\#$Y5F_#. QV)P,?8XK-
M<1@:%+"<)X"5' 8%X:A7MB*U#%X?-*L7C)RC3Q-6CA6[QHIRA#FFM'3U\$>'
M?$7A\:7!HN9_&/B:)M:DU:2:?2M&L?+.F/'B^6Q$5U%/+#%/>Q/YL8*HYE!D
M'H98_#[ACB/A[#Y52R.'UG._$"EB^(?[9J8O&Y7E67RQ>'R>%)?VE#+/]OP=
M=TZ%;%T)/'15/V-13<JKX\6^)\VR;-WCJF9I4>',DJ1RR& A1I8_,L5SK'1G
M_LKQ7M*%2E"I4I8:<?9S?-*/LVH.II]AX)\U;+[1IQ\-WNN>$)X8'U>2V>\T
M[^P=<-[<ZQ;F_P#]'U./456.]8K&ME(\45N4AN%\W'!9?X?*?U&>(RN?#%?B
M#)\;@\!_K#6P\<7E,>"LUJK%9E1>8\V&SB69QA0S*<H4GA<PF\)AHPPM2E3J
M]&+Q7$T:<L2J.,CG.&ROB&E4JPRZ%6.%QG]K96L-0RZLL+^]P,\')SPR3D\3
M",YUE*K2?LV:#IGP^U.YL9I]+T2P.H^&+>YEMYM</]G:/J":S?6=Q)-;WFO:
M7?23RV,5M.T<=]++#N,J64JS(*SR#)_#'-<33J5\NX=RV6:<)9-CIQK\0R_L
MK(<QJ8[,<+F7-A,7Q+E>:5*GL*.#Q,J=/&X[$X2/-;+Z[Q-,K-<;Q=E]'%4J
M..S/$K!9Y6H4ZM+*[8S,,'++<+B*4:=7#93CL+3I0Q52O2C.>%A3J65.6*IN
MG)F9#HO@9?#JN[Z),JV4C/K,>LSIKC^)$UK[/%ID.BR3I_Q))M-Q-]IDM 1
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M)*=#%UL)+!8-2>(KQ=##4:V78&O&7LU";2JX^DHI-8CF=GY;7XT?=!0 4 %
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MIDQM9R54DJV /P_0]_H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MHW_/QXE_\+3QC_\ +Z@!/^$+T7_GOXE_\+3QC_\ +V@ _P"$+T7_ )[^)?\
MPM/&/_R]H /^$+T7_GOXE_\ "T\8_P#R]H /^$+T7_GOXE_\+3QC_P#+V@ _
MX0O1?^>_B7_PM/&/_P O: #_ (0O1?\ GOXE_P#"T\8__+V@ _X0O1?^>_B7
M_P +3QC_ /+V@ _X0O1?^>_B7_PM/&/_ ,O: #_A"]%_Y[^)?_"T\8__ "]H
M /\ A"]%_P">_B7_ ,+3QC_\O: #_A"]%_Y[^)?_  M/&/\ \O: #_A"]%_Y
M[^)?_"T\8_\ R]H /^$+T7_GOXE_\+3QC_\ +V@ _P"$+T7_ )[^)?\ PM/&
M/_R]H /^$+T7_GOXE_\ "T\8_P#R]H /^$+T7_GOXE_\+3QC_P#+V@ _X0O1
M?^>_B7_PM/&/_P O: #_ (0O1?\ GOXE_P#"T\8__+V@ _X0O1?^>_B7_P +
M3QC_ /+V@ _X0O1?^>_B7_PM/&/_ ,O: #_A"]%_Y[^)?_"T\8__ "]H /\
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M/7?Q\7^+_P#Y>T -/PZ\+?\ /'6__"N\7?\ R]H :?AOX3_Y]]9_\*WQ;_\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M5.HXQN+7-'FOR.HYUHQLO:Q=7%5H4W?X8PGC*UG!PE)>RYY2]FKU-$^$5]'
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M4O?J1T2@X6LFDE*$96;=GS1;::E"G.*LIPB]^[K,H* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * (&MK=IX
MKIH(C<P1RQ0SF-3-%%.8VFB23&](Y6BB:1 0KM&A8$JN!:7M[O,E%VTND^9)
M]TGJNS;MNP[=HNZ6UFU9M=FUH^Z".VMX9I[B*"*.>Y\K[1,D:K+/Y*E(?-<
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M*%1% 5551A551@*J@     # H;=VV]=VWO?NQ)))))))626B26R2Z)#J "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
-"@ H * "@ H * /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ey.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ey.jpg
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M/M(P)_!ZWYW:QK6JZB,Y\E9(;.T!_P!FVAC*K]0V[_:)YK\NS/P$I\6357Q
M\0^-^*TFI/+Z6)P&09$IIWYJ>3X#"3HTNRE3JJI:UZDFKGK4N('@E;+<MP&"
MTM[1PJ8C$6\ZU6=__);>1<MO!WANTQLTN&0K_%<M+<?FLSNGY(![5[F3_1^\
M(,D4?J_!.78NI'5U,WJXS-W)KK*EF.)Q&'5^T:,8^5C"MQ%G-6ZECJL%_+14
M*"7HZ482^^39O06EK:#;:VUO;+T"P0QPC\HU6OT_+<BR3)8*ED^3Y7E-.*LJ
M>6Y?A,!!+MRX6C2BE\CR:M>O6=ZU:K5?>I4G-_?)LL5ZID% !0 4 % !0 4
M?-^J?M6?!_1M3U+1[W4M<2]TG4+[2[Q(_#FIR1K=Z?=2VERL<J1%)$6>%PDB
M$JZ@,IP10!1/[7OP5_Z"?B#Z#PSJN?H/W/6@#L?$O[07PV\*:1X6U[4K[57T
M7QEI[ZCH&IZ?HM]?6EQ'$(S/;326\;?9;^W\U?/LK@1SQD2*5W0S! "Q\/\
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M3/?UH ,#&,#&,8QQ@]1CT/I0 O3VQ^&,T % !0 4 % !0 4 % !0 4 % !0
&4 % '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_f1a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_f1a.jpg
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M+1IKGH.36GNU:<HU.1J\7R7UB2Q+JU\NH^)UN"+G3+FREDE.$<F4NB/'_#B
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5]"OK#C"@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_f1b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_f1b.jpg
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MK:;-:6VM86F!R?CC_D5]4_[<O_3C:5^$?29_Y,CQK_W;?_K79">_PO\ \CW
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MXJ^&-3Q?X#R#)\-Q%A,!7PF*RW/:&9T\JJ/ 9C;*L5A6J>!6-C6R[#XF./\
MK5!>WQ<L-"$</*-;F=:'#E.:+)<PQ%:6&G.,H5</*DZJ52E>M">L^3EJ2BZ?
M++W8*;;E=;/S6Y^'6O09\AK*[4?=$4[12?BL\<2*?I*P]^U?QOG/T1?%'+N>
M665N',^IQ_APP>9U<%BI+^_2S3"X+#4Y7OI'&U(VL^>[:7VM#C#*IV56.)PS
MZ\])3@O1T9SDU_VXGY'6^"M3U&"XN/#.K1.ESI\'G0&1E+QPAH1]G9E+*Z!9
MXWMW5B/+)7)41@?O?T;N-.,,!FV;^#''>"Q&'S?A/*UF&6U,55IU<3A,NA4R
M^G_95>M1J5J6*H0I9IA,3E6(I5:D(X)U**J2H4\+&'S_ !-@<%.C1SO+YQ]C
MBZOLZJ@G&,JC51^UC%J+A)NE.-6+BGSVE92<[^C5_7I\:<GXX_Y%?5/^W+_T
MXVE?A'TF?^3(\:_]VW_ZUV0GO\+_ /(]P/\ W,_^H>((/-N8M(T#[/>ZI9@Z
M5:;AIVC#55<BVM\&5OLESY!7)V#*>8"QPVWCRWCLYP7 7A8LJXEXWR"-3@;(
M76APAX=1XYIXEQR;*>26.JO(,Y_LV=-.2H4U+#_68SJRY:GL;PV]G0EF&;>U
MPN!KVQ^(Y7C,R_L]P_?UKJFEB*'M%+3F=I<MDM.;6M]IU'_H,^)O_"/'_P J
MJ\;^V^+_ /HXOC1_XS[#_P"@4V]A@_\ H6Y)_P")$_\ YO#[3J/_ $&?$W_A
M'C_Y54?VWQ?_ -'%\:/_ !GV'_T"A[#!_P#0MR3_ ,2)_P#S>;T>N0)'&KVN
MN2NJ*KRG0-30R,J@-(52S"*7(+%5 52<*  !7ZC@_$W+:&$PM#$Y)XFXW$T<
M/0I8C&U/"SC2A4Q=>G2C"KBIT</P_3P]&>(J*565*A3A1IRFX4H1@HI>5/*Z
MCG.4:^5TXN4G&"S; R4(MMJ"E+$.345HG)MNUV[D\.LP32QPK::O&78*K3:/
MJ4$2D]Y)9;9(XU]6=E4=S7JY=XB97F6.PN7T<@X^PU3%UHT85\Q\/N,,MP-&
M4]IXK'XW)Z&$PE%?;K8BK3I1WE)&-3+:M*G*H\1E\E33DXTLQP52H_*%.G6E
M.4NT8Q;?8Y2R_P"2BZO_ -@F/_T5IE?A7#G_ "EYQ]_V0>#_ /4+@L]_$_\
M)'9?_P!C"?\ Z7CCT*OZS/D#D_''_(KZI_VY?^G&TK\(^DS_ ,F1XU_[MO\
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MYM%)+,<9:.BOB*C?WN5Q/^$:\/\ _0'T_P#\!8O_ (FH_P"(->%/_1O>$O\
MPRX+_P"5#_MK-O\ H8XS_P 'S_S#_A&O#_\ T!]/_P# 6+_XFC_B#7A3_P!&
M]X2_\,N"_P#E0?VUFW_0QQG_ (/G_F'_  C7A_\ Z ^G_P#@+%_\31_Q!KPI
M_P"C>\)?^&7!?_*@_MK-O^ACC/\ P?/_ ##_ (1KP_\ ] ?3_P#P%B_^)H_X
M@UX4_P#1O>$O_#+@O_E0?VUFW_0QQG_@^?\ F:%I865@ACL;2VM$8@LMO#'
M&(& 7\M5WMCNV3[U]=D7"_#?"U"IA>&\AR?(,/6E&=>EE&783+XXB<(N,*F(
M^JTJ3KU(Q;BJE9SFD[<UCCQ&*Q.*DI8G$5J\HW476J3J<J>K4>9OE5^D;(MU
%[ISG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_f1c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_f1c.jpg
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H4TI\R32[(YZ^+Q6)Y?K&)Q%?E^'V]:I5Y;_R\\I6W>Q;KWSG"@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_f2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_f2.jpg
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M'[0G"3QEH7/LKD]#W%?SUAO#SC;@?C?A2AQ3PUFF4+_6C(J<,55H>URZM/\
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K<\:;5G3C5Y?:QA;1)35H^[&T;HWJ_43R@H * "@ H * "@ H * "@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_f3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_f3.jpg
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ME7KX5PI4_BE"MAZO+?K*-&K4E%>;27F='D=N/3M^E?JFW1KY-6/*V\ODT+0
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MN:;32>F[.'*YYA!5?J.'I5E>/M/:4:=3E?O*-N?:Z6MM#F/*^'O_ $&KP?\
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MI]I([ZOZ1/FS%U[1;?7;);*>26#R[B.Y@F@*B2&>)7574,"K?+(ZE3_>R""
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D+LON2,>5>?WO_,  .@Q^F*+)6LK<JLNED]Q_@+3 * "@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>arrow.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 arrow.jpg
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0[1<N6/,TDWRQOLA];DG_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
